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Summary (Figure 1) 
Drug-resistance tuberculosis (DR-TB) is a major challenge facing TB control. Limiting person-
to-person transmission is key. This can be done by reducing time to drug susceptibility 
diagnosis and effective treatment initiation, which reduces infectiousness. Furthermore, DR-
TB patients have suboptimal outcomes even on effective treatment and we have few methods 
for monitoring treatment response. If patients are not responding to treatment, better methods 
are required to measure infectiousness so that transmission may be limited.  
First, to alleviate the under-diagnosis of drug-resistance stemming from additional sputa not 
submitted for drug susceptibility testing (DST) and infrastructural barriers, we showed that 
cartridge extract (CE) from used TB-positive Xpert MTB/RIF (Xpert) tests is directly usable 
for MTBDRsl (a second-line molecular DST). Furthermore, we showed that CE was useful for 
spoligotyping for molecular epidemiology. 
Second, we showed that this CE approach is feasible on Xpert MTB/RIF Ultra (Ultra), which 
is Xpert’s successor. We also evaluated the risk of rpoB amplicon escape during the extraction 
and the usefulness of material in other cartridge chambers for different molecular tests. In short, 
cross-contamination was possible but appears extremely unlikely. Only the diamond cartridge 
compartment contains useful material. 
Third, MTBDRsl itself has limitations. For example, it only measures susceptibility to two drug 
classes. We assessed the feasibility of ultra-deep sequencing (single molecule overlapping 
reads, SMOR) on CE. SMOR had more actionable results (useful for clinical decision making) 
on Xpert CE than Ultra CE, and detected micro-heteroresistance missed by conventional DST. 
Next, to evaluate the utility of new tools for treatment response, we leveraged a MDR-TB drug 
trial (NeXT, Clinicaltrials.gov #NCT02454205) to collect serial sputa. We assessed if sputa 




phenotype measured by the most probable number (MPN) assay. More bacilli were culturable 
with exponential cell free extract (EPCFE) and the MPN assay detected bacilli only culturable 
Figure 1: Overview of DR-TB care cascade and where this study aims to address key 




with EPCFE in 22-30% of patients. As Xpert is confounded by DNA associated with dead 
bacilli, we also evaluated if Xpert for treatment monitoring is improved through use of a DNA-
binding dye that blocks DNA amplification; however, the dye did not reduce Xpert-positivity.  
Lastly, it is crucial to know when patients are non-infectious. New methods for detecting bacilli 
in cough aerosol were developed. First, to improve ease-of-use over the cough aerosol sampling 
system (CASS) reference standard, we designed a N95 mask containing a gelatine filter 
(gMask). Secondly we designed a liquid CASS (LCASS) to capture aerosol in liquid rather than 
solid media. gMasks showed patients remained infectious into treatment for longer than 
detected using CASS or LCASS, and that LCASS with EPCFE detected aerosol DCTB . 
In summary, this work shows time-to-treatment initiation for XDR-TB could be reduced by 
doing second-line DST on CE from used cartridges. Targeted next generation sequencing on 
CE is feasible, but optimisation is required. Furthermore, we showed that EPCFE improved 
culturability (sputum and culture) by detecting patients with DCTB missed by conventional 
methods. New methods for measuring infectiousness indicated some patients remain infectious 







Dwelmbestande tuberkulose (DR-TB) is 'n groot uitdaging wat TB-beheer in die gesig staar. 
Ten einde die epidemie uit te roei, is dit nodig om die oordrag van person-tot-person te 
verminder. Dit kan gedoen word deur die tyd-tot-diagnose en tyd-tot-effektiewe behandeling te 
verminder, wat die duur van aansteeklikheid dus verminder. Boonop het DR-TB-pasiënte 
suboptimale uitkomste, selfs vir effektiewe behandeling, en daar is min goeie metodes om die 
die reaksie van die behandeling te monitor. As pasiënte nie op behandeling reageer nie, sal 
aansteeklikheid steeds verhoog word. Om oordrag te beperk, is beter metodes nodig om 
aansteeklikheid beter te bepaal. 
Ons het eerstens getoon dat die “cartridge extract” CE) van gebruikte TB-positiewe Xpert 
MTB/RIF toetse toetse gebruik kan word om die onderdiagnose van DR-TB te verminder. Die 
onderdiagnose is a.g.v. die feit dat  addisionele sputa nie vir medisyne-vatbaarheidstoetsing 
(DST) ingesamel word nie asook, die infrastruktuur beperkings wat met DNA toetsing gepaard 
gaan. CE is direk bruikbaar vir MTBDRsl ('n tweede-lyn molekulêre DST). Verder het ons 
aangetoon dat CE nuttig was vir akkurate spoligotipering vir molekulêre epidemiologie. 
Tweedens het ons getoon dat hierdie benadering uitvoerbaar is op Xpert MTB/RIF Ultra (Ultra) 
CE, wat die opvolger van Xpert is. Ons het ook die risiko vir ontsnapping van rpoB-amplikon 
tydens die ekstraksieproses en die bruikbaarheid van CE van ander kamers in die Xpert in Ultra 
vir verskillende molekulêre toetse geëvalueer. Kortom, kruisbesmetting was moontlik, maar dit 
blyk uiters onwaarskynlik. Slegs die diamant-CE-gedeelte bevat nuttige materiaal. 
Derdens het MTBDRsl beperkings. Gegewe hierdie beperkinge, het ons die uitvoerbaarheid 
van ultra-diepe-opvolging (“single molecule overlapping reads”, SMOR) op CE ondersoek. 
SMOR het meer uitvoerbare resultate (d.w.s nuttig vir kliniese besluitneming) op Xpert gehad 
as Ultra CE en het heteroweerstandigheid waargeneem wat deur konvensionele DST op isolate 





Volgende, om vas te stel of nuwe metodes vir die monitering van behandeling nuttig kan wees, 
het ons gebruik gemaak van 'n MDR-TB-behandelings-ondersoek (NeXT, Clinicaltrials.gov # 
NCT02454205) om seriële sputa te versamel. Ons het beoordeel of sputa verskillende 
kultureerbare tuberkelbacilli (DCTB) bevat met 'n dormansie-geassosieerde fenotipe. Die 
aantal bacilli was gekwantifiseer me die “most probable number” (MPN) toets. Meer bacilli 
was kweekbaar met eksponensiële selvrye ekstrak (EPCFE) gedurende behandeling, en die 
MPN-toets het gevind dat 22-30% van bacilli slegs met EPCFE gekweek kon word. Aangesien 
Xpert verwar word deur DNA wat verband hou met dooie basille, het ons ook ondersoek of die 
gebruik van Xpert as ‘n behandelingsmoniteringsinstrument verbeter word deur die gebruik van 
'n DNA-bindende kleurstof; die kleurstof het Xpert egter nie verbeter nie. 
Laastens, is dit uiters belangrik om te weet wanneer pasiënte nie meer aansteeklik is nie. Nuwe 
metodes om TB-basille in hoes-aërosol op te spoor, is ontwikkel. Die eerste, wat die 
gebruiksgemak verbeter ten opsigte van die CASS-verwysingstandaard vir hoes-
aërosolmonsters, was 'n N95-masker wat 'n gelatienfilter (gMask) bevat wat aërosol vasvang. 
Die tweede metode [vloeibare CASS (LCASS)] het aërosol in vloeistof eerder as vaste media 
vasgevang. gMasks het getoon dat pasiënte  langer deur die behandeling aansteeklik bly as met 
CASS of LCASS, en dat LCASS met behulp van EPCFE DCTB in aerosol kan opspoor. 
Samevattend wys hierdie werk dat die inisiëring van tyd tot behandeling vir XDR-TB kan 
verminder word deur tweedelyn DST op CE uit gebruikte cartridges te doen. SMOR op CE is 
uitvoerbaar, maar optimalisering is nodig. Verder het ons aangetoon dat EPCFE deur 
behandeling teenwoordig is end at dit die kweekbaarheid verbeter het deur pasiënte met DCTB 
op te spoor wat deur konvensionele metodes gemis is. Nuwe metodes om aansteeklikheid te 
meet, dui daarop dat sommige pasiënte langer aansteeklik is tydens behandeling as wat huidige 
paradigmas suggereer 
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The leading infectious cause of death worldwide is tuberculosis (TB), caused by the pathogen 
Mycobacterium tuberculosis (Mtb), which claimed 1.3 million lives in 20171. TB is therefore 
a major focus of organisations such as the World Health Organization (WHO) and the Global 
Fund. Early diagnosis is one of the major challenges to reaching the End TB 2030 goals to 
eliminate TB. Although one focus of this thesis is the diagnosis of drug-resistant TB, there are, 
importantly, many challenges in the diagnosis of active TB too. These have been extensively 
reviewed to date2. 
1. Drug resistant tuberculosis 
The emergence of drug-resistant (DR-) TB is major challenge that threatens to destabilise gains 
made in TB control. The burden of DR-TB ranges from 1% to 70% in some high burden 
countries1 (Figure 1A). In South Africa, despite comprising a smaller percentage of the total 
TB burden, DR-TB consumes approximately 60% of the annual budget for TB management3. 
Similarly in the United States, MDR and XDR-TB were 8 to 25 times more costly than non-
DR-TB patient4.  
Importantly, modelling studies5 have shown that at least 80% of DR-TB is caused by person-
to-person transmission (based on DR-TB incidence reports of high burden countries), rather 
than treatment-related acquisition of resistance (Figure 1B). This fact that transmission is the 
major driver of DR-TB is supported by house-hold contact and molecular fingerprinting studies 
showing that in high-burden countries such as South Africa and China, approximately 80% of 
DR-TB cases are likely due to primary transmission6-9.  
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Key to breaking the cycle of DR-TB transmission is starting patients on effective treatment 
earlier. This requires earlier diagnosis of drug-resistance. It is also important to identify patients 
with DR-TB who are not improving (treatment response) and have a high degree of 
infectiousness. 
2. Drug susceptibility testing for drug-resistant tuberculosis 
Only 40% of the estimated 558 000 incident cases of multi-drug resistant (MDR-)TB  
(resistance to the first-line drugs rifampicin and isoniazid) are reported. Worryingly, studies 
have shown that due to gaps in the TB care cascade in high burden countries like South Africa 
and India, only 20-40% of reported DR-TB cases are successfully treated (Figure 2A and 
B)1,10,11. Of the 558 000 MDR-TB cases, 8.5% are estimated to be extensively drug-resistant 
(MDR plus resistance to fluoroquinolones and a second-line injectable agent; XDR)1.  XDR-
TB is associated with especially poor outcomes. For example, studies have shown in KwaZulu 
Natal, South Africa, 11-90% of patients with XDR-TB died before treatment initiation and 
36% of patients who were treated died at follow-up12,13. Patients with DR-TB are also often 
discharged back into communities despite being possibly infectious14.   
  
Figure 1: [A] Percentage of incident drug-resistant tuberculosis cases in 2017 amongst 
people who have TB for the first time1. [B] Estimated proportion of incident MDR-TB cases 
resulting from transmission (rather than acquisition during previous treatment in the same 
person). Current global notifications were consistent with a vast majority of MDR 
tuberculosis cases resulting from transmission4. 
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There are several reasons for this gap in the care cascade, one of which is the need for collection 
of a second sputum. According to WHO-recommendations, national algorithms dictate that 
once TB diagnoses are confirmed and rifampicin-resistance suspected this second sputum is 
collected and used for additional drug-susceptibility testing15,16. However, patients often do not 
return for a follow-up visit, due to various reasons (e.g. transport, time off work, travel costs, 
too ill.),  and treatment initiation has been shown to be delayed as long as 55 days17, in which 
a patient may still be infectious. Some patients also struggle to produce a second sputum, 
especially in countries with a high HIV co-infection rate, which further limits additional 
specimen collection18-21. 
Figure 2: [A] Care cascade for patients with at least rifampicin-resistant (RIF-R) 
tuberculosis. In South Africa3 and [C] India4. Many patients with at least rifampicin-





2.1. Current methods for drug-susceptibility testing 
Xpert MTB/RIF (Xpert) is a nucleic acid amplification test that detects Mycobacterium 
tuberculosis complex DNA (MTBC) and resistance to rifampicin, a first line anti-TB drug, 
directly from sputa and is endorsed by the Food and Drug Administration (FDA) and WHO22-
24. The latest data from 2016 shows that over 25 million Xpert cartridges have been bought and 
consumed worldwide25. It is an easy 3 step process that requires the addition of sample reagent 
to a sputum, loading the sample reagent-sputum mix into an Xpert cartridge and running this 
on the GeneXpert platform (Figure 3)24.   
Several national algorithms, with recommendation from the WHO, state that if a patient is 
tested with Xpert and rifampicin resistance is detected, a second sputum is to be collected for 
drug-resistance testing (DST) for resistance to isoniazid, fluoroquinolones and second-line 
injectables16,24,26,27. These tests are done either phenotypically, which involve waiting on 
cultures for up to 42 days or done using molecular methods such as the WHO-endorsed line 
probe assays (LPAs) namely, MTBDRplus (rifampicin and isoniazid) and MTBDRsl 
(fluoroquinolones and second-line injectables). These are done on sputa but requires certain 
biosafety and laboratory infrastructure for DNA extractions form the sputa. Suboptimal 
sensitivity on sputa have also been shown and thus LPAs sometimes needs to be done on the 
culture which adds further delays28-31. Despite national algorithms mandating the use of LPAs 
 
Figure 3: Workflow of Xpert cartridge preparation. Takes approximately 2 min of hands on 
time and 2 hours run time. 
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for DST, poor adherence has been reported32-34, for example, in South Africa, 34% of Xpert 
RIF-resistant patients failed to receive MTBDRplus and, of those confirmed to have MDR-TB, 
28% did not receive second-line DST21. Novel approaches to reduce this gap in the TB care 
cascade is therefore a major research priority35,36 
2.2. New tests for drug-susceptibility testing 
Xpert has recently been superseded by an improved molecular test, Xpert MTB/RIF Ultra 
(Ultra) which also detects for MTBC and rifampicin resistance but has increased sensitivity for 
paucibacillary samples (though specificity is overall reduced) due to the addition of two 
different multicopy amplification targets (IS6110 and IS1081) and the use of melt-curves to 
detect resistance and improved rpoB probes37-39. Furthermore, a new first-line molecular DST 
test, the FluoroType MTBDR (FT), which is a non-symmetric [linear after the exponential 
(LATE)] PCR together with lights-on/lights-off probes has been designed and tested in clinical 
settings40. It has been designed as an automated qualitative test for detection of MTBC-DNA 
as well as resistance to rifampicin and isoniazid. Importantly it also gives the resistance 
mediated mutation associated with the resistance calls. It has been shown to have high 
sensitivity and specificity on clinical samples41,42. However, unlike the LPAs, the FT has not 
been endorsed by the WHO. 
2.3. Heteroresistance and drug-susceptibility testing 
The phenomenon of heteroresistance is becoming more prevalent. Heteroresistance can either 
be polyclonal – mixed-infection of two separate strains or the emergence of a sub-population 
of very rare, spontaneous DR-TB mutants in the presence of an antibiotic; or monoclonal – 
heterogeneity that occurs when one pure clone differentiates into drug-susceptible and drug-
resistant populations at a high frequency. The former is more common (Figure 4)43-47.  
Polyclonal heteroresistance is more difficult to detect on pure clones from these samples as 
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they would either be fully resistant or fully susceptible during culturing47. Heteroresistance to 
both first –and second line drugs for TB has been reported, and these are often missed by 
conventional DST methods. Genetic diversity of Mtb is often lost during phenotypic DST as 
sub-culturing causes selection bias, especially in polyclonal heteroresistant cases47-49. 
Furthermore, molecular assays such as Xpert and LPAs often miss heteroresistant population 
as they are present at lower frequencies and are masked by the larger population of drug-
susceptible bacteria or only detect certain resistance conferring mutations50.  The misdiagnosis 
of these can lead to poor patient outcomes and better tools are necessary to ensure patients are 
on effective treatment51. 
 
 
Figure 4: Clonality of heteroresistance. Heteroresistance can either be polyclonal (top panels) 
which exists as result of mixed infections or from rare resistant mutants that slowly increase in 
proportion during antibiotic treatment in a population of susceptible bacteria. It can also be 
monoclonal, which is generated from a single clone that differentiates into two populations 
(susceptible and resistant) at high frequency in the absence of antibiotic pressure40. 
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2.4. Next generation targeted deep sequencing 
A promising new method for a near-complete drug-resistance profile is the use of next 
generation sequencing methods such as targeted deep sequencing45,52. This will allow a 
complete antibiogram and detect proportions of resistant alleles down to f <1%. This is 
especially important for the detection of heteroresistance45,49. One such technology is the 
single-molecule overlapping reads (SMOR) method, which was developed and patented by 
The Translational Genomics Research Institute, Northern Arizona University which has been 
shown to obtain fast and accurate drug resistance profiles for both first and second-line anti-
TB drugs53-55. 
2.5. Knowledge gaps for drug resistance testing 
We aimed to address the above gaps by determining whether MTBC-DNA can be recovered 
from used Xpert and Ultra cartridges - that would otherwise have been discarded - and whether 
this could be used, without further DNA extraction methods, to generate a complete first and –
second-line DST result from one sample. We aim to do this firstly using routine molecular DST 
methods as well as making use of SMOR. 
3. Treatment response monitoring 
Not only do we need to find ways to improve the diagnosis of DR-TB, but with large numbers 
of patients who default or have treatment failure, proper tools for monitoring treatment 
response in DR-TB patients are paramount. This would aid in regimen change and in-patient 
hospital management, for example, if we could detect at an early stage if a patient is likely to 
fail treatment, certain interventions could be taken to reduce the chance of this happening, 
thereby potentially improving outcomes. Current techniques such as culture and smear, which 
are slow, have relatively poor sensitivity and specificity, 24-57% and 81-85%, for predicting 
relapse and treatment failure respectively, even when performed several times 
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longitudinally56,57. Molecular diagnostics such as Xpert also has limitations such as the inability 
of the test to distinguish between DNA from live and dead bacteria. 
3.1. Culture methods for treatment monitoring 
A widely used standard for treatment monitoring is culture and smear, where if a patients is 
culture and smear negative it suggests that treatment is effective, however smear has low 
sensitivity and culture can take up to 42 days for a result and does not quantify the number of 
bacteria present56. There has also been several studies that indicate that there is a sub-
population of differentially culturable tubercle bacteria (DCTB) in a dormancy-related state 
and that are drug-tolerant, which in turn allows them to proliferate through treatment. This sub-
population has not yet been studied in terms of their association with treatment outcomes 58,59. 
As these DCTB cannot be quantified using standard cultures (they often fail to grow), a 
modified culture method has been developed where resuscitation promoting factors (RPFs) or 
exponential phase cell free extract (EPCFE) from growing TB strains (which contain both RPFs 
and other rescue pathway proteins) are added during culture to promote growth58-61. The Most 
Probable Number (MPN) assay is a method that can be used to quantify the number of bacteria 
present in a starter culture through a serial dilution and has often been in microbiology, it can 
also be used to monitor the effect of one media against another61,62. 
3.2. Molecular tests for treatment monitoring 
Xpert is a current WHO-endorsed test for TB diagnosis. Part of how the Xpert works that bacilli 
(not necessarily alive or intact) are trapped on a filter and washed with a wash fluid prior to 
DNA extraction via sonication (Figure 5A)24,63. This step is meant to remove any extracellular 
DNA, however, we have shown in our previous work it does not remove DNA-associated 
debris or DNA from non-viable cells (Figure 5B) and can lead to false-positive results, due to 
the bactericidal effects of the TB drugs or in in patients with previous TB (although the 
candidate contributed significantly as a co-author to two publications on the topic of false-
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positive PCR results in previously-treated patients it is not the primary focus of this thesis and 
hence not discussed extensively; these publications are in Appendices I and II).64-67 
3.3.1 Photoactive dyes used for viable PCR (vPCR) 
Photo-reactive dyes, such as propidium monoazide (PMA) and ethidium monoazide (EMA) 
have been used to intercalate free DNA or DNA from non-intact cells by forming covalent 
bonds upon light-exposure; thereby preventing this DNA from being amplified. This technique 
is called viable polymerase chain reaction (vPCR)68-71. One of the limitations however are that 
some decontamination procedures can induce cell death while keeping cell membranes intact, 
in which case PMA and EMA have reduced sensitivity72,73. However, a novel dye, PEMAX, 
designed by GenIUL has been created to overcome this limitation74. It has been shown by 
Friedrich et al that dead DNA that accumulate through treatment because of the TB drugs 
confounds Xpert and thus Xpert remains positive further into treatment which makes it a poor 
diagnostic for treatment monitoring64 (Figure 6). The use of vPCR together with Xpert may 
improve the specificity of Xpert for the detection of viable bacilli and thus reduce increase the 
 
Figure 5: [A] Manufacturer-supplied graphics showing that bacteria (viable or non-viable) are 
trapped on a filter and washed before DNA extraction (via sonic horn) to remove any extra-
cellular DNA56 as part of the Xpert test. [B] However, this does discriminate between alive or 
dead bacilli: a comparison of Xpert cycle threshold values (CT; mean ± SEM) from a dilution 
series of bacilli showed similar CT values when Xpert was performed on intact bacilli or non-





diagnostic accuracy for monitoring treatment. A study was done in South Africa where they 
looked at the effect of anti-TB drugs (isoniazid, rifampin, pyrazinamide, ethambutol, 
streptomycin, moxifloxacin) on the detection of TB with Xpert both in vitro and on clinical 
specimens and how PMA could improve TB detection by Xpert. They did not however, look 
at the effect of new anti-TB drugs such as bedaquiline and linezolid. The study showed that 
treatment of sputum with PMA increases the specificity of Xpert and reduces false-positivity 
but only by a small measure based on which antibiotic is used during treatment75.  
3.3. Knowledge gaps for treatment monitoring 
We therefore aimed to improve routinely used diagnostics for treatment monitoring, especially 
in patients with DR-TB. We did this by using the MPN assay to detect and quantify DCTB 
from patients enrolled in a longitudinal drug-trial comparing standard MDR-TB treatment to 
the new regimen containing both bedaquiline and linezolid. Furthermore, we aimed to improve 
on Xpert for treatment monitoring by pre-treating sputa from the same patients with the new 
PEMAX double-dye, to reduce the rates of false-positives through treatment. 
Figure 6: Data from patients for culture (Lowstein-Jensen medium and Bactec MGIT 960), 
smear microscopy and Xpert from baseline and at follow-up visits through treatmet. The 
proportion of positive tests for Xpert delines at a slower rate throughout treatment compared 
to culture and Xpert, likely due to detection of dead DNA64. 
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4. The infectiousness of TB patients of treatment 
It is important to improve on diagnostics to ensure patients are placed, and stay, on effective 
treatment as this reduces the risk that a person remains infectious. This is especially important 
for DR-TB given person-to-person transmission is the major driver of transmission (Figure 
1A). The current paradigm is that patients who are smear-positive (detectible acid fast bacilli 
in their sputa) are more infectious and that those on effective treatment who convert to smear 
negative status and are no longer infectious, however, there is little data on this for patients 
with DR-TB76-78. Furthermore, we have recently shown, in a large study (n=500) looking at the 
determinants of infectiousness, that despite the current paradigm that patients with DR-TB are 
less infectious than those with DS-TB, almost half of patients with DR-TB, after taking into 
account treatment duration, were infectious using the CASS method, and that some were repeat 
positive, despite likely effective treatment. However, even though patients who were positive 
were sampled again, patients were not sampled longitudinally throughout treatment (the 
candidate was a co-author of this output, which is included in Appendix III). 
It is therefore important to have tools to measure the infectiousness of patients, especially 
longitudinally, to better understand transmission, reduce the DR-TB burden, and inform on 
regimen changes and hospital discharge management strategies.   
4.1 Tools for measuring infectiousness 
4.1.1 Sampling on solid media (agar) 
The Cough Aerosol Sampling System (CASS) is a technology that was developed to capture 
aerosol particles from patients with TB and quantifies both the size and distribution of 
individual particles by incorporating a six-stage Anderson Cascade Impactor (ACI)79. This 
system works by having a patient cough into a machine containing an ACI which houses 7H11 
agar plates on six stages, each stage has varying size distribution and makes use of the inertia 
of the particles to separate them according to size. After a sampling time of 5 min, the machine 
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is taken to a Bio Safety Level 3 laboratory where the agar plates are removed, incubated for up 
to 6 weeks and the colonies counted.  
The CASS has been used as a proxy measure for infectiousness in several house-hold contact 
studies and has been shown to predict transmission better than standard smear microscopy 
methods80-82. Although it is the only validated tool for measuring infectiousness it does have 
some limitations, namely that it is a large instrument that requires intensive infrastructure 
which limits its use in field settings or in larger studies and it is dependent on a short spell of 
forced coughing. Finally, it depends on solid culture where previous studies have shown that 
liquid culture is more sensitive for TB culturing83-85. 
4.1.2 Sampling in liquid media 
Aerosol sampling using liquid has been validated before in other bacteria such as Legionella 
spp.86 and Campylobacter spp.87 as well as for the influenza virus88-90 using SKC BioSamplers, 
but has not been reported for TB bacteria. It has the advantage of both using culturing in liquid, 
which as mentioned before has proved to be more sensitive for TB bacteria, but can also be 
used for molecular assays such PCR which allows for rapid identifications. Furthermore, it can 
be used in combination with various culturing media, such as the MPN containing broth 
supplemented with EPCFE which promotes growth of DCTB58,91. 
 4.1.3 Face mask sampling 
Another novel method to measure infectiousness includes using a mask altered to contain a 
gelatine filter which traps aerosolised Mtb particles. The filter can then be solubilised and the 
particles recovered92. This has been used to study patients with chronic obstructive pulmonary 
disease (COPD)93 as well as in patients with TB both in the UK as well as in Pretoria, South 
Africa, however not on patients with DR-TB nor longitudinally92,94 A major advantage of this 
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method is that it is portable, relatively inexpensive compared to solid agar or liquid broth 
methods and it does not depend on a short periods of forced coughing.  
4.2 Knowledge gaps for measuring infectiousness 
We aimed to address some of the limitations of the standard CASS by developing a method for 
capturing aerosols in liquid media from DR-TB patients. We also included culturing with 
EPCFE to determine if there were DCTB in aerosols during longitudinal sampling. 
Furthermore, we designed a mask containing a gelatine filter which can be solubilised to detect 
of there were culturable bacteria in the captured cough aerosol. These would both measured 
with CASS as reference standard, including longitudinally. 
5. Study rationale and concluding remarks 
In summary, while efforts are being made to reduce incidence rates and the number of deaths 
caused by TB, the emergence of drug-resistant TB threatens that goal and is a public health 
crisis. In order to better understand and control the drug-resistance epidemic many steps need 
to be taken. This includes strengthening health system, finding new TB drugs, and reducing 
transmission of drug-resistant TB, among others. In order to address the latter we examine 
ways to reduce the gap in the TB care cascade by finding ways to place people on effective 
treatment sooner, thereby reducing the time they remain infectious. We have also looked at 
ways to improve current diagnostic methods for treatment monitoring to ensure patients remain 
on effective treatment, and finally will develop and test new tools to measure the infectiousness 
of patients throughout treatment to determine if placing patients on effective treatment does 





Summary of knowledge gaps and aims (Figure 7) 
While there are many factors contributing to the DR-TB problem, there are several key 
knowledge gaps that are a focus of this thesis that, if answered, may help to reduce the burden 
of DR-TB (Figure 2). These gaps include: 1) improving diagnosis of DR-TB to ensure patients 
are started on effective treatment sooner 2) improving diagnostics for treatment monitoring to 
ensure patients remain on effective treatment and 3) discovering novel ways of measuring the 
infectiousness of patients to determine when a person is truly non-infectious. We therefore 
aimed to address these three main questions by finding ways to improve diagnostics for 
treatment initiation and treatment monitoring as well as discovering new tools to measure 
infectious throughout treatment 
Aim 1: To investigate whether used Xpert MTB/RIF and Xpert MTB/RIF Ultra cartridges 
contain salvageable genomic DNA useable for further testing including genotypic DST, strain-
typing and next generation sequencing.  
Sub-aim 1a: 
To use the cartridge extract (CE) from the diamond-shaped protrusion on the back of used 
Xpert MTB/RIF (Xpert) and Xpert MTB/RIF Ultra (Ultra) cartridges as well as other chambers 
of the cartridge to determine if Mtb genomic DNA remains and use this as a template for 
MTBDRplus, MTBDRsl and FluoroType MTBDR to determine both diagnosis and drug 
susceptibility testing (DST) from one specimen within 24 hrs. 
Sub-aim 1b: 
To determine if CE from used cartridges can be used as a template for molecular strain typing 





Figure 7: Overview of key knowledge gaps, the study aims to address them, and the key methods involved. tuberculosis. 
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To determine if CE from Xpert and Ultra is feasible as template DNA for next generation 
sequencing methods such as single molecule overlapping reads (SMOR) to get a full drug-
resistance panel result from both first and second-line drugs and to see if there are any 
heteroresistance markers missed by conventional DST methods. 
Aim 2: To determine if modified routinely available diagnostics, Xpert-vPCR and culture with 
added exponential phase cell free extract, are more sensitive for treatment monitoring 
compared to standard Xpert and culture as reference standards. 
Sub-aim 2a: 
To use a photo-activated dye technology combined with Xpert to prevent the amplification of 
DNA from non-viable and non-intact cells by comparing cycle threshold values generated from 
on clinical specimens to improve the sensitivity of Xpert. 
Sub-aim 2b: 
To use the MPN assay to monitor whether exponential phase cell free extract added to sputum 
from patients on treatment results in improved culturablity of a sub-population of bacilli in a 
dormancy related state. 
Aim 3: To compare of new methods of cough aerosol sampling (liquid sampling, gelatine 
mask) for quantifying the aerolised bacterial load of patients with DR-TB on both standard-of-
care regimen and the new MDR-TB regimen (incl. bedaquiline and linezolid) through 
treatment, compared to a reference standard using the solid-agar ACI-based CASS.  
Sub-aim 3a: 
To validate the liquid cough aerosol sampling system (LCASS) by capturing respirable cough 




To determine using the MPN assay containing exponential phase cell-free extract can be used 
to culture differentially culturable cells from aerosols captured in liquid media using the 
LCASS. 
Sub-aim 3c: 
To sample the cough aerosol of DR-TB patients using a mask containing a gelatine filter (which 
traps aerosolised bacilli) and to compare rates of positivity to both LCASS and CASS done on 




Originality of study 
No studies have previously looked at salvaging genomic Mtb DNA from the PCR-reaction mix 
in the diamond chamber at the back of the cartridge. There has been two studies which used 
the remnants (sample reagent-and-sputum mix added to the cartridges) for further testing, (for 
one of which the candidate is a co-author which can be found in Appendix IV)95,96. While this 
is a useful approach it requires additional DNA extractions steps and has to be done in timeous 
manner as the sample reagent prolonged exposure to sample reagent can degrade DNA and 
potentially introduce mutations24,97. 
Previous studies have examined the utility of dyes such as EMA and PMA but none have done 
so systematically with longitudinal time points, have employed a rigorous microbiological 
reference standard. Two studies have tested the validity of PMA on Mycobacterium 
tuberculosis, one of which tested the effect of treating sputa from patients up until 12 weeks 
after treatment initiation with PMA prior to Xpert testing68,75 (29, 33). However, neither of the 
studies made use of the novel double dye technology (PEMAX – comprising of both EMA and 
PMA, GenIUL) nor on longitudinal sputum samples from patients that are currently on the new 
MDR-TB regimen of bedaquiline and linezolid. Furthermore, it has been shown that TB DNA 
can persist longer than 12 weeks in a patient and so we tested sputa collected throughout 
treatment (either 6 months or 24 months depending treatment arm)64. 
There has been studies that have made use of the MPN assay to differentially culture TB 
bacteria from patients but never from patients with DR-TB nor patients receiving the new 
regimen of MDR-TB treatment58. The MPN assay will also be used on samples collected from 
the LCASS, which has not been done previously. 
The validity of the CASS system has been shown in previous studies80,82 (including a submitted 
manuscript for which I am co-author, Appendix III) and so it is an accurate reference standard 
against which to measure the new tools we developed to measure infectiousness. Previously, 
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the SKC BioSamplers have been used to measure other bacteria as well as the influenza virus 
but has never been used to measure M. tuberculosis in cough droplets from patients with TB86-
88,90. Furthermore, our design for the LCASS is unique and was manufactured for our use.  
There has been previous data published on the use of face mask for aerosol testing. This was 
tested both on patients with COPD as well as patients with TB and was tested on patients 
recruited from Leicester and The Gambia as well as Pretoria, South Africa92-94. However, these 
were small cohorts and did not look at the effect treatment has on infectiousness, neither was 
it compared to the only validated tools for measuring infectiousness, CASS. Furthermore, a 
study was recently published outlining the development of a Respiratory Aerosol Sampling 
Chamber (RASC) in which a patients sits in an isolated room and various measurements are 
taken including sampling their aerosol. While this study provided important data, it only looked 
at pre-treatment patients and not how infectiousness changes on treatment, nor did the make 
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Mycobacterial genomic DNA from 
used Xpert MTB/RIF cartridges can 
be utilised for accurate second-
line genotypic drug susceptibility 
testing and spoligotyping
Rouxjeane Venter1, Brigitta Derendinger1, Margaretha de Vos1, Samantha Pillay1,2, Tanya 
Dolby2, John Simpson2, Natasha Kitchin1, Ashley Ruiters2, Paul D. van Helden1, Robin M. 
Warren1 & Grant Theron1
Xpert MTB/RIF (Xpert) is a widely-used test for tuberculosis (TB) and rifampicin-resistance. Second-line 
drug susceptibility testing (DST), which is recommended by policymakers, typically requires additional 
specimen collection that delays effective treatment initiation. We examined whether cartridge extract 
(CE) from used Xpert TB-positive cartridges was, without downstream DNA extraction or purification, 
suitable for both genotypic DST (MTBDRplus, MTBDRsl), which may permit patients to rapidly receive a 
XDR-TB diagnosis from a single specimen, and spoligotyping, which could facilitate routine genotyping. 
To determine the limit-of-detection and diagnostic accuracy, CEs from dilution series of drug-susceptible 
and -resistant bacilli were tested (MTBDRplus, MTBDRsl). Xpert TB-positive patient sputa CEs (n = 85) 
were tested (56 Xpert-rifampicin-susceptible, MTBDRplus and MTBDRsl; 29 Xpert-rifampicin-resistant, 
MTBDRsl). Spoligotyping was done on CEs from dilution series and patient sputa (n = 10). MTBDRplus 
had high non-valid result rates. MTBDRsl on CEs from dilutions ≥103CFU/ml (CT ≤ 24, >“low” Xpert 
semiquantitation category) was accurate, had low indeterminate rates and, on CE from sputa, highly 
concordant with MTBDRsl isolate results. CE spoligotyping results from dilutions ≥103CFU/ml and sputa 
were correct. MTBDRsl and spoligotyping on CE are thus highly feasible. These findings reduce the need 
for additional specimen collection and culture, for which capacity is limited in high-burden countries, 
and have implications for diagnostic laboratories and TB molecular epidemiology.
Of the 10.4 million individuals with active tuberculosis (TB) in 2015, 580 000 were rifampicin (RIF) resistant or 
multidrug-resistant (MDR), defined as resistance to isoniazid (INH) and RIF1. Only ~20% of MDR-TB cases were 
diagnosed and started on treatment, and only half started on treatment were cured1. Extensively drug-resistant 
(XDR)-TB, which is MDR with resistance to a fluoroquinolone (FQ) and a second-line injectable drug (SLID) 
comprises 10% of MDR-TB cases, yet is even more underdiagnosed than MDR-TB, very costly to treat, and rep-
resents an emerging public health emergency2–6.
Xpert MTB/RIF (Xpert) (Cepheid, United States) is a Food and Drug Administration and World Health 
Organization (WHO)-endorsed nucleic acid amplification test (NAAT) that rapidly detects Mycobacterium 
tuberculosis complex-DNA and RIF-resistance directly from sputa7–9. Over 25 million Xpert MTB/RIF cartridges 
have been consumed and over 30 000 test modules are installed worldwide10. The WHO and several national 
programmes recommend that if Xpert detects resistance, an additional sputum is collected for further drug 
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susceptibility testing (DST) using line probe assays (LPAs), such as MTBDRplus (RIF and INH) and MTBDRsl 
(FQs and SLIDs), or phenotypic testing1,9,11,12.
Patients, however, often do not rapidly return to the clinic to give another sputum or receive DST results. For 
example, a study in South Africa found that, even after MTBDRplus roll-out, time-to-treatment since initial diag-
nosis was unacceptably long (~55 days), and that this was partly due to challenges with patient loss-to-follow-up13. 
Furthermore, many patients do not produce sufficient sputum of adequate quality, especially in settings with high 
rates of HIV14–17.
MTBDRplus and MTBDRsl have suboptimal sensitivity on specimens, and culture is often required prior to 
DNA extraction and further genotypic testing. Not only can this cause diagnostic delay, but many high burden 
countries lack the necessary biosafety and laboratory infrastructure for mycobacterial culture and DNA extrac-
tion18–21. Furthermore, culture can result in the loss of potentially clinically-meaningful resistance22. There is 
hence a need to reduce delays in the diagnosis of drug-resistant TB and use rapid methods that minimise reliance 
on culture through the direct testing of specimens23.
Poor adherence to diagnostic algorithms using MTBDRplus and MTBDRsl has been reported5,24,25. For exam-
ple, in South Africa, 34% of Xpert RIF-resistant patients failed to receive MTBDRplus and, of those confirmed 
to have MDR-TB, 28% did not receive second-line DST with MTBDRsl – despite both LPAs being mandated by 
the national programme21. Novel approaches to reduce this gap in the TB care cascade, which is worsened by 
the requirement for extra patient visits and additional specimen collection, is a major research priority26,27. If 
TB-testing and first- and second-line DST were possible on the first available specimen, fewer patients would 
potentially be lost and patients could be diagnosed earlier. This could result in earlier effective treatment initia-
tion, fewer patient- and health systems-costs, and better long-term clinical outcomes.
We therefore conducted a proof-of-concept evaluation on whether M. tuberculosis-complex genomic DNA 
in the PCR-reaction mix from used Xpert cartridges (cartridge extract; CE) - that would otherwise be discarded 
- was detectable in an accurate manner using MTBDRplus and MTBDRsl. The feasibility of genotyping on CE 
by spoligotyping was also tested as this would potentially be useful for research laboratories and programmes 
seeking to implement routine strain surveillance. We explored the feasibility of Sanger sequencing on CE, as this 
may be useful for additional genotypic DST. Critically, we evaluated CE for all tests without additional down-
stream DNA extraction or purification, as not only would extraction require equipment not readily available in 
routine diagnostic laboratories in high burden settings, but it would complicate laboratory workflows and reduce 
the attractiveness of our approach. If the CE approach was feasible, it would mean that many laboratories would 
already have instrumentation available for mycobacterial genomic DNA extraction in the form of GeneXpert10 
and not need to procure new equipment.
Material and Methods
Ethics statement. Methods and protocols were carried out in accordance with relevant guidelines and 
regulations. The study was approved by the Health Research Ethics Committee of Stellenbosch University 
(N09/11/296) and the City of Cape Town (#10570). Permission was granted to use anonymised residual speci-
mens collected as part of routine diagnostic practice and thus informed consent was waived.
Xpert MTB/RIF on dilution series of drug-susceptible- and drug-resistant bacilli. A triplicate ten-
fold dilution series was made using phenotypically-confirmed drug-susceptible (DS)-TB, MDR-TB and XDR-TB 
clinical isolates (0–106 CFU/ml) in phosphate buffer (33 mM Na2HPO4, 33 mM KH2PO4; pH 6.8) with 0.025% 
Tween80 (Sigma-Aldrich, United States). Colony counts were done by plating on 7H11 Middlebrook agar (BD 
Biosciences, United States). Dilutions containing bacilli (1 ml aliquots) were tested by Xpert (54 in total: six dilu-
tions ranging from 101–106 CFU/ml in triplicate for three strains and hence 18 dilutions each for the DS, MDR, 
and XDR strains) as well as 0 CFU/ml controls in triplicate, according to the manufacturer’s instructions9. Used 
cartridges were stored at 4 °C prior to CE extraction within 24 h and freezing of the CE at −20 °C.
Xpert MTB/RIF on clinical specimens. Used Xpert-TB-positive cartridges done on sputa from people 
with symptoms suggestive of TB tested as part of the South African national TB diagnostic algorithm were col-
lected between February 2016 and November 2016 from the National Health Laboratory Services (NHLS), a 
South African National Accreditation System-accredited, quality-assured diagnostics laboratory in Cape Town, 
South Africa11. Cartridges were stored at 4 °C prior to CE extraction within 5 days. Fifty-six Xpert TB-positive, 
RIF-susceptible cartridges and 29 Xpert-TB-positve RIF-resistant cartridges were collected. When the NHLS 
did a MGIT 960 liquid culture on sputum from RIF-resistant patients, we collected the isolate [20/29 (69%) had 
available isolates]. Isolates were not available from Xpert TB-positive, RIF-susceptible specimens as culture is not 
routinely done in these patients11,28.
Recovery of mycobacterial genomic DNA from used Xpert MTB/RIF cartridges. The transparent 
diamond-shaped reaction chamber on the back of the cartridge was punctured with a sterile fixed-needle insulin 
syringe (1 ml; 29 G) (Fig. 1) in a biosafety level 2 cabinet. The full CE volume, typically ~15 µl, was withdrawn and 
stored in sterile, safe-lock micro-centrifuge tubes at −20 °C prior to analysis. Each cartridge and the surrounding sur-
face was wiped down thoroughly with 1% sodium hypochlorite and 70% EtOH before and after extraction and UV 
sterilization was done after each batch of extraction. Used needles were discarded in a sharps container containing 
1% sodium hypochlorite. Before and after each cartridge extraction session, hood surface area was decontaminated 
with sodium hypochlorite and EtOH and UV sterilised. No DNA extraction or purification steps were done on CE.
Line probe assays on cartridge extract. MTBDRplus and MTBDRsl (both version 2.0) were done 
according to the manufacturer’s instructions29,30 except for Xpert TB-positive, RIF-susceptible clinical specimens 
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RIF-resistant clinical specimen CEs (n = 29) and the dilution series, 5 µl (the recommended imput volume) CE 
was used in order to have enough CE remaining for Sanger sequencing. MTBDRplus and MTBDRsl results were 
reported as susceptible or resistant (RIF and INH for MTBDRplus; FQ and SLID for MTBDRsl), indeterminate 
[M. tuberculosis complex DNA-positive (reported by the test as TUB-positive) but no gene loci control bands] or 
TUB-band negative. LPA strips were read by two independent, experienced readers blinded to each other’s calls 
and Xpert results (and, for dilution series, the strain used).
Spoligotyping on cartridge extract. Spoligotyping was done as described31,32 on 2 µl CE from the 
MDR-TB dilution series. A set of Xpert TB-positive, RIF-susceptible cartridges (n = 10) done on specimens and 
separate from those used for genotypic DST on CE were collected with paired culture isolates from an ongo-
ing research study. To determine whether the correct spoligotype was obtained from CE, crude DNA extracted 
through heat inactivation from the corresponding culture isolates was spoligotyped. SITVIT was used to identify 
strain families33.
Targeted Sanger sequencing on cartridge extract. For dilution series, PCR clean-up and Sanger 
sequencing on 5 µl CE was done by the Stellenbosch University Central Analytical Facility using primers over-
lapping with LPA-binding sites (Supplementary Table 1). The gyrA and rrs regions in the DS-TB and XDR-TB 
strains were sequenced.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Patient characteristics. A summary of the patient demographic and clinical data is in Table 1. For 
Xpert TB-positive, RIF-susceptible patients the median age (IQR) was 40 (31–49) years and for RIF-resistant specimens 
was 35 (23–42) years. 37/55 (67%) of RIF-susceptible patients and 12/20 (60%) of RIF-resistant patients were male.
Feasibility and diagnostic accuracy of MTBDRplus and MTBDRsl on dilution series Xpert 
TB-positive cartridge extract. Xpert detected M. tuberculosis-complex DNA in all dilutions ≥102 CFU/
ml and correctly identified RIF-susceptibility and -resistance (Fig. 2). MTBDRplus showed poor overall sensitivity 
for M. tuberculosis-complex DNA [22% (12/54) TUB-band-positive] in CE from Xpert TB-positive cartridges. 
MTBDRplus had high rates of non-actionable (TUB-band negative or TUB-band positive but indeterminate) and 
false RIF-heteroresistant results (Figs 2 and 3).
In contrast, MTBDRsl on CE had high sensitivity and specificity [87% (47/54) and 100% (9/9) respectively] 
for M. tuberculosis-complex DNA and a limit of detection of 103 CFU/ml. Susceptibility and resistance to FQs and 
SLIDs were correctly detected for all strains ≥103 CFU/ml, corresponding to CT ≤ 24 (the higher CT range of the 
Xpert “low” semiquantitation category) in all but one sample (one replicate of the MDR-TB strain was indeter-
minate for FQs; Fig. 3). Once non-actionable results were excluded, overall sensitivities and specificities of 87% 
(13/15) and 96% (25/26) for FQ-resistance and 94% (15/16) and 97% (30/31) for SLID-resistance, respectively 
were obtained. When the threshold of ≥103 CFU/ml (CT ≤ 24) was applied, the sensitivity and specificity were 
both 100% (12/12 and 23/23, respectively) for FQs and for SLIDs (12/12 and 24/24, respectively).
Figure 1. Cartridge extract extraction procedure. (a) The arrow indicates the diamond-shaped reaction chamber 
where the PCR amplification takes place and contains cartridge extract with mycobacterial genomic DNA. The 
needle is placed at the top of the diamond and the film is slowly and carefully pierced. (b) The needle is then 
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Diagnostic accuracy of MTBDRplus and MTBDRsl on clinical specimen Xpert TB-positve car-
tridge extract. Xpert MTB/RIF rifampicin-susceptible specimens. As with the dilution series, MTBDRplus 
had high rates of indeterminate and false-resistance results on clinical specimen CE (Table 2). However, most 
MTBDRsl results from Xpert TB-positive, RIF-susceptible clinical specimen CE were valid (TUB-positive, not 
indeterminate, and no false-susceptible or -resistant results): 53/56 (95%) for FQ (two TUB-band negative, one 
indeterminate) and 51/56 (91%) for SLID (two TUB-band negative, three indeterminate). The few CEs that 
yielded indeterminate MTBDRsl results corresponded to “low” or “very low” Xpert semiquantitation levels 
(CT > 24). The median (IQR) CT of indeterminate (26.3, 24.4–26.7) vs. determinate (17.62, 15.6–20.6) MTBDRsl 
results differed (p < 0.001), indicating that indeterminate results are likely a function of low DNA concentrations 
in CE. There was not enough CE volume remaining or a matching clinical isolate for confirmatory testing from 
the three MTBDRsl-detected SLIDs resistant patients.
Xpert MTB/RIF rifampicin-resistant specimens. MTBDRsl on Xpert TB-positive, RIF-resistant CE had 24/29 
(83%) valid results. For FQs, 14/24 (58%) were susceptible and 10/24 (42%) were resistant. For SLIDs, 15/24 
(63%) were susceptible and 9/24 (37%) resistant. The five non-valid results were TUB-band-negative [2/29 (7%)] 
or indeterminate for both FQs and SLIDs [3/29 (10%); Table 2]. All CEs corresponding to the higher CT ranges 
of the Xpert “low” semiquantitation category (CT ≤ 24) had valid results, whereas those that had indeterminate 
or TUB band-negative results corresponded to the lower semiquantitation levels (CT > 25.0). The median (IQR) 
CT of indeterminate (29.1, 26.5-31.1) vs. determinate (20.5, 16.−23.2) results differed significantly (p < 0.001).
MTBDRplus and MTBDRsl performance on Xpert MTB/RIF cartridge extract by smear status. MTBDRplus had 
high non-valid result rates irrespective of smear status. However, MTBDRsl on CE from smear-negative spu-
tums had significantly higher rates of non-actionable results [5/23 (22%) vs. 1/43 (2%) for FQ, p = 0.01; 6/23 
(23%) vs. 2/43 (5%) for SLIDs, p = 0.01] compared to smear-positive patients (Supplementary Table 2).
Concordance of MTBDRsl results on cartridge extract and culture isolates. Of the 29 Xpert TB-positive, 
RIF-resistant patients, 20 (69%) matched culture isolates were collected while the remaining nine had negative or 
contaminated cultures. The CEs and isolates showed 18/20 (90%) matching MTBDRsl FQ results and 17/20 (84%) 
matching SLID results. There were 2/20 (10%) discordant TUB-band MTBDRsl results on culture isolates (one 
TUB-positive and FQ and SLID sensitive, one TUB-positive and FQ and SLID resistant) where both CE results 
were TUB-band negative. There was also 1/20 (5%) discordant SLID result (CE showed resistance but the isolate 
showed susceptibility). Importantly, all three discordant results corresponded to a “very low” semiquantitation 
(CT > 28.0). All TUB-band, susceptibility and resistance calls were concordant at CT ≤ 24, indicating that the 
diagnostic accuracy of MTBDRsl on CE vs. isolates is likely comparable at this threshold.
Spoligotyping on cartridge extract. Dilution series. Spoligotyping resulted in a readable strain type for 
dilutions ≥103 CFU/ml, corresponding to the same threshold seen for MTBDRsl.
Clinical specimens. Spoligotyping on specimen CE and crude DNA from matched culture isolates were highly 
concordant 10/10 (100%) at the threshold defined by the dilution series (Table 3). A variety of strain families were 
observed with Beijing as the predominant family type [6/10 (60%)] as well as 2/10 (20%) LAM and 2/10 (20%) 
T1 family type.
Targeted sequencing on extract from used Xpert MTB/RIF cartridges. Dilution Series. Targeted 
Sanger sequencing was done on dilution series CE. For the rrs PCR on CE, sequence shorter than the expected 
length was observed. PCR of gyrA from CE from dilutions 103–104 CFU/ml resulted in sequence expected length, 
however high background noise occurred and the sequence did not align to H37Rv [NC_000962]. gyrA on CE 
from dilutions 105–106 CFU/ml aligned to the reference genome, however, several SNPs known to be present in 
the resistance determining regions (identified by sequencing of the corresponding isolate) were not detected. Due 
to the relatively poor limit of detection and accuracy of Sanger sequencing on dilution series CE, we did not do 




susceptible (n = 56)
Xpert rifampicin - 
resistant (n = 29)
Age, median (IQR) 40 (30–49) 35 (23–42; p = 0.086)
Male gender (%) 37/55 (67)* 12/20 (60)*
Smear-positivity (%) 37/50 (74)* 6/16 (38)*
Culture-positivity (%) Not done 19/21 (90)*
 TTP, median (IQR) N/A 10 (8–20)
Xpert CT, median IQR 17.9 (16.3–22.1) 20.5 (16.9–24.8)
Table 1. Patient demographic and clinical data. *Missing data: Gender (n = 1 for RIF-susceptible, n = 9 for RIF-
resistant); Smear status (n = 6 for Xpert RIF susceptible, n = 13 for Xpert RIF-resistant); Culture results (n = 8 
for RIF-resistant results). Abbreviations: Xpert - Xpert MTB/RIF; IQR - interquartile range; TTP - time-to-
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Figure 2. Results of MTBDRplus and MTBDRsl on Xpert CE from a dilution series of DS-, MDR- and 
XDR-TB strains. MTBDRplus (irrespective of concentration and strain) had high TUB-band negativity and 
indeterminate rates. However, MTBDRsl had high sensitivity and specificity and low indeterminate rates. For 
each dilution, left bars are for rifampicin (MTBDRplus, top row) or fluoroquinolones (MTBDRsl, bottom row) 
and right bars are for isoniazid (MTBDRplus) or second-line injectables (MTBDRsl). Data from LPA on DS-TB, 
MDR-TB and XDR-TB strains are shown. The experiment was done in triplicate. Abbreviations: CFU – colony 
forming; DS-TB – drug susceptible TB; MDR-TB – multidrug resistant TB; XDR-TB – extensively drug resistant 
TB; units; Xpert - Xpert MTB/RIF.
Figure 3. Xpert MTB/RIF quantitative information [average cycle threshold (CT) values] (line graph, right 
y-axes) versus bacterial load (CFU/ml) in a triplicate dilution series for MTBDRplus (a) and MTBDRsl 
(b) done on CE. Left y-axes (bars) show the proportion of assays with non-valid results, disaggregated into 
non-actionable (TUB-band negative, indeterminate) and non-valid (false-susceptible, false-resistant). For 
each dilution, left bars are for rifampicin (MTBDRplus, top) or fluoroquinolones (MTBDRsl, bottom) and 
right bars are for isoniazid (MTBDRplus) or second-line injectables (MTBDRsl). Beyond 103 CFU/ml, there 
were no false resistance or susceptibility calls for MTBDRsl, which corresponds to CT ≤ 24. CT ≥ 38 (horizontal 
dashed line) correspond to a negative Xpert. Error bars show standard error (SE) of average CT. Right y-axes 
show CT corresponding to Xpert semiquantitation levels of very low (CT > 28), low (CT = 22–28), medium 
(CT = 16–22) and high (CT < 16). Pooled data from LPAs on DS-TB, MDR-TB and XDR-TB strains are 
shown. Abbreviations: CFU – colony forming; DS-TB – drug susceptible TB; MDR-TB – multidrug resistant 
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All Xpert TB-positive specimens Xpert TB-positive specimens with CT ≤ 24
Xpert rifampicin-susceptible Xpert rifampicin-resistant Xpert rifampicin-susceptible Xpert rifampicin-resistant
MTBDRplus (n = 56) MTBDRsl (n = 56) MTBDRsl (n = 29)* MTBDRplus (n = 49) MTBDRsl (n = 49) MTBDRsl (n = 20)*
TUB-band positive (%) 
47/56 (84)
TUB-band positive (%) 
47/54 (96)
TUB-band positive (%) 
27/29 (93)
TUB-band positive (%) 
45/49 (92)
TUB-band positive (%) 
49/49 (100)
TUB-band positive (%) 
20/20 (100)
Rifampicin (%) Fluoroquinolones (%) Fluoroquinolones (%) Rifampicin (%) Fluoroquinolones (%) Fluoroquinolones (%)
Susceptible 0/47 (0) Susceptible 53/54 (98) Susceptible 14/27 (52) Susceptible 0/56 (0) Susceptible 49/49 (100) Susceptible 11/20 (55)
Resistant 47/47 (100) Resistant 0/54 (0) Resistant 10/27 (37) Resistant 45/49 (92) Resistant 0/49 (0) Resistant 9/20 (45)
Indeterminate 0/47 (0) Indeterminate 1/54 (2) Indeterminate 3/27 (11) Indeterminate 0/49 (0) Indeterminate 0/49 (0) Indeterminate 0/20 (0)
Isoniazid (%) Second-line injectables %) Second-line injectables (%) Isoniazid (%) Second-line injectables (%) Second-line injectables (%)
Susceptible 11/47 (23) Susceptible 48/54 (88) Susceptible 15/27 (56) Susceptible 11/49 (23) Susceptible 46/49 (94) Susceptible 14/20 (70)
Resistant 0/47 (0) Resistant 3/54 (6) Resistant 9/27 (33) Resistant 0/49 (0) Resistant 1/49 (2) Resistant 6/20 (30)
Indeterminate 36/47 (77) Indeterminate 3/54 (6) Indeterminate 3/27 (11) Indeterminate 34/49 (69) Indeterminate 2/49 (4) Indeterminate 0/20 (0)
TUB-band negative (%) 
9/56 (16)
TUB-band negative (%) 
2/56 (4)
TUB-band negative (%) 
2/29 (7)
TUB-band negative (%) 
4/49 (8)
TUB-band negative (%) 
0/49 (0)
TUB-band negative (%) 
0/20 (0)
Table 2. Results of MTBDRplus and MTBDRsl drug susceptibility testing using cartridge extract on clinical 
specimens. MTBDRplus had high indeterminate results and rifampicin-resistance false-positive rates. MTBDRsl 
had low indeterminate rates for both DS-TB and DR-TB specimens and performance improved when MTBDRsl 
was done only on specimens with CT ≤ 24. *For the 29 Xpert RIF-resistant specimens we were able to retrieve 
20 paired culture isolates used for MTBDRsl. 18/20 matched for FQs and 17/20 for SLIDs, the 2/20 done 
on crude DNA had LPA results whereas the LPA on CE was TUB-band negative. 1/20 did not match for the 
SLID resistance. Both the TUB-band negative and discordant SLIDs result corresponded to “very low” semi-
quantitation level. When defined threshold of CT ≤ 24 was applied all LPAs on CE matched LPA from culture 
isolates.
Table 3. Spoligotyping results performed on CE done on sputum specimens and paired culture isolates at 
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Discussion
Our key findings are: (1) MTBDRsl on CE enabled genotypic drug-susceptibility testing for FQs and SLIDs with 
high accuracy and low indeterminate rates when the Xpert semiquantitation category was at least “medium” or 
CT ≤ 24 (corresponding to ≥ 103 CFU/ml), (2) spoligotyping was feasible and accurate on CE at the same thresh-
old, (3) MTBDRplus was not feasible or accurate on CE and (4) neither was Sanger sequencing. These data have 
implications for the routine diagnosis of drug-resistant TB, researchers, and test developers.
Xpert is one of the most widely used tests for TB and drug-resistance9,34 and although it is a significant 
advancement, time-to-treatment – especially for MDR- and XDR-TB - is still very long35–38. Our results show 
that accurate second-line drug testing using MTBDRsl is possible on CE from Xpert cartridges that would oth-
erwise be discarded. This potentially allows for a rapid, single-specimen diagnosis of XDR-TB without addi-
tional specimen collection. Importantly, we defined a threshold at which this approach is feasible, meaning that 
MTBDRsl assays do not need to be wasted on CE unlikely to give a valid result. Using this threshold, we showed 
that on clinical specimen CEs, susceptibility and resistance calls were concordant with those from the isolate19,39. 
Furthermore, we showed that it is possible to do spoligotyping on CE at this threshold, which will inform strain 
surveillance and research studies on relapse and reinfection where specimens are limited. Collectively, these find-
ings may reduce the need for culture.
Although our data suggest that the MTBDRsl will work on CE from cartridges with an Xpert semiquantita-
tion category of at least “low”, we suggest that, in laboratories where CT cannot be readily calculated, a category 
of at least “medium” is used to guide use of this strategy unless the laboratory is comfortable with some sem-
iquantitation low specimens not having a valid MTBDRsl result. Alternatively, if smear microscopy is availa-
ble, smear-positivity may be used to guide use of CE, however, some smear-negative specimens in whom this 
approach would work (103-104 CFU/ml) would be unnecessarily excluded.
When considering the CE approach, it is important to identify a safe and sterile environment to avoid con-
tamination. Although Xpert sample reagent as well as the sonication lysis step within the cartridge helps ensure 
M. tuberculosis is no longer culturable (and therefore poses minimal infectious risk40), steps to minimise the risk 
of rpoB amplicon cross-contamination should be implemented. These can include working in a dedicated cabi-
net or room and sterilising the work area with UV and disinfectant after CE is collected. Importantly, however, 
cross-contamination of other Xpert cartridges with rpoB amplicons appears unlikely. Although Xpert’s automated 
pre-amplification wash step does not remove large pieces of debris-associated genomic DNA, it does efficiently 
remove high concentrations of contaminating rpoB amplicons from assays like MTBDRplus41,42. NAATs without 
such a wash step may be more vulnerable to CE rpoB amplicon cross-contamination.
Our study differed from a previous study which showed that sequencing, MTBDRplus, spoligotyping and 
MIRU-VNTR typing are feasible on the sputum mixed with Xpert sample reagent43. However, this sample 
reagent method has a number of disadvantages: 1) often no volume remains, 2) prolonged exposure to sample 
reagent degrades DNA and potentially introduces mutations9,40, and 3) it still requires DNA extraction prior 
to PCR. Furthermore, DNA extraction adds cost and is not always feasible in laboratories in high burden 
countries; whereas the CE method yields directly usable material and does not need additional extraction 
or purification steps. An advantage, however, of using the sputum mixed with Xpert reagent buffer, is that 
it likely avoids high MTBDRplus error rates (TUB-band negative, indeterminate, false-positive) seen with 
CE. This could be due to the large amount of rpoB amplicons in Xpert TB-positive CE, which share bind-
ing sites with MTBDRplus probes and confound the assay resulting in non-valid results. Furthermore, the 
rpoB PCR that occurs as part of MTBDRplus may sequester reagents away from the multiplex inhA and katG 
amplification reactions. Testing for mutations conferring INH resistance using CE might hence be possible 
with the Genoscholar INH II line probe assay (which does not contain rpoB probes)44. Sequencing from CE 
thus primarily appears to be driven by rpoB amplicon interference (although a PCR clean-up was done prior 
to sequencing, this would have co-purified rpoB amplicons). Further investigation with primers optimised for 
minimal-input DNA may be warranted, however, it appears that, for sequencing, the best approach to avoid 
contaminating amplicons might be to PCR from the specimen-Xpert sample reagent mixture43. Given the rates 
of non-valid CE results below the defined threshold, we suggest that specimen-Xpert sample reagent mix be 
kept in the event that CT falls >24. 
The results presented here should be interpreted in context of their limitations. For the clinical specimens 
tested from the NHLS, matched culture isolates were not available for Xpert RIF-susceptible specimens, as 
per the national algorithm. However, the dilution series experiments showed very high concordance between 
MTBDRsl on CE vs. the isolates. The utility of CE depends on the downstream test used and MTBDRsl sus-
ceptible or non-valid results should be interpreted from CE the same as when they are done on patient spec-
imens (i.e., further investigation, including culture, is recommended)45. Realistically, cartridges may need to 
be transported from remote locations and so the effect of storing cartridges for prolonged duration (>5 days) 
and at ambient temperature requires further systematic testing. Using bacilli in buffer can have limitations, 
which is why we also used patient clinical specimens, which are a better material to test than bacilli added to 
sputum (the former has bacilli within a sputum matrix, whereas in the latter bacilli are typically freely floating 
in bubbles). 
In conclusion, CE contains template DNA for second-line DST using MTBDRsl, resulting in accurate results 
highly concordant with those from isolates, provided bacillary load in the specimen corresponds to at least a 
“medium” Xpert semiquantitation category of CT ≤ 24. This potentially facilitates XDR-TB detection within days 
from a single specimen. Spoligotyping is also feasible on CE and works consistently at this threshold. Our method 
provides an opportunity to potentially reduce the burden associated with addition specimen collection, such as 
patient treatment delay, pre-treatment loss-to-follow-up, and increased patient and provider costs. Furthermore, 
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extract from used Xpert MtB/
Rif Ultra cartridges is useful for 
accurate second-line drug-resistant 
tuberculosis diagnosis with minimal 
rpoB-amplicon cross-contamination 
risk
Rouxjeane Venter1,3, Stephanie Minnies1,3, Brigitta Derendinger1, Happy tshivhula1, 
Margaretha de Vos1, Tania Dolby2, Ashley Ruiters2, Robin M. Warren1 & Grant theron  1*
Xpert MtB/Rif Ultra (Ultra) detects Mycobacterium tuberculosis and rifampicin resistance. Follow-on drug 
susceptibility testing (DST) requires additional sputum. Extract from the diamond-shaped chamber of 
the cartridge (dCE) of Ultra’s predecessor, Xpert MTB/RIF (Xpert), is useful for MTBDRsl-based DSt but 
this is unexplored with Ultra. Furthermore, whether CE from non-diamond compartments is useful, the 
performance of FluoroType MTBDR (FT) on  CE, and rpoB cross-contamination risk associated with the 
extraction procedure are unknown. We tested MTBDRsl, MTBDRplus, and FT on CEs from chambers 
from cartridges (Ultra, Xpert) tested on bacilli dilution series. MTBDRsl on Ultra dce on tB-positive sputa 
(n = 40) was also evaluated and, separately, rpoB amplicon cross-contamination risk . MTBDRsl on Ultra 
dce from dilutions ≥103 cfU/ml (ctmin <25, >“low semi-quantitation”) detected fluoroquinolone (FQ) 
and second-line injectable (SLID) susceptibility and resistance correctly (some SLIDs-indeterminate). At 
the same threshold (at which ~85% of Ultra-positives in our setting would be eligible), 35/35 (100%) FQ 
and 34/35 (97%) SLID results from Ultra dCE were concordant with sputa results. Tests on other chambers 
were unfeasible. No tubes open during 20 batched extractions had FT-detected rpoB cross-contamination. 
false-positive Ultra rpoB results was observed when dce dilutions ≤10−3 were re-tested. MTBDRsl on Ultra 
dCE is concordant with isolate results. rpoB amplicon cross-contamination is unlikely. These data mitigate 
additional specimen collection for second-line DST and cross-contamination concerns.
Drug-resistant tuberculosis (TB) remains a global threat1. Of 10 million estimated incidence cases reported 
in 2017, 588 000 were rifampicin-resistant2. Of these ~458 000 were multidrug-resistant (MDR). Despite the 
improved roll-out of rifampicin-resistance testing, many patients are not diagnosed appropriately or started on 
effective treatment, resulting in huge TB care cascade gaps3,4. For example, in South Africa, 84% of patients with 
drug-resistant TB have access to rifampicin-susceptibility testing, but only 47% of these are started on likely 
effective treatment4. Similarly, in India, only 41% of the MDR-TB burden was diagnosed in 2013 and, of these, 
just 32% started on treatment5. Innovative approaches are needed to ensure more patients receive comprehensive 
drug susceptibility testing (DST).
Previous work showed that mycobacterial genomic DNA can be recovered from the rear diamond-shaped 
chamber of used Xpert MTB/RIF (Xpert) cartridges after the test is complete. This diamond cartridge extract 
(dCE) is useful for downstream testing with the MTBDRsl line probe assay (LPA) (Hain Lifescience, Germany), 
the only World Health Organization (WHO)-endorsed molecular test for second-line drug resistance, and 
1DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, SA MRC Centre for Molecular and Cellular 
Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch 
University, Cape Town, South Africa. 2National Health Laboratory Services, Cape Town, South Africa. 3These authors 
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spoligotyping6, a method useful for monitoring the molecular epidemiology of TB outbreaks. This additional 
testing does not require extra specimen collection nor additional downstream DNA extraction, both of which can 
exacerbate patient loss within the diagnostic care cascade.
As Xpert is a real-time PCR that generates quantitative information, a cycle threshold value (CT <24) was iden-
tified at which downstream dCE testing using MTBDRsl was successful and fully concordant with MTBDRsl results 
on matching isolates7. However, Xpert dCE was not useful for first-line DST using the WHO-endorsed MTBDRplus 
assay, likely due to interference from large numbers of Xpert rpoB amplicons. In addition to the dCE approach, 
others8,9 have shown it is possible to test leftover specimen-sample reagent mix remaining after Xpert, however, 
remnant volume is not always present and DNA extraction and downstream clean-up might still be needed.
Xpert MTB/RIF Ultra (Ultra) recently superseded Xpert as WHO-endorsed frontline molecular test-of-choice 
for TB and rifampicin resistance10. Compared to Xpert, Ultra has higher sensitivity in paucibacillary samples, 
however, specificity is overall lower11–13. Ultra is a different assay compared to Xpert and it is not necessarily given 
that the extract approach would be feasible on Ultra dCE. We aimed to confirm that Ultra dCE would be useful 
for second-line DST. Furthermore, we asked if extract from other chambers within the cartridge other than the 
diamond (i.e., chambers that are likely rpoB amplicon-free), may contain DNA. We quantified this DNA using 
a Mycobacterium tuberculosis complex 16S rRNA real time qPCR and evaluated whether this DNA was useful 
for first-line DST using the FluoroType MTBDR (FT) (Hain Lifescience, Germany) assay14,15. A test such as FT 
could, for example, be used to check for isoniazid mono-resistance or confirm Ultra rifampicin-resistance results.
Lastly, as the cartridge extraction (CE) procedure involves aspirating fluid rich in rpoB amplicons, it may rep-
resent a source of cross-contamination. We sought to evaluate this risk, both under a prolonged exposure scenario 
(where collection tubes were purposely exposed during extended batch extractions) and an absolute worst-case 
scenario (directly adding dCE to a sample later tested by Ultra). Showing that the extracted cartridge approach 
in Ultra is compatible with MTBDRsl and represents minimal rpoB amplicon cross-contamination risk would 
increase the likelihood of implementation, especially as Xpert is in the process of being phased out in lieu of Ultra. 
In turn, this could reduce both sputum collection requirements for complete DST and time-to-effective-treatment 
initiation.
Methods
Ethics statement. Methods and protocols were carried out in accordance with relevant guidelines and 
regulations. The study was approved by the Health Research Ethics Committee of Stellenbosch University 
(N09/11/296) and the City of Cape Town (10570). Permission was granted to use anonymised residual specimens 
collected during routine diagnostic practice and thus patient informed consent was waived.
Ultra and Xpert on dilution series of Mycobacterium tuberculosis strains. Culturing of 
genotypically-confirmed drug-susceptible (DS-TB) and extensively-drug resistant (XDR) M. tuberculosis iso-
lates were done in a Biosafety Level (BSL) 3 laboratory to an OD600 of 0.6–0.8 (Fig. 1A). A triplicate tenfold 
dilution series from three separate cultures [100–104 colony forming units (CFU)/ml] was prepared in phosphate 
buffer (33 mM Na2HPO4, 33 mM KH2PO4; pH 6.8) with 0.025% Tween80 (Sigma-Aldrich, United States). Colony 
counts were done on 7H11 Middlebrook agar (BD Biosciences, United States). A total of 52 dilutions [four dilu-
tions, 101–104 CFU/ml in triplicate for both strains plus a negative control for each strain; (4 × 3 × 2 + 2) × 2] 
were made up to 1 ml and tested by Ultra (n = 26) or Xpert (n = 26) per the manufacturer’s instructions16,17. 
Used positive cartridges were stored prior to extraction at 4 °C for ≤3 days. Crude DNA (heat inactivated for 
Figure 1. Study flow diagrams for the (A) in vitro experiment, (B) MTBDRsl on Ultra CE from clinical sputa 
experiment, and the (C) evaluation of rpoB amplicon cross-contamination risk experiment.
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2 hours at 100 °C) from the same strains served as positive controls for downstream tests (16S rRNA gene qPCR, 
MTBDRplus, MTBDRsl, FT).
Ultra on sputum from TB patients. Forty used positive Ultra cartridges done on NALC-NaOH decon-
taminated sputa from pre-treatment TB patients with known drug resistance [5 rifampicin-mono-resistant, 15 
MDR, 10 pre-XDR (resistance to rifampicin, isoniazid and either a fluoroquinolones or a second-line injectable), 
10 XDR] were collected from November 2015 to September 2017 and dCEs were extracted as described previ-
ously6 (Fig. 1B). To confirm MTBDRsl results from dCEs, MTBDRsl was done per the manufacturer’s instructions 
directly on corresponding decontaminated sputa18,19. Ultra cartridges were processed in a manner blinded to 
MTBDRsl results.
Recovery of mycobacterial genomic DNA from used Ultra and Xpert cartridges. Preparation of 
work space. BSL2 hood surfaces were sterilised [1% NaOCl (bleach), 70% EtOH, 5 min UV irradiation] before 
and after each batched extraction. Each cartridge was wiped with 1% bleach and 70% EtOH before and after each 
extraction.
Description of cartridge design. To investigate the feasibility of testing extract from Ultra and Xpert cartridge 
chambers, an understanding of their design and inner processes is required. As described previously, each car-
tridge has a similar design consisting of a foot, valve, body, reaction tube and lid20,21. The five internal chambers 
hold buffers and lyophilised PCR reagents used for sputum homogenisation, washing away debris, and DNA 
extraction, purification, and amplification22. The Xpert and Ultra procedures, including the processes inside the 
cartridges and the contents of each chamber are described in the supplement. After assay conclusion, the vol-
umes typically remaining in each chamber are ~500 µl for Chamber 1 (C1), ~3 ml for Chamber 2 (C2), ~5 ml 
for Chamber 3 (C3) and ~500 µl for Chamber 4 (C4) [Chamber 5 (C5) had no volume remaining after test 
completion].
Diamond chamber extract. dCEs were extracted from all positive cartridges by puncturing the rear chamber 
with a sterile 29 G × 1/2′′ 1 ml insulin syringe (Avacare, South Africa) (Fig. 2A,B) as described previously6. The 
full volume was extracted (~15 µl for Xpert; ~35 µl for Ultra). CEs were stored in microcentrifuge tubes at −20 °C 
prior to analysis.
Other chambers. Five cartridge chambers (C1, C2, C3, C4, C5) were accessed by inserting a 22 G spinal needle 
(Becton Dickinson, United States) fixed a 5 ml syringe (Fig. 2A; a pipette may also be used for C1) and the entire 
volume withdrawn (Fig. 2A,B). C5 had no remaining volume left after Xpert or Ultra test completion. No DNA 
extraction or purification steps were done for downstream assays.
16s rRNA gene quantitative PCR (qPCR) on cartridge extract. CEs from C1–4 and dCE from Ultra 
and Xpert done on the serial dilutions were tested (heat extracted crude DNA from matching isolates was used as 
positive control). For each qPCR, 5 µl iTaq Universal SYBR Green Supermix (Bio-Rad), 0.3 µl (300 nM) of M. tuber-
culosis specific forward (V4 515F) primers, 0.3 µl (300 nM) of M. tuberculosis specific reverse (V4 806R) primers 
(Table S1) and 1.4 µl nuclease-free water was used23. 3 µl CE was added and amplification occurred using a Bio-Rad 
CFX-96. The threshold used to determine if a reaction was excluded from subsequent analyses was defined as a Cq 
value greater than the average of the triplicate negative controls for that run. Chambers with a Cq less than that aver-
age value were considered positive for M. tuberculosis complex (MTBC) DNA and used for MTBDRplus, MTBDRsl 
and FT.
Figure 2. (A) Entry points through the lid of the cartridge for access to different cartridge chambers. (B) Top-
down cross-section of the inside of the cartridge corresponding to the access points.
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MtBDRplus and MtBDRsl line probe assays on cartridge extract. Diamond chamber 
extract. MTBDRplus and MTBDRsl (both version 2.0) were performed on dCEs from Ultra and Xpert done on 
the in vitro dilution series. For Ultra done on sputa from patients, only MTBDRsl was done. 5 µl dCE was used for 
MTBDRplus and MTBDRsl each. MTBDRplus and MTBDRsl results were reported as described24: either actiona-
ble [TUB-band positive and determinate (gene-specific locus bands present)] or non-actionable [TUB-band neg-
ative or TUB-band positive but indeterminate (gene-specific locus band absent)]. Susceptibility calls were made 
for all actionable results. Banding patterns were read by two experienced independent readers blinded to each 
other’s calls, the Ultra and Xpert results, and, for the dilution series experiement, the strain antibiograms (if there 
was a discrepancy between readers, a third experienced reader reviewed results and did the final classification).
Other chambers. MTBDRplus and MTBDRsl were done on C2 and C4 CEs from both Ultra and Xpert done on 
the dilution series. C1, C3, and C5 were not tested with LPAs as their CEs were 16S rRNA qPCR-negative or there 
was no volume remaining to test after the Ultra or Xpert test had completed (C5).
FluoroType MTBDR on cartridge extract. Diamond chamber. dCEs from Ultra and Xpert cartridges 
done on the in vitro dilution series were tested by FT using the manufacturer’s instructions25. A total of 26 tubes for 
each test (Ultra, Xpert) were tested [four dilutions from 101–104 CFU/ml in triplicate for both strains plus a negative 
control for each strain, (4 × 3 × 2 + 2)]. As Xpert dCE had a volume of ~15 µl, after MTBDRplus (5 µl), MTBDRsl 
(5 µl), and the 16S rRNA qPCR (3 µl) were all done on the same Xpert dCE, the remaining volumes (5–14 µl) were 
made up to 20 µl with dH2O for FT (the recommended input volume)25. All Ultra dCEs (~35 µl originally) had 20 µl 
remaining and the full 20 µl was used for FT. FT results were classified in a manner similar to that for the line probe 
assays: actionable (MTBC detected; rifampicin and isoniazid susceptible or resistant) or non-actionable (no MTBC 
detected, MTBC indeterminate or MTBC detected but rifampicin or isoniazid indeterminate).
Other chambers. FT was done on C2 and C4 (as for LPAs) from both Ultra and Xpert cartridges used for the 
dilution series.
evaluation of rpoB amplicon cross-contamination risk. Amplicon escape during batched cartridge 
extractions. During all Ultra and Xpert diamond chamber extractions, 1.5 ml microcentrifuge tubes containing 
100 µl sterile dH2O were positioned in the same BSL2 cabinet (Fig. 3A). Three tubes remained open throughout all 
extractions for each batch extraction and three remained closed (negative controls). Tubes were stored at −20 °C for 
later FT testing. A total of 20 batches of cartridges were extracted [n = 120 tubes in total from the 20 batches, n = 60 
open tubes and n = 60 closed tubes including triplicates], with a median (IQR) number of cartridges per batch of 
17.5 (10.5–27.5). There were also three tubes open for each individual cartridge extraction but these were not tested 
further based on results of the open tubes during batched extraction, which revealed no cross-contamination. 
Furthermore, extractions procedures were done by a total of five different users to reflect user variability.
Spiking of amplicons. The same XDR-TB strain with known Xpert and Ultra rpoB resistance profiles was used 
in the dilution series (Fig. 1C). Ultra and Xpert were each done on 1 ml of a 104 CFU/ml concentration (in trip-
licate). dCEs were extracted and used for a dilution series (100, 10−3, 10−6, and 10−9; each 1 ml final volume). For 
all dilutions, 5 µl was added to 700 µl of the DS-TB strain (104 CFU/ml) and tested with Ultra [700 µl was used as, 
when combined with the recommended two-fold sample reagent volume, the 2 ml input volume is reached with 
minimal sample unused (~100 µl)].
Results
Mycobacterium tuberculosis complex genomic DNA detection in different chambers from car-
tridges done on dilution series. Though qPCR-positive results were obtained from C2, C4 and the dCE 
(Fig. S1), these results were highly variable even at high concentrations of bacilli (at least 104 CFU/ml), suggesting 
interference. As C2, C4 and dCE gave positive qPCR results on cartridges done on some dilutions, and C1 and C3 
gave none, we only explored the utility of the former for downstream testing using MTBDRplus, MTBDRsl, and FT.
MtBDRplus and MtBDRsl on extract from cartridges done on dilution series. TB detec-
tion. More Ultras were MTBC-positive at lower CFU titres than Xpert [e.g., 4/6 (67%) of the 101 CFU/ml ali-
quots vs. 1/6 (17%) for Xpert at the same concentration for both strains] (Fig. 4). MTBDRplus had high rates of 
non-actionable results across all dilutions irrespective of the cartridge chamber extract originated from (diamond, 
C2, C4) or initial test (Ultra, Xpert) (Fig. 4). MTBDRsl had actionable results for all Ultra dCEs ≥103 CFU/ml 
and, for Xpert, all but one dCE ≥103 CFU/ml (one Xpert replicate at 103 CFU/ml was MTBDRsl-non-actionable). 
MTBDRsl on C2 and C4 had non-actionable results across all dilutions (Ultra and Xpert).
Resistance detection. MTBDRsl correctly identified FQ and SLID resistance on Ultra dCE done on all XDR strain 
aliquots ≥103 CFU/ml (Fig. 5). On the DS-TB strain, MTBDRsl identified FQ susceptibility in all three 104 CFU/
ml replicates and in 2/3 (67%) replicates for SLIDs (one indeterminate). At 103 CFU/ml for the DS-TB strain, 2/3 
(67%) were correctly identified as FQ susceptible (one indeterminate) and all were SLID-indeterminate. The CTmin 
threshold at which all MTBDRsl results was feasible on Ultra CE was <25, which was used for further experi-
ments. Similar results were obtained for MTBDRsl on Xpert dCE.
MtBDRsl on extract from cartridges done on clinical specimens. TB detection. As MTBDRplus 
was not feasible in the in vitro assessment, it was not done on CE from Ultras done on clinical sputa. MTBDRsl 
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on dCE from Ultra done on clinical sputa had 37/40 (93%) actionable results (the rest were non-actionable). 
Non-actionable results corresponded to “trace” or “very low” semi-quantitative categories.
Resistance detection. Of the actionable results, 35/37 (95%) fell within the defined threshold (CTmin <25) and 
of these all FQ results were concordant with MTBDRsl on sputum and all but one SLID result were concordant 
(false-susceptible). Though this percentage is slightly higher than the number of patients with CTmin <25 in our 
setting, which was determined to be 86% (based on an evaluation of Ultra done in sympotmatic patients in pri-
mary care26), which further show that this approach would benefit the majority of patients in our setting. Of the 
2/37 (5%) results that were actionable but fell above the defined threshold, one was concordant with MTBDRsl on 
sputa and one was indeterminate for FQs and discordant for SLIDs (false-resistant).
Figure 3. Evaluation of rpoB cross contamination risk experimental set-up and results. (A) Configuration of 
the environmental exposure experiment within a Biosafety level 2 cabinet. Three microcentrifuge tubes were 
open throughout each batched extraction procedure and three remained closed [median (IQR) extractions 
per batch 17.5 (10.5–27.5)]. No exposed tubes were FT rpoB-positive. In parallel to evaluate if, in an absolute 
worst case scenario, rpoB cross-contamination was probable, dCE from a (B) Ultra or (C) Xpert done on a 
drug-resistant strain was added to a drug-susceptible strain and the resultant mixture tested by Ultra. When 
samples of DS-TB contained CE at higher concentrations (undiluted, 10−3), false-resistant (solid black circles) 
or indeterminate rifampicin resistance (grey circles) are seen. All samples containing CE dilutions beyond 
10−6 showed true rifampicin susceptibility (white circles). Error bars represent CTmin values for each dilution. 
Some images were obtained from the Noun Project: microcentrifuge tube (without changes), Anthony Ledoux, 
https://thenounproject.com/term/eppendorf/1699532/; spray bottle (without changes), John Winowiecki, 
https://thenounproject.com/search/?q=spray%20bottle&i=2236898; sharps container, Juicy Fish (with 
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Receiver operator curve for determining actionable results. An Ultra rpoB CTmin threshold of <25.4 was defined 
for dCEs done on clinical sputa with sensitivities of 97% (95% CI 87–100) and specificities of 100% (55–100) 
(Fig. 6).
FluoroType MTBDR on extract from cartridges done on dilution series. Diamond chamber. FT 
had similar results to MTBDRplus on CEs. For example, 3/24 (12%) Ultra dCEs were MTBC-positive (the others 
negative) for both strains (Fig. S2). In the three Ultra dCEs with a TB-positive FT result, all had indeterminate 
susceptibility results for at least one drug. A total of 18/24 (75%) Xpert dCEs were FT MTBC-positive, however, 
of these 13/24 (54) were indeterminate for at least one drug.
Chamber 2. FT on Ultra C2 had MTBC positivity rates of 10/12 (83%) and 11/12 (92%) for DS-TB and XDR-TB, 
respectively. On Xpert C2, FT TB positivity rates were 5/12 (42%) and 7/12 (58%) for DS-TB and XDR-TB, 
respectively. In MTBC-positive extracts (Ultra and Xpert), most resistance calls were indeterminate or discordant 
with the paired isolate.
Chamber 4. FT done on C4 from Ultra had 8/12 (67%) and 9/12 (75%) TB positivity rates for DS-TB and 
XDR-TB strains respectively, and 3/12 (25%) and 1/12 (8%) on for C4 from Xpert respectively. As for C2, resist-
ance calls were mainly indeterminate or discordant with paired isolate.
Figure 4. MTBDRplus and MTBDRsl on cartridge extract results for TB detection. dCE (left-most column), 
C2 (middle column) and C4 (right-most column) from M. tuberculosis-positive cartridges on dilution series 
(DS-TB and XDR-TB strains) are shown. MTBDRplus had mostly non-actionable results (not positive or 
negative). MTBDRsl had actionable results on all Ultra- and Xpert-positive dCE at >103. Though some 
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rpoB amplicon cross-contamination risk evaluation. Exposure of open tubes during batched extractions. 
All sixty tubes exposed were FT MTBC-negative and had no rpoB amplification.
Amplicon spiking for absolute worst-case cross-contamination scenario. Of the Ultra dCEs done on XDR-TB and 
spiked into DS-TB for re-testing with Ultra, evidence of cross-contamination was seen when dCEs were diluted 
less than 10−6 before addition to the DS-TB strain [3/3 (100%) of 100 dilutions and 2/3 (67%) of the 10−3 dilutions 
showed false-resistance (1/3 of the 10−3 was resistance indeterminate)] (Fig. 3B). Similar results were obtained 
for Xpert dCE (Fig. 3C).
Discussion
We have validated MTBDRsl on CEs from used Ultra cartridges for genotypic second-line DST. We show: 
(1) MTBDRsl on Ultra dCE when CTmin <25 enabled DST concordant with sputum results, (2) risk of rpoB 
extract cross-contamination is unlikely if standard aseptic protocols are followed, (3) neither 16S rRNA qPCR, 
MTBDRplus, MTBDRsl nor FT are feasible on other cartridge chambers, nor was MTBDRplus or FT on Ultra and 
Xpert dCEs. These data support the use of Ultra extract for second-line genotypic DST.
We defined a threshold at which MTBDRsl is likely to work on Ultra dCE from the vast majority of 
Ultra-positive patients, thereby avoiding time and resources wasted on dCE unlikely to give a valid result. We are 
mindful that there were some indeterminate SLID results (in line with previous reports of higher MTBDRsl inde-
terminate result rates for SLIDs vs. FQs)27–29. However, all dCE SLID-indeterminate results from the dilution series 
Figure 5. MTBDRsl drug susceptibility results on dCEs from Ultra and Xpert on dilution series. All 
results ≥103 CFU/ml for the XDR-TB strain had resistance results concordant with the isolate. Some SLIDs 
indeterminate results were seen for the DS-TB >103 at the same concentrations but MTBDRsl results were 
otherwise concordant with those on the isolate.
Figure 6. Receiver operation area under the curve of actionable vs. non-actionable results of MTBDRsl on 
Ultra diamond cartridge extract done on DR-TB clinical sputa to determine a CTmin threshold at which this 
approach is not feasible. MTBDRsl yields actionable results on cartridge extract from Ultra at a CTmin threshold 
of <25.4 with a sensitivity of 97% (87.1–99.9; 95% CI) and specificity of 100% (54.9–100; 95% CI) respectively.
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were from the DS-TB strain and there were no indeterminate SLID results on XDR-TB dCEs. On clinical sputum 
(and falling within our threshold), one MTBDRsl SLID susceptibility result was discordant with sputum (one 
false-negative). We thus suggest that MTBDRsl Ultra dCE results are interpreted in the same manner as recom-
mended by the WHO for MTBDRsl on clinical specimens30. If, for example, MTBDRsl on dCE is non-actionable 
or susceptible, MTBDRsl on sputum or isolates should be done. If there is still no evidence of resistance in a high 
burden setting, phenotypic DST should still be done given the suboptimal rule-out accuracy of MTBDRsl19,30.
The possibility of contamination from rpoB amplicons during extractions has not been investigated. We 
implemented systematic testing for possible environmental contamination. No tubes exposed for each extraction 
batch were rpoB-positive when tested with FT. FT was used for testing for rpoB amplicons as it is more sensitive 
than MTBDRplus14,15.
We further tested a worst-case contamination scenario with dCEs from both Ultra and Xpert cartridges done 
on a XDR-TB strain, diluting these dCEs, and adding them to a DS-TB strain which was subsequently tested by 
Ultra. The undiluted and most concentrated dCE dilutions (100, 10−3) showed false rifampicin-resistance indi-
cating that, although the GeneXpert platform does have proven ability to remove large numbers of amplicons31, 
it was not able to remove all amplicons during the pre-amplification wash steps, however, amplicons diluted 
beyond 10−3 were successfully removed to the point of not being detected22,32,33. These results, together with those 
from the environmental samplings during extractions, shows that when standard aseptic techniques are used, 
amplicon cross-contamination is highly unlikely except in the artificial worst case scenarios. Finally, it should 
be noted that, in line with good practice in any molecular biology laboratory providing results for patient man-
agement, dCEs should not be collected in the same room where rpoB-based tests are done, and that the risk of 
cross-contamination from the dCE approach is only pertinent to tests for rifampicin resistance.
We suggest that diagnosticians considering implementing this approach use the cartridge  itself as a transport 
vessel (upright and in sealed containers) to a central laboratory where dCE can be extracted appropriately (the dia-
mond is a sealed chamber and should remain safe during transport). Most peripheral laboratories will be unable to 
do the dCE procedure safely and downstream molecular DST like MTBDRsl. This cartridge transport can interface 
with existing specimen referral networks. If dCE is planned purely for molecular epidemiology, we suggest that 
dCE be extracted and stored at −80 °C or alternatively the whole cartridge be stored at −20 °C until extractions 
can be done in a batched, centralised fashion. The long term stability of these approaches will require examination.
We further hypothesised that liquid from other cartridge chambers may avoid interference by rpoB amplicons. 
However, upon testing, this approach gave variable non-replicable results. This was true for qPCR, MTBDRplus, 
MTBDRsl and FT assays. This may also be due to very low concentrations of template in these chambers, for 
example C3 – which is the “wash chamber”, and/or remnant PCR inhibitors (e.g., salts from the sample reagent). 
In light of this, we believe that the presence of these amplicons may prevent newer approaches, such as next 
generation sequencing methods, from performing well on dCE without to clean up steps. This warrants further 
investigation. CE from the diamond chamber hence remains the best option for downstream genotypic DST.
The results of this study should be interpreted within its limitations, namely aseptic techniques done in an 
assay- or procedure-specific biosafety cabinet are needed to minimise amplicon cross-contamination. However, 
this infrastructure should already be implemented per WHO guidelines34 where LPAs are done routinely for 
patient care. Furthermore, per good laboratory practice, CEs should not be collected in the same room where 
rpoB- or IS6110/1081-based assays are done, nor should either procedure be done by the same personnel on a 
daily basis. Lastly, further investigation into cross-contamination risk should be done in a routine diagnostic 
setting. This should include multiple operators.
We also acknowledge that this method may increase risk of needle stick injury. Standard biosafety protocols should 
be strictly adhered to. We were recently funded to develop a device that can eject material from cartridges in a safe 
manner. Another limitation is MTBDRplus was not feasible on Ultra CEs and we suspect this is due to interference 
from both rpoB and IS6110/1081 amplicons. Thus, combined with the large volumes (and hence diluted targeted 
DNA) recovered from non-diamond chambers in Ultra and Xpert, MTBDRplus (and also likely FT) on extract from 
any Ultra cartridge chamber is in all likelihood not useful for isoniazid or confirmatory rifampicin DST. Finally, 
although the diamond chamber is a closed system and appears protected against desiccation, we acknowledge that 
some desiccation may occur over prolonged periods that this requires future systematic evaluation. However, we rec-
ommend that extract method is done on an as fresh a cartridge as possible (either at a peripheral or central laboratory), 
in order to reduce the delays of DR-TB diagnosis. Formal evaluation of CE stability pre-extraction may be useful.
We conclude that dCEs from Ultra at the CTmin threshold (<25), can be used for genotypic second-line DST 
(MTBDRsl). Ultra and MTBDRsl on dCE therefore allows for the rapid rule-in detection of XDR-TB on a single 
specimen.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on request.
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Background: Full drug susceptibility testing (DST) is a key barrier to tuberculosis control. 
Mycobacterial genomic DNA from used Xpert MTB/RIF Ultra (Ultra) cartridges can be used 
for molecular tests like MTBDRsl, however, the feasibility of next-generation targeted 
sequencing methods like Single Molecule Overlapping Reads (SMOR), capable of detecting 
more targets and micro-heteroresistance (<1%), is unexplored. We evaluated if SMOR on 
cartridge extract (CE) from Xpert MTB/RIF (Xpert) and its successor Ultra was feasible. 
Methods: Cartridges TB-positive and rifampicin-susceptible (n=27) or rifampicin-resistant 
(n=23) by Xpert and rifampicin-susceptible (n=32) or rifampicin-resistant (n=17) by Ultra had 
CE used for SMOR (inhA, katG, rrs, eis¸ gyrA). Where paired cultures were available had 
phenotypic DST (pDST). MTBDRplus and MTBDRsl results were collected from rifampicin-
resistant patients.  
Results: SMOR on Ultra CE had less actionable (i.e., presence of >10 total-reads and, if 
resistant, >0.1% resistance reads) reads vs. Xpert CE [13/49 (27%) vs. 27/50 (54%); p=0.005]. 
Ultra CE shotgun sequencing revealed multiple copies of rpoB, IS6160/1081, and pncA 
amplicons. CTmin thresholds at which SMOR yielded actionable results were <17 (“high”) and 
<23 (“low”) for Ultra and Xpert, respectively. SMOR calls were mostly concordant (compared 
to pDST or LPA) for Ultra and Xpert CEs for all drugs except rifampicin. However, SMOR 
detected non-rpoB heteroresistance missed by conventional DST in 9/99 patients [9%; 3/49 
(6%) for Ultra, 6/50 (12%) for Xpert]. 
Conclusion: This proof-of-concept study shows SMOR on CE to be feasible; potentially 
leading to the full and rapid rule-in detection of second-line resistance on used Ultra cartridges, 




Tuberculosis (TB) is the leading infectious cause of death in the world and the emergence of 
drug-resistant (DR-) TB is a growing concern. Globally the incidence rate for reported DR-TB 
is 4% among new cases and 19% among previously treated cases but varies based on 
geographical location, for example it ranges from 3% and 7% in South Africa to 38% and 72% 
in Belarus, respectively 1.  
Currently the World Health Organization (WHO) endorses the use of the Xpert MTB/RIF 
(Xpert) - now superseded by the Xpert MTB/RIF Ultra (Ultra) - and the line probe assays (such 
as MTBDRplus for detecting rifampicin and isoniazid resistance and MTBDRsl for detecting 
resistance to fluoroquinolones and second-line injectables) as molecular tests for drug 
susceptibility testing (DST). Conventional phenotypic testing on culture isolates (which is slow 
and requires biosafety infrastructure) is also recommended when results from molecular tests 
are inconclusive, discordant or, due to suboptimal sensitivity, susceptible1. However, despite 
recent improvements in detection of DR-TB due to molecular tests such as the LPAs, which 
reduce time-to-treatment-initiation, treatment initiation in programmatic conditions can still be 
as long as 55 days2. Only 22% of the estimated DR-TB cases have treatment success1-5. These 
delays are caused by many factors, including poor adherence to national diagnostic algorithms, 
suboptimal specificities and sensitives of tests, long incubation times for culture, and failure to 
acquire additional samples for patients for further testing4,6-9.  
Previously, a proof-of-concept study evaluated whether Mycobacterium tuberculosis genomic 
DNA was recoverable from the PCR-reaction mix in used Xpert cartridges (CE – cartridge 
extract) for downstream DST testing using MTBDRplus, MTBDRsl as well as spoligotyping10. 
It was found that CE from Xpert cartridges with a semi-quantitation result within the ‘low’ 
range and below a CTmin ≤ 24, had MTBDRsl results concordant with that on sputa and that 
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spoligotyping was feasible. This potentially obviates loss in the patient diagnostic care cascade 
due to additional sputa not being available or initially submitted for DST. 
Further exacerbating the problems facing DR-TB diagnosis are heteroresistant sub-populations 
of bacilli. These are often masked by larger populations of drug-susceptible bacilli and can 
remain undetected by both phenotypic and molecular DST techniques which leads to a delay 
in effective treatment. This in turn means the patient may remain infectious while a definitive 
diagnosis is sought and contribute towards transmission11-15. Furthermore, often patients are 
placed on ineffective treatment and allows for the drug-resistant sub-populations to proliferate, 
leading to poor patient outcomes14,16. The presence of resistant alleles is also often lost during 
sub-culturing which leads to inaccurate phenotypic DST results13,17,18. 
Previous studies done to determine the use of next-generation sequencing (NGS) using the 
single-molecule overlapping reads (SMOR) method are in theory able to result in fast and 
accurate drug resistance profiling to enable individualised treatment plans19-21. SMOR can also 
detect resistant alleles down to <1%12,18. While this method has been tested on various 
materials, it has never been assessed for use on CE. 
We therefore tested the feasibility of SMOR on CE from used Xpert and Ultra cartridges to 
address several limitations that include: 1) the need to collect additional specimens for further 
sub-culture and DST if a patient has DR-TB 2) the inability of MTBDRplus to detect resistance 
to rifampicin and isoniazid on CE, and 3) detection of resistance-conferring mutations not in 
loci targeted by commercial molecular DSTs. We also explored if the addition of reagents to 




Material and Methods  
Ethics statement 
The study was approved by the Health Research Ethics Committee of Stellenbosch University 
(N09/11/296 and N14/10/136) and the City of Cape Town (#10570). Permission was granted 
to use anonymised residual specimens collected as part of routine diagnostic practice and thus 
informed consent was waived.  
Definitions 
An actionable result is defined as a result that can be used for clinical decision making (i.e. a 
susceptible or resistant result) where the total number of SMOR reads is >=10, and, if resistant, 
>0.1% proportion of the total reads are resistant. A non-actionable result is one that cannot be 
used for clinical decision making (i.e. it is indeterminate because it has <10 total reads and/or 
the resistant reads are <=0.1% of the total reads for that locus. CTmin
 – minimum cycle threshold 
value for Ultra or Xpert (proxy for bacillary load- a larger CTmin value corresponds to lower 
bacillary load and vice versa). 
Sample collection 
Used positive Xpert and Ultra cartridges done on sputa from people with symptoms suggestive 
of TB tested as part of the South African national TB diagnostic algorithm were collected 
consecutively between September 2016 and August 2017 from the National Health Laboratory 
Services (NHLS) and ongoing studies at Stellenbosch University, South Africa. Cartridges 
were stored at 4 °C for a maximum of 5 days prior to extraction as previously described10. 
Forty-nine Ultra cartridges were collected of which 32 were Ultra TB-positive rifampicin-
susceptible and 17 were Ultra TB-positive rifampicin-resistant (Figure 1A). Fifty Xpert 
cartridges were collected in total, of which 27 were TB-positive, rifampicin-susceptible 
59
Stellenbosch University https://scholar.sun.ac.za
cartridges and 23 were TB-positive rifampicin-resistant (Figure 1B). These included all semi-
quantitation criteria for both Xpert and Ultra. 
Phenotypic and genotypic drug susceptibility results  
DST results from LPAs (MTBDRplus and MTBDRsl) done as part of the routine national 
algorithm for patients suspected of having DR-TB were collected from the NHLS for all 
rifampicin-resistant cartridges. Phenotypic drug susceptibility testing (pDST) was done on 
paired sputa that were collected where possible (Figure 1). For the rifampicin-susceptible 
cartridges, a subset collected were from the NHLS and unfortunately clinical isolates were not 
available for pDST. For those rifampicin-susceptible cartridges that were collected as part of 
ongoing studies, clinical isolates were available (as part of standard culture diagnosis) and were 
thus used for pDST for this study. Standardised pDST was done for rifampicin, isoniazid, 
amikacin, kanamycin, ofloxacin and pyrazinamide using a MGIT960 system with EpiCenter 
software as previously described (BD Diagnostics, USA)22. DSTs were performed using 
WHO-recommended critical concentrations (1.0 μg/ml for rifampicin,0.1 μg/ml for isoniazid, 
2.0 μg/ml for ofloxacin, 1.0 μg/ml for amikacin, 2.5 μg/ml for kanamycin and 100.0 μg/ml for 
PZA)23,24. 
Single Molecule Overlapping Reads 
A universal tail amplicon sequencing approach was used. Primers were designed to target six 
genes in M. tuberculosis25-28. These cover frequently-detected loci conferring resistance to 
isoniazid, rifampicin, ofloxacin, moxifloxacin, amikacin, kanamycin, and capreomycin. 
SMOR was used as previously described to achieve reads for each of the aforementioned 
resistance loci 21. 
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Whole genome shotgun sequencing on Ultra cartridge extract 
Sequencing was performed as follows on one Ultra CE (rifampicin-susceptible, medium semi-
quantitation) and one Xpert CE (rifampicin-susceptible, high semi-quantitation) to determine 
the possible cause of interference. ReSeqTB whole genome sequencing methods were done29. 
Briefly, approximately one microgram of DNA per sample was fragmented using a Q800R2 
sonicator (QSonica, Newtown, CT, USA) with the following parameters: 3 minutes sonication 
with 15 seconds pulse on, 15 seconds pulse off, and 20% amplitude.  The fragmented DNA 
was size selected to target 600-650bp by fragment separation using the Agencourt AMPure XP 
beads (Beckman Coulter).  WGS DNA library preparations were performed using the 
NEBNextUltra II DNA Library Prep Kit for Illumina (New England BioLabs) with the 
following modifications. The adapters and 8 bp of index oligonucleotides (Integrated DNA 
Technologies, San Diego, CA) were used in place of those supplied in the NEB preparation kit 
30. A dual-indexing approach was  utilized31.  The samples were sequenced on an 
Illumina NextSeq using either a 300 cycle v2 mid output kit (Illumina) with the standard 
Illumina procedure.  The appropriate sequencing primers were added to the cartridge30. 
ThermoGo and ThermoStop to improve sequencing reads on cartridge extract 
ThermoGo is a modified nucleic acid that supresses mispriming and ThermoStop is a reversible 
hot start agent that prevents non-specific enzyme activity. These were both added to a subset 
of cartridge extract from both Xpert and Ultra as per manufacturer’s instructions to assess 





actionableSMOR read counts and actionable results on Ultra and Xpert 
SMOR reads per locus 
When SMOR reads per loci were compared for each patient from Ultra-positive CEs, the 
median (IQR) reads were, from highest to lowest, rpoB: 19317 (210-27078), gyrA: 33 (4-2008), 
katG: 31 (5-3270), inhA: 9 (3-32), rrs: 3 (1-180), eis: 1 (1-96) (Table 1, which also includes 
SMOR read counts on Xpert CE). Significant differences were seen between loci (Figures 2A 
and 2B. Ultra had significantly less reads for inhA, katG, gyrA, eis and rrs than SMOR on Xpert 
CEs (Table 1). 
SMOR reads as a function of bacillary load (CTmin) 
SMOR reads on Ultra CE did not correlate with bacillary load (Figure 3A), suggesting 
interference. SMOR on Xpert CE showed a significant positive correlation with CTmin increase 
[Spearman’s rank correlation coefficient: r (CI 95%) = -0.6 (-0.7 – 0.3); p=0.001) with the 
exception of 4 samples that had non-actionable results at lower CTmin values (Figure 3B).  
Actionable vs non-actionable results 
Ultra had overall less actionable results compared to Xpert [13/49 (27%) vs 27/50 (54%); 
p=0.005]. Per loci, SMOR on Ultra CE had significantly less actionable results for gyrA, eis 
and rrs compared to Xpert CE (Figure 4A, Table 1). Non-actionable results were found across 
all semi-quantitations. All actionable results corresponded to “high” and “medium” semi-
quantitations (and one “Trace” result). A CTmin threshold at which SMOR on Ultra CE would 
be actionable was defined to be < 17.45 (high semi-quantitation) with sensitivities and 
specificities of 77% and 97% respectively (Figure 3A).  
Xpert CEs had SMOR actionable results for and non-actionable for 23/50 (46%) (Figure 4C). 
All SMOR non-actionable results corresponded to the “medium”, “low” and “very low” Xpert 
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semi-quantitations (with the exception of one being a “high” semi-quantitation). Actionable 
results had mostly “high” and “medium” results and three “low” results. A CTmin threshold at 
which SMOR on Xpert CE would be actionable vs non-actionable was defined to be < 23.25 
(“low” semi-quantitation) with sensitivities and specificities of 88.9% and 73.9% respectively 
(Figure 4D).  
SMOR resistance detection on CE 
Standard DST results 
Of the 49 Ultra CEs, 32 were rifampicin-susceptible and 17 were rifampicin-resistant. Of the 
32 rifampicin-susceptible samples, 8 (25%) had pDST data for rifampicin and isoniazid only 
and 16/32 (50%) had pDST data for rifampicin and isoniazid, fluoroquinolones (FQs) and 
second-line injectables (SLIDs). Of the rifampicin-resistant samples, 17/17 (100%) pDST and 
LPA data was collected (Figure 1A). 
Of the 50 Xpert CE samples, 27 were rifampicin-susceptible and 23 were rifampicin-resistant. 
Of the 27 rifampicin-susceptible samples, only 10 (37%) had pDST data for rifampicin and 
isoniazid. Of the rifampicin-resistant samples, 19/23 (83%) and 23/23 (100%) had pDST and 
LPA results for rifampicin, isoniazid, FQs and SLIDs respectively (Figure 1B). Results below 
only include results for which there were DST data (pDST or LPA) available. 
Rifampicin (Figure 5; Table 2) 
Of the SMOR on Ultra CE rifampicin results for which there was DST data, 24/43 (56%) were 
concordant and 20/44 (45%) were discordant. Interestingly, one Ultra rifampicin-resistant 
discordant result was a false-positive rifampicin-resistant result (CX404), as both pDST and 
LPAs indicated rifampicin-susceptibility, while SMOR detected various single nucleotide 
polymorphisms (SNPs) <1%, as well as 74% of the H526N and 24% of the L511P SNPs. 
Follow-up data from routine diagnostics done at a later time point as part of the national 
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algorithm indicated this patient was found to have a heteroresistant infection using standard 
LPA methods (this patient was also isoniazid-susceptible by SMOR but resistant using standard 
DST methods).  
Most discordant rifampicin results corresponded to the rifampicin-susceptible Ultra CEs and 
were detected as either low-heteroresistant (LHR, < 1%) or heteroresistant (HR, < 10%) by 
SMOR (Figure 5), giving sensitivities and specificities of 94% and 30% respectively (Table 2). 
If a stricter threshold for SMOR-resistance call is defined as > 1% proportion of total reads 
with resistance markers (i.e. HR or R calls only), the numbers would change to 34/43 (79%) 
concordant and 9/44 (21%) discordant (p=0.0001) with sensitivities and specificities of 94% 
and 66% respectively. Similarly for SMOR on Xpert CE, 27/48 (56%) were concordant with a 
sensitivity and specificity of 94% and 21% respectively and if the > 1% criteria were applied 
these would change to 94% and 66% respectively (p=0.0001). 
Isoniazid 
SMOR targeting inhA-promoter and katG had 17/49 (37%) actionable results with DST data 
for Ultra CE. Of these 15/17 (88%) were concordant with pDST and/or LPA results and 2/17 
(12%) were discordant [one was false-resistant (high semi-quantitation)] and one false-
susceptible [(medium semi-quantitation, this patient was later diagnosed with heteroresistant 
infection as mentioned above)] resulting in a specificity of 94%. Of the 13 isoniazid-resistant 
samples detected by pDST and/or LPA, none were actionable and so sensitivity could not be 
determined. 
Of the Xpert TB-positive CEs with available DST data, 23/30 (77%) were actionable for 
isoniazid. Of these, SMOR was concordant with 21/23 (91%) of samples and discordant with 
2/23 (9%) (both were false-positives with “low” and “very-low” semi-quantitation 
respectively) resulting in sensitivities and specificities of 100% and 78% respectively. 




Of the SMOR on Ultra CE actionable results with pDST or LPA data collected 15/35 (43%) 
were actionable and all were found to be concordant. As none of these were resistant, 
sensitivities could not be calculated but specificity was 100% (15/15).  
There were 18/23 (78%) results that were actionable for FQs on Xpert CE and had DST data 
available. Of these, SMOR was concordant with 16/18 (89%). SMOR detected false-resistance 
in for 2/18 (11%) of the CEs where the LPA was susceptible (one was low and one medium 
semi-quantitation). Of the two discordant samples one was LHR, and so if the threshold for 
SMOR-resistance call is applied these number change to 17/18 (94%) concordance. The one 
Xpert CE sample that was FQ resistant according to LPAs was SMOR non-actionable and so 
sensitivities could not be calculated, specificity was 89% (16/18) (unchanged when stricter 
criteria was applied). 
Second-line injectables 
SMOR targeting rrs and eis-promoter had 12/36 (33%) actionable results with DST data 
available of which 11/12 (92%) were concordant (one had LHR detected for capreomycin by 
SMOR but was susceptible for amikacin and kanamycin; high semi-quantitation). Again 
sensitivity could not be calculated but specificities were 92% (11/12) and 100% (12/12) 
respectively for < 1% and >1% SMOR-resistance call threshold categories respectively. 
SMOR for SLIDS on Xpert CE had 20/23 (87%) actionable results with DST data available. 
Of these 18/20 (90%) were concordant and 2/20 (10%) were discordant [one false positive (low 
semi-quantitation) and one false negative (very low semi-quantitation)]. The false-positive 
result was classified as heteroresistant by SMOR with 1.89% of the population showing a 
mutation in G1484T rrs mutation. The false-susceptible result was detected for a patient who 
had XDR-TB infection (as classified by national algorithm). The semi-quantitation was very 
low (CTmin = 31.9) which is likely the reason for discordance. 
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Whole genome (shotgun) sequencing on Ultra cartridge extracts 
Whole genome shotgun sequencing (WGS) revealed Xpert CE had large amounts of rpoB 
amplicons as expected. Ultra CE, in addition to rpoB amplicons, had the presence of 
IS6110/1081 amplicons as well as pncA amplicons (Figure 4). Notably there were 5 different 
IS6110 amplicon sizes.   
ThermoGo and ThermoStop on cartridge extract 
The combination of ThermoGo and ThermoStop did not significantly improve the total number 
of actionable results. It did, however, improve the number of reads in some samples regardless 
of semi-quantitation or CTmin value. The total number of reads were only significantly improved 
for rpoB Xpert CE (100%, p= 0.002) and Ultra CE rpoB and rrs (94% and 76% respectively; 





We have previously shown that genomic DST could be done on Xpert CE. We have now shown 
that targeted deep sequencing is 1) feasible on Xpert CE at a similar CTmin that was previously 
defined (at least medium semi-quantitation), 2) that it was also feasible on Ultra CE but had 
more non-actionable results and only actionable at low CTmin (high bacillary load), 3) WGS 
revealed that in addition to interfering rpoB amplicons, Ultra CE also contained various other 
amplicons that potentially confound SMOR, and 4) SMOR detected heteroresistance missed 
by conventional tests and had good specificities for resistance detection making it a good rule-
in test. 
As hetero-resistance is becoming a growing concern, new tools for detection of underlying sub-
populations of resistant infections that may be missed by conventional molecular tests is 
needed. Targeted deep sequencing methods such as SMOR allows for detection of 
heteroresistance <1% which would be useful in a per-patient diagnostic approach, especially 
in cases where patients have had previous TB and may be failing treatment or have relapsed. 
Often it is difficult to collect more than one sputum for patient or to wait for culture to become 
positive therefore it would be very convenient to sequence straight from CE. We have shown 
that it is possible to do SMOR on Xpert CE at a similar CTmin that was defined previously for 
molecular tests, and can be used to rule-out samples on which SMOR in unlikely to work.  
While SMOR did detect resistance missed by conventional tests, most fell above defined CTmin 
threshold. Further investigations should be done to determine the clinical relevance of the 
findings. While sensitivities could not be calculated for certain resistance conferring loci, non-
rpoB specificities were good and indicates that SMOR could be used as a rule-in test and when  
susceptible results are obtained, the same procedure for LPAs as outlined by national 
algorithms is followed. Given the high proportion of false-resistant rpoB results, likely due to 
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amplicon interference from tests, it is suggested that rifampicin results from SMOR not be 
taken as actionable.  
SMOR on Ultra CE worked less well, although high sensitivities and specificities were 
detected, the cut-off threshold category for which SMOR on Ultra would be actionable was 
17.45 (high semi-quantitation) and is not representative of results in most clinical settings.  
WGS revealed that in addition to the rpoB amplicons, Ultra CE had pncA, IS6110 and IS1081 
amplicons as well which maybe be causing additional interference in the sequencing. 
Curiously, the total read counts for rpoB were still higher than the multi-copy IS610/1081 
amplicons.  This could be due to various reasons such as unforeseen dynamic with the 
spreading of IS6110 primers across multiple sites, that there are multiple degenerate primer 
sites with minor variations in the IS6110 target regions thereby decreasing amplification 
efficiency, that this sample behaved differently because it had a very high TB load or could 
also be that the rpoB primers are amplifying something in addition to Mtb. The addition of 
ThermoStop and ThermoGo did not improve reads in a predictive way other than for rpoB and 
this might once again only be due to large amounts of rpoB-amplicons in the CE. 
The results of this preliminary study should be interpreted within the context of the limitations. 
We only had one Xpert CE sample with known FQ or SLID resistance to compare SMOR 
resistance detection to, for which SMOR was non-actionable. While we did have follow-up 
data for some patients, this was not the main aim of the study and further investigations to the 
clinical relevance detected by SMOR should be done. Further optimisation for SMOR CE 
should also be done, this will include reducing or removing the interfering amplicons34. 
This study shows promise for future testing for low level drug-resistance using one sample per 
patient which can be used to inform per patient treatment, especially for patients that have had 




Figure 1: Flow-diagram of sample collection for [A] Ultra and [B] Xpert cartridges. Cartridges 
were either collected as part of programmatic testing for the national algorithm or as part of 
several ongoing studies at Stellenbosch University (SU), South Africa. Cartridge extract was 
recovered from all collected cartridges and was used for Single Molecule Overlapping Read 
(SMOR) analysis. As per the national algorithm, all samples that are Ultra or Xpert rifampicin-
resistant get follow up DST with LPA testing for first and second-line drugs (MTBDRplus, 
MTBDRsl; grey dashed-arrows). All resistant isolates collected and sent to SU were used for 
pDST as part of ongoing studies (rifampicin, isoniazid, ofloxacin, amikacin and pyrazinamide). 
Ultra and Xpert rifampicin-susceptible cartridges were collected where possible as part of other 
ongoing studies and used for subsequent pDST (either for rifampicin and isoniazid, or for 
rifampicin, isoniazid, ofloxacin, kanamycin, amikacin and pyrazinamide) where possible. 
SMOR, LPA results and pDST results (grey boxes, grey arrows) were compared. 
Abbreviations: NHLS – National Health Laboratory Service, CE – cartridge extract, R – 
resistant, S – susceptible, RIF – rifampicin, INH – isoniazid, OFX – ofloxacin, AMK – 
amikacin, KAN – kanamycin, PZN – pyrazinamide, pDST – phenotypic drug susceptibility 
testing, LPA – line probe assay (MTBDRplus, MTBDRsl). 
Figure 2: Total reads across all patients and all loci (rpoB, inhA, katG, gyrA, eis, rrs) detected 
by SMOR vs CTmin per loci for [A] Ultra and [B] Xpert cartridge extract. Total reads shows 
trend of declining with increase in CTmin (i.e. decrease in bacillary load), this occurs more 
rapidly for SMOR on Ultra than for Xpert (with the exception of 4 samples). p-values indicate 
Spearman’s correlation coefficient. Dotted lines represent 95% CI. 
Figure 3: Total reads detected by SMOR per loci (rpoB, inhA, katG, gyrA, eis, rrs) for [A] 
Ultra and [B] Xpert cartridge extracts. Similar results were seen for all loci (except rpoB) but 
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significant differences were seen between loci. **** p-value <0.0001, *** p-value <0.001, ** 
p=< 0.01, * p=<0.05. 
Figure 4: [A] SMOR on Ultra CE had actionable results for 13/49 (27%) of results and 
36/49 (73%) non-actionable results (p=0.001) All of the actionable results had “high” or 
“medium” semi-quantitation categories (and one “Trace”). Non-actionable span across all 
semi-quantitation categories. [B] rpoB CTmin threshold of < 17.45 (Youden’s index) was 
determined for when SMOR on Ultra would yield actionable results with a sensitivity and 
specificity of 76.9% [IQR (%): 50.5-93.4] and 97.2% [IQR (%): 87.5 - 99.9] respectively. This 
corresponds to the “high” semi-quantitation result. [C] SMOR on Xpert CE had actionable 
results for 27/50 (55%) of results and 23/50 (45%) non-actionable results (p=0.42) with a 
majority of the actionable results corresponding to “medium” and “high” semi-quantitation 
categories. [D] A CTmin threshold of < 23.25 SMOR on Xpert was determined to yield 
actionable results with a sensitivity and specificity of 88.9% [IQR (%): 73.7-96.9] and 73.9% 
[IQR (%): 54.9 – 88] respectively. This corresponds at least a “medium” and some “low” semi-
quantitation results. Overall SMOR on Ultra CE had significantly less actionable results than 
Xpert CE (p=0.005). Dotted lines represent 95% CI. Abbreviations: SMOR – single molecule 
overlapping reads, CE – cartridge extract, CTmin – minimum cycle threshold value , AUC – area 
under the curve, PPV – positive predictive value, NPV – negative predictive value. 
Figure 5: SMOR on Ultra CE had more non-actionable results for Ultra (p=0.005). There were 
several non-rpoB discordant results [9/99 (10%); 3/49 (6%) and 6/50 (12%) for Ultra and Xpert 
respectively; black circles] where SMOR detected resistance but conventional DST missed and 
one instance [1/99 (1%)] where SMOR was susceptible but conventional DST were resistant 
(very low semi-quantitation). Corresponding semi-quantitations can be seen next to discordant 
results. SMOR results per patient shown as either low heteroresistant (LHR; light pink squares), 
heteroresistant (HR; dark pink squares), resistant (R; red squares), susceptible, (S, green 
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squares) or non-actionable (grey squares). Concordance (hollow circle) or discordance (solid 
black circle) with either pDST and/or LPA results as reference (or only Xpert-rifampicin results 
as reference for XX700-XX726) for Ultra and Xpert CE are shown across both 
rifampicin-resistant –and -susceptible results. Asterix marks cases with special circumstances 
– CX404 was Ultra and SMOR rifampicin-resistant but LPA -and pDST-susceptible as well as 
SMOR isoniazid-susceptible but LPA -and pDST-resistant, results done on specimens 
collected later as part of national algorithm indicated the patient had a heteroresistant infection. 
XX927 was Xpert rifampicin-susceptible but resistant on LPA and pDST, SMOR detected the 
presence of a 24% HR population for this patient. There were some patients where LPA and 
pDST data were unavailable or inconclusive (black cross). Abbreviations: RIF – rifampicin, 
INH – isoniazid, FQ – fluoroquinolones, SLID – second-line injectables, pDST – phenotypic 
drug susceptibility testing, LPA – line probe assay (MTBDRplus, MTBDRsl), CE – cartridge 
extract, H – high, M – medium, VL – very low semi-quantitation. 
Figure 6: Results of whole genome sequencing on [A] Ultra cartridge extract which revealed 
mainly rpoB amplicons as well as pncA, IS6110 and IS1081 amplicons. Notably there were 5 


























Table 1: Total SMOR reads per loci on CE and the proportion of results for which SMOR gave 
an actionable result (≥ 10 reads, and > 0.1% resistance detected) for Ultra and Xpert (Ultra and 
Xpert not done on same patient sputa). Xpert had higher reads than Ultra for all loci except 
rpoB and Xpert had overall a higher proportion of actionable SMOR results than Ultra (this 
was driven by additional actionable results predominantly in the gyrA, eis and rrs loci). P-
values represent Mann Whitney test (for total reads per loci between Ultra and Xpert) and test 
of proportions (for proportion actionable reads between Ultra and Xpert).
 Total reads (median, IQR) 



























p-value 0.20 0.0001 0.005 0.0005 0.0004 0.0001 
 Total proportion actionable reads 
Ultra 46/49 (93%) 22/49 (45%) 33/49 (67%) 29/49 (59%) 16/49 (32%) 20/49 (40%) 
Xpert 48/50 (96%) 36/50 (72%) 41/50 (82%) 40/50 (80%) 28/50 (56%) 41/50 (82%) 
p-value 0.62 0.09 0.42 0.02 0.02 0.0001 
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Table 2: Results for which SMOR on CE was concordant and discordant for samples for which DST (either phenotypic or LPA) results were 
available and sensitivity and specificity of SMOR based on DSTs as reference standard. Data is shown [% (N/N)] for when “true” resistance is 
classified as including < 1% resistance and >1 % resistance detected. Certain sensitivities could not be calculated as true resistant samples were 
either non-actionable or, in one case, detected as susceptible by SMOR. SMOR was mainly concordant on all non-rpoB loci resulting in strong 
specificities for both Ultra and Xpert, making it a candidate for a rule-in test. 
 Resistance  < 1%  Resistance  > 1% 
 RIF INH FQ SLID  RIF INH FQ SLID 
Ultra CE 





















94 (16/17) 0 (0/1) - -  94 (16/17) 0 (0/1) - - 
30 (8/27) 94 (15/16) 100 (15/15) 11/12 (92)  66 (18/27) 94 (15/16) 100 (15/15 ) 100 (12/12) 
Xpert CE 





















96 (23/24) 100 (4/14) - 0 (0/1)  96 (23/24) 100 (4/14) - 0 (0/1) 




Table 3: Effects of ThermoStop (TS) and ThermoGo (TG) on total reads (actionable and non-actionable) of SMOR on Ultra and Xpert CEs. The 
total amount of actionable reads did not improve with addition of TS and TG. However, reads improved overall for some samples. Significant 
differences were only seen for rpoB in both Ultra and Xpert CE as well as rrs in Ultra CE. P-values represent test of proportions (SMOR actionable 




   
 Ultra  Xpert 
 rpoB inhA katG gyrA eis rrs  rpoB inhA katG gyrA eis rrs 
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Background: Methods to monitor drug-resistant TB treatment response, such as culture are 
slow and do not detect differentially culturable TB bacilli (DCTB) which are present in a 
dormancy-associated state. Furthermore, molecular methods are confounded by presence of 
DNA from dead bacilli which can lead to false positives. New methods, which include the use 
of exponential cell free extract (EPCFE) allow for detection of DCTB, or that render 
mycobacterial DNA from non-live cells non-amplifiable (which can improve the specificity of 
PCR tests), require evaluation.  
Methods: Patients in a drug trial receiving the then-stand-of-care multi-drug resistant (MDR-) 
TB regimen or a shorter regimen were longitudinally-sampled. Sputum smear microscopy, 
MGIT960, the most probable number (MPN) assay (containing EPCFE or 7H9 broth and 
quantifies bacterial load) were each done (367 time points, 43 patients). Standard Xpert 
MTB/RIF (Xpert) and a modified viable PCR (vPCR) Xpert with a photoactive dye to reduce 
the amplification of DNA from non-intact cells were done (182 time points, 20 patients. 
Results: MPN assay with added EPCFE detected more bacilli overall in both arms (but not 
between arms). Furthermore, MPN assay with EPCFE detected 14/47 (30%) and 9/41 (22%) 
positive patients in the routine and intervention arms respectively (missed by 7H9-negative). 
A subset of these patients were also missed by MGIT960 sputum culture [10/14 (71%) and 5/9 
(55%) for each arm] and Xpert [2/8 (25%) and 2/6 (33%) for each arm; some Xpert results 
non-actionable]. MGIT960s was negative beyond week 24 but MPN had positive results at 
later time points, both with and without EPCE supplementation. Compared to culture and 




Conclusion:  EPCFE supplementation enables DCTB detection missed by other methods. The 
clinical importance of these populations requires clarification. The dye-based approach does 




Tuberculosis (TB) is the biggest infectious cause of death worldwide1.  Globally, the total 
incidence of drug-resistant TB is 558 000 and the treatment success rate for multi-drug resistant 
(MDR-) TB is 55% [34% for extensively-drug resistant (XDR-) TB],  yet in some countries it 
is as low as 32%2,3. Poor treatment outcomes have been reported globally and are due to many 
factors, including HIV-coinfection as well as lengthy and ineffective treatment regimens4-10. It 
is therefore imperative to have accurate tools for monitoring treatment response to ensure 
patients remain on effective treatment, and reduce the chance of treatment failure and 
transmission from patients on treatment. New regimens for MDR-TB are desperately needed. 
The current standard for treatment monitoring include sputum culture and smear, which are 
either slow or have relatively poor sensitivity and specificity for predicting treatment 
failure11,12. Culture can take up to 42 days for a result to be generated and is further confounded 
by the fact that there exists a sub-population of bacteria not culturable by conventional 
methods13-15.  
The proportion of differentially culturable tubercle bacilli (DCTB) has been found to increase 
through treatment. These bacilli are drug tolerant and detecting them is a challenge that  
requires modified culture methods13,16. Such methods may utilize exponential phase cell free 
extract (EPCFE) [which contains resuscitation promoting factors (RPFs) and other rescue 
proteins] to encourage DCTB growth13,16. These methods often have, as a readout, the Most 
Probable Number (MPN). The MPN assay is a common microbiological technique that is used 
to estimate the concentration of viable bacilli in a sample. This is done via a dilution series 
(which is done in replicate) and growth in each dilution is scored and used to back-calculate 
the total bacteria in the starter sample17. The MPN method can therefore be used to measure 
the culturability of different media against one another, for example to see if more bacilli are 
quantifiable in EPCFE supplemented broth versus standard 7H9 broth. 
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Xpert MTB/RIF (Xpert; Cepheid) is a nucleic acid amplification test (NAAT) and is endorsed 
by the World Health Organization (WHO). However, it is not currently recommended for this 
purpose as false-positive results may be obtained from DNA from non-viable bacilli which 
accumulate due to the bactericidal effects of the TB drugs18-21. This was demonstrated by 
Friedrich et al, where for example, at week 8 on treatment, culture had between 26%-42% 
positive results where Xpert had 84% positive results18. Novel, photoactive dyes such as 
propidium monoazide (PMA) and ethidium monoazide (EMA) have been used previously in a 
technique called viable PCR (vPCR) and was shown to intercalate with free DNA or DNA in 
non-intact cells through covalent bonds. This blocks DNA from being amplified22-27. When 
used in conjunction with Xpert, such techniques may improve diagnostic accuracy for 
treatment monitoring. Specifically, a novel double dye, PEMAX (produced by GenIUL, Spain) 
to overcome limitations of PMA and EMA such the inability to bind DNA from cells that are 
still intact but no longer metabolically active, may also improve specificity.  
We therefore aimed to do a preliminary investigation to improve these two conventional 




Study design and ethics 
Methods and protocols were carried out in accordance with relevant guidelines and regulations. 
The study was approved by the Health Research Ethics Committee of Stellenbosch University 
(M15/10/041).  
Parent study 
This study was nested within a funded clinical drug trial (NExT; Clinicaltrials.gov 
#NCT02454205) which evaluated a new multi-drug resistant MDR-TB regimen containing 
bedaquiline and linezolid (intervention arm; 6 month regimen) compared to the standard 
MDR-TB treatment (standard treatment arm containing fluoroquinolones and second-line 
injectables; 24 month regimen). All persons who were eligible for the Cape Town arm of the 
NExT study were also asked to participate in this study. Eligible persons were recruited from 
the Western Cape, South Africa from November 2015 to December 2018 (Table S1). NExT 
patients were followed up through treatment and post-treatment (Figure 1A). Three sputa were 
collected over the course of 48 hours and randomly used for culture and smear, MPN assay 
(both with EPCFE and standard 7H9) and Xpert (both vPCR-Xpert and standard Xpert) (Figure 
1B). 
Sputum processing 
Culture and smear 
Sputa were decontaminated using the N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) 
method using the commercial kit MycoPrep (BD Biosciences, United States). Briefly, an equal 
volume of NALC-NaOH (0.5 M NaOH, 0.37 g/L N-acetyl-L-cysteine and 0.05 M trisodium 
citrate dehydrate) was added to the sample and vortexed, after a 15 min incubation at room 
temperature (RT), specimens were neutralized with phosphate buffer (PB) (33 mM Na2HPO4, 
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33 mM KH2PO4; pH 6.8) and centrifuged at maximum speed (4000 x g) for 15 min at RT. The 
pellets were resuspended in 1.5 ml PB, 500 µl was used for liquid culture inoculation using the 
MGIT 960 system (BD Biosciences) supplemented with 800 µl PANTA (containing an 
antibiotic mixture of polymyxin B, amphotericin B, nalidixic acid, trimethoprim and azlocillin; 
BD Biosciences). After 30µl was used for smear microscopy using Ziehl-Neelsen staining 
technique (ZN; acid fast stain), the rest of the specimen was biobanked at -20°C.  
Most probable number assay 
Sputa were decontaminated as described above. EPCFE was made as described 13. Briefly, 
frozen stocks of 1 ml exponential phase culture (H37Rv, OD600 0.6-0.8) were inoculated into 
7H9 Middlebrook broth (BD Biosciences) and cultured to mid-exponential phase (OD600 0.6-
0.8). The liquid culture was centrifuged for 20 min at maximum speed (4000 x g) at RT and 
the supernatant was sterilized by passing it through 0.22 µm PES syringe filters twice. The 
EPCFE was supplemented in 1:1 ratio with fresh 7H9 liquid broth (7H9) and PANTA. The 
EPCFE mixture and fresh 7H9 with PANTA only was aliquoted into 48 well plates (Nunc, 
Thermo Fischer) (450 µl, three replicates rows each). A serial dilution was created across the 
plate using 50 µl of decontaminated sputa (Figure 2). Colony forming units were also counted 
by plating 100 µl decontaminated sputum onto 7H11 Middlebrook agar plates (BD 
Biosciences). The number of bacteria recovered from the MPN assay was determined as 
previously described13. 
Contamination controls were done by incubating 1 ml liquid aliquots of both the EPCFE 
mixture and the 7H9 + PANTA, as well as plating these on 7H11 agar plates and incubating 
them for 8 weeks at 37°C. Potential growth from the MPN assay was confirmed by plating any 
growth on blood agar as well checking for acid fast bacilli through smear microscopy of each 
positive well as described above (Figure S1). 
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Viable PCR using PEMAX dye 
Sputa was collected for n=20 of the patients (n=10 routine, n=10 intervention) over the course 
of treatment (182 time points). Sputa were decontaminated as above with the exception that 
2.7 % NALC and 0.5% trisodium citrate was used for decontamination as described previously 
24 and the pellet was resuspended in 2 ml PB. Samples were prepared for testing using the 
PEMAX reagent monodose (GenIUL, Spain) by aliquoting 500 µl each into a control tube (no 
PEMAX) and a tube containing the PEMAX dye (50nM). These were then mixed via pipetting 
and incubated at 37°C in the dark prior to photo-activation using the PhAST Blue system (15 
min, 100%) (GenIUL, Spain). Xpert sample reagent (SR) was then added to the tubes to a total 
of 2 ml, incubated for 15 min at RT and tested with Xpert as per manufacturer’s instructions.  
Statistical analysis 
Data were analysed using GraphPad Prism (version 8.0.1). The D'Agostino & Pearson 
normality test was used to determine distribution of data and all paired analysis was done using 
the Wilcoxon matched-pairs signed rank t-test. Comparisons of results across arms were done 
using the Mann Whitney t-test. Comparisons of proportions were calculated using Stata 






There were 21 patients enrolled in the routine treatment arm and 22 in the intervention arm of 
the parent study. There were no significant differences in number of unfavourable outcomes 
between treatment arms (p=0.39). Of the 21 patients enrolled on the routine treatment arm, 
7/21 (33%) had unfavourable outcomes [1/7 (14%) lost to follow up, 2/7 (29%) failed 
treatment, 4/7 (57%) were lost to follow-up]. Of the patients enrolled on the intervention arm 
5/22 (23%) had unfavourable outcomes [1/5 (20%) failed treatment, 3/5 (60%) were loss to 
follow-up and 1/5 (20%) died – cause of death was TB meningitis]. A detailed report of the 
parent study’s clinical outcomes is under preparation by the NExT study leads. 
Routine microbiology 
Smear and culture  
At week 0, in the routine arm, 9/20 (45%) and 11/21 (52%) of patients were smear (ZN) and 
culture-positive respectively (Table 1). This declined through treatment with most patients 
converting to negative by week 10 of treatment [2/13 (15 %; p=0.07) and 3/17 (18%; p=0.02) 
smear and culture respectively] (Figure 3A). All patients were smear and culture negative after 
week 16 of treatment. In the intervention arm, 8/21 (38%) and 17/22 (77%) of patients were 
smear and culture-positive at week 0 (Table 1). This declined steadily: at week 10 having 2/21 
(10%; p=0.02) smear positivity and 2/22 (5%; p=0.0001) culture positivity smear and culture 
positivity respectively with all patients converting to negative results after week 16 (Figure 
3B). There were no significant differences seen in the proportion of positive tests throughout 
treatment between arms (Table 1). 
Xpert MTB/RIF 
Xpert results had a higher proportion of positive results, especially later into treatment, 
compared to smear and culture. For example at week 0, culture positivity was 12/21 (57%) and 
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18/22 (77%) for routine and intervention arms respectively, while Xpert was 8/10 (80%) and 
6/10 (60%) and at week 8 culture positivity was 5/16 (31%) and 4/20 (20%) respectively and 
Xpert was 68 (75%; p=0.04) and 7/9 (78%; p=0.003) respectively. Xpert-positive results at 
week 0 were 8/10 (80%) and 6/10 (60%) for the routine and intervention arm, respectively 
(Table 1, Figure 3). This remained stable until week 10 where it declined to 4/8 (50%) in the 
routine arm and converted to negative results after week 40 (Figure 3A). In the intervention 
arm, the proportion of positive tests stayed similar until week 24 with 1/9 (11%) being positive 
after which all convert to negative results (Figure 3B). 
Novel methods for treatment monitoring 
Most Probable Number (MPN) Assay 
There was no significant difference in the proportion of positive patients between routine arm 
and intervention arm for the first 24 weeks since treatment initiation (Table 1), nor between the 
MPN readouts with 7H9+PANTA (7H9 MPN) or the modified MPN assay with added EPCFE 
(EPCFE MPN) within each arm. With the exception of week 0 for both arms [median (IQR) 
MPN number: 1.8 (0.0-5.6) vs 3.5 (1.9-4.3) for 7H9 vs. EPCFE; p=0.005 for routine arm, and 
3.3 (1.3–7.9) vs. 4.8 (2.8-8.4); p=0.04 for intervention arm], and week 1 of routine arm [3.5 
(1.4-8.3) vs. 3.9 (1.4-8.7); p=0.03] suggesting a mixed-population of DCTB and culturable 
bacilli prior to week 0. 
Routine arm: Across time points, the routine arm had 33/200 (17%) positive results for the 7H9 
MPN assay and 46/200 (23%) positive EPCFE MPN assay results (p=0.11) respectively. There 
were 6/20 (30%) positive results at week 0 for the 7H9 MPN assay and 11/20 (55%; p=0.11) 
for the EPFCE-MPN assay and time to negativity was longer than for standard culture and 
smear, where positivity was still seen up to week 40 (Figure 4A). At week 24, 1/13 (8%) were 
positive for EPCFE only. There were 3 cases of MPN positives late into treatment at week 40 
where 2/8 (25%) were EPCFE-positive and 1/8 (13%) 7H9-positive, and at week 84 where 1/4 
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(25%) were EPCFE -and 7H9-positive (Figure 5A, S2). These were all negative by 
conventional methods (smear and culture).  
Intervention arm: The intervention arm had 34/178 (19%) and 44/178 (25%) were positive 
results for 7H9 MPN and EPCFE MPN (p=0.24) respectively across the time points. There 
were 6/19 (32%) and 8/19 (42%;p=0.50) patients positive at week 0 for the 7H9- and EPCFE 
MPN assay respectively which declined steadily through treatment. EPCFE had a slightly 
higher proportion of positive results than 7H9 MPN and MGIT 960 after week 6 (Figure 3A 
and B). At week 24 (the final week of treatment in the intervention arm) there were 1/17 (6%) 
positive for the EPCFE MPN assay only (Figure 5B). An additional specimen was collected 
for one of the patients at week 26, as they were showing clinical signs of treatment failure, and 
this was positive for both 7H9 and EPCFE MPN assays (Figure 5B, S1).   
Patients MPN-positive in both arms and negative by conventional diagnostics 
There were several instances across all time points [14/47 (30%) and 9/41 (22%) (p=0.40), for 
routine and intervention arms respectively], where only EPFCE detected positive growth and 
was missed by 7H9 MPN methods. Of these 10/14 (71%) and 5/9 (56%) were missed by 
MGIT960 sputum culture (Figure 5A and B) and, 2/8 (25%) and 2/6 (33%) were also missed 
by Xpert (and vPCR-Xpert; some Xpert data were not available). Furthermore, even though 
there were no significant differences seen between total bacilli quantified with either EPCFE 
and 7H9 MPN for most time points, ΔlogMPN data across all time points shows that EPFCE-
positive samples contained more total bacilli than those detected by 7H9 MPN methods for 
both routine [median (IQR): 1.9 (1.4-3.9) vs. 1.6 (0.0-2.8) for EPCFE and 7H9 MPN 
respectively; p=0.0001] and interventions arms [2.4 (1.7-4.6) vs. 1.7 (0.8-3.4) for EPCFE and 
7H9 MPN respectively; p=0.0001] (though no significance differences where seen between 
arms for either MPN method) (Figure 6A and B).  
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Viable PCR - modified nucleic acid amplification testing 
Routine arm: Of the patients that had vPCR results, the routine arm had 8/10 (80%) and 9/10 
(90%) positive results for standard Xpert and modified vPCR-Xpert at week 0 respectively 
(Figure 4A, Table 1). At week 40, 1/5 (20%) of patients were positive for Xpert and 0/5 (0%) 
for the vPCR Xpert, suggesting possible false-positive Xpert result, however similar results 
were seen at week 1 and 24 (all of which had “very low” semi-quantitation results), which may 
be due to variable sampling and sensitivity of Xpert at low bacillary load. After W65 all patients 
were negative (Figure 4A). Rates of vPCR-Xpert positivity were similar to Xpert and both had 
higher proportion positive results compared culture methods (Figure 4A, S3). The differences 
between CTmin values (ΔCTmin) did not differ significantly between Xpert and vPCR-Xpert 
throughout treatment (Figure 7A). 
Intervention arm: There were 6/10 (60%) and 8/10 (80%) positive for Xpert and vPCR-Xpert 
respectively at week 0 (Table 1). At week 24, 1/9 (11%) and 2/9 (22%) were positive for Xpert 
and vPCR-Xpert respectively (Figure 4B). An equal number (four) of patients were positive 
only for Xpert or vPCR throughout treatment (all but one had “very low” semi-quantitation, 
data not shown). As with the routine arm, ΔCTmin values did not differ significantly between 
Xpert and vPCR-Xpert throughout treatment (Figure 7B) except at week 1 [median (IQR): 18.4 
(17.1-23.4) vs. 17.0 (14.1-21.2); p=0.02] and at week 4 [22.7 (21.4-27.6) vs. 19.0 (16.8-24.7); 
p=0.02] of treatment, which may be due to sample size. All patients for which we had follow 




Previous studies have shown that modifying current, widely available diagnostics may be 
useful to increase their treatment monitoring potential. In this study, we looked at improving 
both standard culture and Xpert testing. Our key findings are: 1) including exponential phase 
cell-free extract to increase detection of differentially culturable bacteria did identify positive 
growth that standard culture (and Xpert) missed throughout treatment, 2) when positive for 
both standard 7H9 MPN and EPCFE MPN there were significantly more quantifiable bacilli 
detected with the EPCFE method, thus indicating DCTB are present through MDR-TB 
treatment, and 3) including a PMA/EMA (PEMAX) dye to sputa for Xpert testing did not 
significantly improve results.  
While previous studies have shown that DCTB can be found in large numbers through 
treatment, including late in treatment, when cultured in the presence of EPCFE or RPFs 13,16, 
we found that although there were patients positive through treatment, the numbers were 
smaller than previously reported 13,14. Though there were both differentially culturable -and 
standard culturable bacilli present in most positive samples, a larger percentage was detected 
using the EPFCE culture method, indicating that there are indeed DCTB present through MDR-
TB treatment. Furthermore, there were several instances where the sample was only culture-
positive using the EPFCE method and these patients would have been missed by standard 
culture otherwise. Of these, for which we had results, EPCFE detected 25% and 33%, as well 
as 71% and 55% for the routine and intervention arms respectively, which was missed by both 
Xpert and MGIT960 sputum culture. However, even if there were Xpert-positive results for 
those detected only by EPCFE (and culture negative), these results should be queried as they 
may be picking up DNA from dead cells due to TB treatment.  
Previous studies have highlighted the fact that the addition of a dye such as PMA or EMA may 
reduce the detection of non-viable bacilli 22,24,25, including increasing specificity for TB 
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detection of viable bacilli using the Xpert MTB/RIF assay 27. In this cohort we found that while 
there were differences between the CTmin values, these were not significant, including later into 
treatment, and while there were some patients that had positive results for standard Xpert only 
and not the vPCR, the converse is also true. We suspect this is due to several factors, one being 
that the microbiome in sputa likely interferes with the ability of the dye to bind to the TB 
bacteria that are present at lower numbers and that the mycobacterium cell wall is much harder 
to penetrate than other bacteria due to the mycolic lipid layer 28 .  
Interesting to note, when looking at the early bactericidal activity (EBA) of the different 
regimens (especially with combinations of drugs used), the rankings would have first-line 
treatment where RIF and INH are combined, followed by BDQ and PZA containing MDR-TB 
regimens and then the FQ and SLID MDR-TB regimen. Though there were limitations in our 
study, this pattern showed in our findings where those with MDR-TB were more likely to be 
positive for any of the test if they were on the then-standard-of-care arm (FQs and SLIDs) 
versus the BDQ containing arm. However, it is possible that EBAs may differ in aerosol 
compared to sputum and this warrants further investigation. 
The findings of this study should be interpreted with the limitations. Firstly, the inclusion 
criteria for the parent study changed after study initiation to include patients that had already 
been on two weeks of prior treatment, possibly affecting the amount of culturable bacteria in 
sputa. This may explain the presence of DCTB in sputa at week 0. Secondly, the criteria for 
treating people with DR-TB changed in South Africa during the study to exclude second-line 
injectables from the regimen and instead include bedaquiline, therefore the final total number 
of n=30 per arm was not reached, however we feel the sample size was big enough to elucidate 
preliminary findings. Finally we only tested patients from Cape Town area which may have 
introduced some bias in our findings as the Western Cape DR-TB epidemic differs to other 
regions in South Africa. DR-TB strains has been shown to be primarily atypical Beijing strains 
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found in the region, and these may react differently to the EPCFE as, for example the 
LAM/KZN strain found in the KwaZulu Natal region. Furthermore EPCFE from a different 
strain (not H37Rv) may also have different effects and should be tested. 
We therefore conclude, that while methods for improving current diagnostics such as including 
EPCFE for detecting DCTB and vPCR dyes such as PEMAX for selecting only viable bacteria 
in sputa may have promise in some cases, for example detecting culture positives that may be 
missed by conventional methods, it did not significantly alter the outcomes of the patients. 
However, focus should be placed on coming up with new and innovative solutions to 
diagnostics for treatment monitoring, such as point-of-care biomarker tests or test that do not 
rely on sputum sampling. It may also be interesting to determine whether the DCTB correlate 
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Figure 1: [A] Overview of study timeline and [B] Sample collection and processing for this 
study. Patients were seen at each of the time points indicated and 3 sputa were collected on the 
same day. If only 2 sputa were collected they were used for culture and smear and MPN assay. 
Sputa were randomly used for either of the methods. Sputa for use in vPCR was 
decontaminated with N-acyl-L-cysteine (NALC) and sodium citrate rather than NaOH as this 
interferes with the dye. Abbreviations: ZN – Ziehl-Neelsen, MPN – most probable number, 
EPCFE – exponential cell free extract, vPCR- viable PCR, Xpert – Xpert MTB/RIF. 
Figure 2: Set up of Most Probable Number (MPN) assay plate. The first three replicate rows 
(A- C; solid circles) contains 450 µl of a 1:1 exponential phase cell free extract (EPCFE) and 
fresh 7H9 broth with PANTA mixture. The second three replicate rows (D-F; dashed circles) 
contain 450 µl of only fresh 7H9 broth with PANTA for comparison. A 1:5 dilution series with 
decontaminated sputa was done across the plate as shown. Plates were scored weekly and kept 
for up to 8 weeks. 
Figure 3: Percentage of positive tests including standard culture (MGIT 960) (squares, light-
grey), smear microscopy (Ziehl-Neelsen staining) (diamonds, dark-grey) and standard Xpert 
(circles, black) on decontaminated sputa for both the [A] Routine arm where time-to-negativity 
(TTN) for smear and culture were 24 weeks for both and, [B] the Intervention arm where TTN 
for smear and culture were 16 and 24 weeks, respectively. Xpert had higher rates of positivity 
throughout treatment, possibly due to the detection of non-viable bacilli form TB treatment. 
Figure 4: Xpert on decontaminated sputa (circles, solid line) versus modified vPCR-Xpert 
[where decontaminated sputa was pre-treated with a viability dye (PEMAX)] (circles, dotted 
line) has similar rates of positivity for and had higher rates than for MPN culture up until week 
24 for both [A] routine arm and [B] intervention arm. EPCFE MPN (triangle, dotted line) had 
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slightly high rates of positivity than for 7H9 MPN (triangle, solid line) for both arms. Notably, 
for routine arm, MPN positivity was detected at week 40 and 84 where Xpert (and vPCR-Xpert 
and) were negative. 
Figure 5: Patients who were positive for MPN in the [A] Routine treatment arm and the [B] 
Intervention treatment arm. There was no significant difference seen for EPCFE MPN vs 7H9 
MPN throughout treatment (except at week 0 for both arms and week 1 of intervention arm). 
There were several instances where EPCFE detected growth that was missed by 7H9 MPN 
[14/47 (30%) and 9/41 (22%) for routine and intervention arms respectively. Red bars (left) 
indicate EPCFE supplemented growth and green bars (right) indicate growth in 7H9 broth only. 
The x-axis indicate logMPN (colony forming units/ ml). P-values were calculated using the 
Wilcoxon matched-pairs signed rank test. 
Figure 6: Difference in logMPN values (ΔlogMPN) between EPCFE and 7H9 MPN results 
across all time points for all positive results for both [A] the routine arm and [B] the 
intervention arm across treatment. Though no significance was seen between total bacilli 
(logMPN) for EPCFE and 7H9 for most time points, significant difference were seen overall 
across all time points for both routine and intervention arms (though not between arms for 
either MPN method). 
Figure 4: Difference in CTmin values (ΔCTmin) between those positive for both Xpert and vPCR-
Xpert in the [A] routine arm and the [B] intervention arm across treatment. There was no 
significant difference detected between the Xpert and vPCR-Xpert samples. P-values of Xpert 
CTmin vs vPCR-Xpert CTmin per patients, per time point were calculated using the Wilcoxon 





























Table 1: Proportion of positive tests through the first 24 weeks of treatment for both routine and intervention arms. Proportion positives between 
arms were not significant by standard diagnostics nor modified diagnostic tests. *P-values for comparisons for a specific time point across arms. 
+P-values for comparisons between the modified and unmodified method within an arm for a specific time point. P-values represent proportion of 
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Background: Understanding when tuberculosis patients on treatment are non-infectious is 
critical, but current tools are suboptimal. To overcome these limitations, we did a pilot study 
to evaluate Mycobacterium tuberculosis detection in cough aerosol captured using a mask 
containing a gelatine filter (gMask; used for MGIT960 culture) or a liquid-based cough aerosol 
sampling system (LCASS) against the reference standard of the validated solid agar CASS. 
Method: For gMasks, initial proof-of-concept and wearing-period optimisation studies (1, 3, 
6 h) were done in 10 pre-treatment patients. We subsequently sampled 45 patients (some of 
which had started treatment) at least once for 1 h (130 total samplings). LCASS (containing 
two reservoirs) were done on a subset (n=14). Contents of each reservoir were randomly 
allocated to MGIT960 or the most probable number assay [with or without supplementation 
with exponential phase cell-free extract (EPCFE) to stimulate growth of differentially-
culturable bacilli (DCTB)]. 
Results: For gMask sampling durations beyond 1 h, no increase in TB detection was observed. 
At the first visit (as close as possible to treatment initiation), CASS, gMask, and LCASS 
positivity rates were 6/44 (14%), 10/43 (23%) and 4/14 (29%) respectively. Of the 10 gMask-
positives, three (30%) were sputum culture-negative. 1/28 (4%) of patients were CASS-
positive one week after enrolment. gMasks had positive results until week 8 [8/82 (10%) gMask 
positive beyond 1 week]. LCASS readouts were not positive beyond baseline except for one 
patient EPCFE positive at week 8.  
Conclusion: Methods for sampling cough aerosol that differ from the validated CASS 
approach can be used to identify different infectious patients. gMasks, which are more scalable, 
may be able to detect Mtb in aerosol in a more sensitive manner from patients on treatment. 





Drug-resistant (DR-) TB is a growing concern with 588 000 incident cases reported in 2017 1. 
Several house-hold contact and epidemiological studies have shown that person-to-person 
transmission is a major driver of DR-TB2-6. Evidence suggests patients on effective treatment 
have a decrease in their infectiousness after two weeks and convert to a smear-negative status. 
However, there while guinea pig models suggest that patients with DR-TB are no longer 
infectious when on treatment7, there remains limited evidence of this for person-to-person 
transmission of DR-TB. This is needed to inform infection control in hospitals8-10. There is 
limited data on the infectiousness of DR-TB throughout treatment, including the new standard 
multi-drug resistant (MDR-) TB regimen which includes bedaquiline. This information is 
needed to inform on regimen strengthening and when patients can be safely discharged11,12.  
The Cough Aerosol Sampling System (CASS) is a technology used to quantify both the size 
and distribution of individual aerosol particles from TB patients using an Anderson Cascade 
Impactor (ACI). The ACI consists of six stages that holds solid agar plates. Each level contains 
specifically engineered holes which allow for particles of certain sizes to travel down through 
the impactor, the diameter of which decrease with each stage. The inertia and sizes of the holes 
allow particles that correspond to the different respirable aerosol ranges (bottom 4 stages) to 
be trapped on specific stages. CASS has been validated against transmission in humans and is 
therefore used as a proxy measure for infectiousness12-15. Though CASS is the only validated 
means of measuring infectiousness, it does have some limitations. Namely, it requires extensive 
infrastructure to run the machine and is dependent on a short period (5 min) of forced cough, 
rather than spontaneous coughing. Recent studies have shown the use of a modified face-mask 
containing a gelatine filter that traps aerosolised Mycobacterium tuberculosis (Mtb) particles 
which can be recovered from the solubilised gelatine filter. This has previously been tested on 
a small subset of TB-positive patients in the United Kingdom and Pretoria, South Africa16,17 as 
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well as patients with chronic obstructive pulmonary disease (COPD)18.  It has, however, not 
been tested on patients with DR-TB, especially in high-burden settings such as the Western 
Cape, nor has it been evaluated longitudinally on patients receiving MDR-TB treatment.  
Another limitation is that CASS captures aerosols on solid media, while liquid have been 
shown to be more sensitive for culturing of TB and has the advantage of permitting rapid 
identification using molecular assays. Liquid culture is also potentially useful for studying the 
influence of novel compounds (e.g., resuscitation promoting factors - RPFs) on the recovery 
of differentially culturable Mtb (DCTB) from the cough aerosol19,20. Liquid aerosol sampling 
technology has not been used for TB previously but has been validated for other bacteria such 
as Legionella spp. and Campylobacter spp. as well as for the influenza virus21-23.  
We therefore aimed to design both a gelatine filter-containing mask (gMask) and a liquid cough 
aerosol sampling system (LCASS) to test on patients who are routinely undergoing CASS as 
part of ongoing studies, which will be used as a reference standard.  
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Materials and Methods 
Study population 
Patients enrolled at Brooklyn Chest Hospital (BCH) were invited to participate in the cough 
aerosol sampling (CASS) study. This study was approved by the Health Research Ethics 
Committee of Stellenbosch University (HREC Ref No: N13/01/001). A large proportion of the 
patients were enrolled in a larger funded clinical drug trial (NExT; Clinicaltrials.gov 
#NCT02454205) which evaluated a new MDR-TB regimen containing bedaquiline and 
linezolid (intervention arm; 6 month regimen) compared to the standard MDR-TB treatment 
(standard treatment arm containing fluoroquinolones and second-line injectables; 24 month 
regimen). For the CASS and gelatine mask (gMask) sub-study, an additional small proportion 
of pre-treatment DS-TB patients were enrolled from other sub-studies. Eligible persons were 
recruited from the Western Cape, South Africa from November 2015 to December 2018 
(Figure 1A).  
Cough Aerosol Sampling System (CASS) 
An ACI that holds 7H11 Middlebrook (BD Biosciences, United States) agar plates with 
Mycobacterial SELECTA-TAB (Mast Group Ltd) was prepared fresh weekly, stored at 4°C, 
and placed in the CASS on the day of use (Figure 2A). The agar plates are removed and 
incubated at 37°C for 6 weeks and scored weekly for growth. Suspected TB colonies are tested 
via Ziehl-Neelsen staining24. The apparatus was set up at BCH in a specifically designed 
negative-pressure booth where the patient could cough into this apparatus for 5 min (Figure 
2B). If a patient produced sputa during coughing, they were ask to deposit this into a collection 




Gelatine Masks (gMask)  
Preliminary studies and optimal duration of wear 
A N95 mask was chosen as this was routinely worn and sturdy enough to support the gelatine 
filter (gMask) (Figure 3A). The patients wearing the gMask were asked to cough spontaneously 
when they needed to. An initial study to determine feasibility of the gMask was tested on 10 
treatment-naïve patients (Figure 1B). A further study was then done on 10 patients to determine 
the optimal duration time of wear for the gMask where a patient was asked to randomly wear 
the gMask for either 1 hour, 3 hours or 6 hours on consecutive days (Figure 1C). A survey was 
also conducted to determine cough frequency while the patient was wearing the gMask as well 
as the times the gMask was worn.  
gMasks sampling through treatment 
Following the preliminary results, patients enrolled for CASS were asked to wear the gMask 
for one hour on the same day. For a sub-set of patients, LCASS was also done on a different 
day (the day the patient would wear the gMask and whether CASS or LCASS were on the first 
or second day were randomised). Patients not enrolled in the clinical drug trial but that were 
enrolled in the CASS study did not get additional LCASS (Figure 1A).   
The gMask was processed by removing the filter (Figure 3B) with sterile forceps and placing 
it in 5 ml N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH; 0.5 M NaOH, 0.37 g/L N-
acetyl-L-cysteine and 0.05 M trisodium citrate dehydrate), using the commercial MycoPrep kit 
(BD Biosciences) to remove any contaminants. The sample was then neutralised by adding PB 
(33 mM Na2HPO4, 33 mM KH2PO4; pH 6.8) and the suspension centrifuged at max speed 
(4000 x g) for 15 min at RT. The pellet was resuspended in 500 µl 7H9 broth and used for 
MGIT culturing to determine if any culturable TB bacteria can be detected. Any leftover 
sample was stored at -20°C. Gelatine filters were used for culture, rather than molecular testing 
methods, as we wanted to determine which patients had culturable bacilli in their sputa. 
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Liquid Cough Aerosol Sampling System (LCASS) 
LCASS, based on the CASS, was designed and manufactured (Figure 2C). It is set up in a 
similar fashion to the CASS with the pipe the patient coughs down connected to the first three 
stages of the ACI (containing 3 SELECTA-TAB 7H11 Middlebrook agar plates) which filters 
out larger particles and allows for the particles corresponding to the respirable range to pass 
through to 2 SKC BioSamplers (SKC Ltd, UK). One sampler contained phosphate buffer (PB) 
and the other 7H9 Middlebrook broth with added Oleic Albumin Dextrose Catalase (OADC, 
BD Biosciences). Sampling was done as described for the CASS. The agar plates were 
incubated at 37°C for 6 weeks and scored weekly for growth. The liquid from both chambers 
were carefully removed, centrifuged at max speed (4000 x g) for 20 min at room temperature 
(RT) and the pellets resuspended in 500 µl PB. All samples from the PB-containing SKC 
sampler and the 7H9-containing SKC sampler were randomly used for either BACTEC MGIT 
960 (BD Biosciences) culturing or the Most Probable Number (MPN) assay using standard 
7H9 broth and exponential-phase cell free extract (EPCFE) from growing H37Rv TB cultures 
to promote growth of DCTB as previously described20. CASS and LCASS sampling occurred 
within 48 hours of each other to give the patient resting time between sampling events. The 
order of sampling was randomized. A patient was seen at first sampling point (week 0), week 
1, week 2 and week 4. If the patient had a positive CASS or LCASS at week 4, they were asked 
to return for further sampling. 
Culture and smear 
Sputa were decontaminated using the NALC-NaOH method as described above. Briefly, an 
equal volume of NALC-NaOH was added to the sample and vortexed, after a 15 min incubation 
at RT, specimens were neutralised with PB and centrifuged at max speed (4000 x g) for 15 min 
at RT. Pellets were resuspended in 1.5 ml PB, 500 µl was used for liquid culture inoculation 
using the BACTEC MGIT 960 system (BD Biosciences) supplemented with 800 µl PANTA 
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(containing a lyophilized antibiotic mixture of polymyxin B, amphotericin B, nalidixic acid, 
trimethoprim and azlocillin; BD Biosciences). After ~30 µl was used for smear microscopy 
using Ziehl-Neelsen staining technique (acid fast stain)24, the rest of the specimen was 
biobanked at -20°C.  
Biosafety methods for collection and transport of samplers 
Aerosol sampling for the CASS and LCASS were done in a negative pressure booth that was 
fitted with HEPA filters and UV lights hidden in sconce to protect patients. All study personnel 
also wore personal protective equipment (masks, gloves, surgical gowns, shoe covers). gMasks 
were placed in double zip-lock bags and a sealed container for transportation. CASS and 
LCASS were likewise sealed in double layers of auto-clave bags, sealed with zip-ties and 
placed in sealed containers for transportation. All the above were processed in a Biosafety level 




Cough Aerosol Sampling System 
A total of 132 time points were sampled across 45 patients and of these time points 7/132 (5%) 
were CASS positive [6/44 (14%) positive at week 0, 1/28 (4%) was positive at week 1] (Table 
1, Figure 4). Of the 6 week 0 positives all but one were pre-treatment DS-TB patients. The 
remaining patient had DR-TB and was enrolled in the intervention arm (C510, they were also 
CASS positive at week 1) (Table 3).  
Gelatine Masks 
Preliminary testing 
Of the initial 10 patients tested, 2/10 (20%) were gMask aerosol culture-positive (gMask-
positive) and one was contaminated. (Table 1). Of the gMask-positive patients 1/2 (50%) were 
CASS-positive and the other CASS-negative. 
Optimal duration times 
Of the patients in the duration study, 4/10 (40%) gMask-positive for all 3 time points (with the 
exception of one of the four – who only had 1 positive time point) (Table 1). The burden of 
bacterial load [using time to positivity (TTP) as a proxy measure] did not differ significantly 
between the duration of wear (p=0.47). One hour was chosen as sufficient time to continue 
with future testing as there was no significance seen between the bacillary loads recovered from 
the aerosol of those positive at different time points. Of the gMask-positive patients 2/4 (50%) 
were CASS positive and of the remaining six patients that were gMask-negative, 2/6 (33%) 
were CASS-positive, indicating gMask may miss patients CASS detects and vice versa (Table 
S1). 
Longitudinal testing  
gMasks were done at 130 time points across 45 patients. A total of 22/130 (17%) were gMask-
positive using the MGIT 960 system across all time points of which 16/22 (73%) were sputum-
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culture positive. At week 0, there were 10/43 (23%) gMask-positive patients and positive 
gMasks were detected at each time point up until week 8 [1/11 (9%)]. At week 10 all gMasks 
tested were negative (Table 1). 
One patient was gMask-positive at only weeks 4 and 6 [this patient defaulted treatment at 6 
months (routine arm)] (Table 3). One patient was gMask positive at week 1 and 8 of treatment 
(this person was also LCASS-positive for that week – intervention arm), this patient was also 
asked to provide an additional sputum at week 28 of treatment as they were showing clinical 
signs of treatment failure, which may be why they were aerosol-positive at week 8 (their 
treatment was extended for an additional four weeks, at which point they were culture-
negative).  
Liquid Cough Aerosol Sampling System  
A subset of 14 were also sampled across a total of 54 time points with the LCASS. Of these, 
4/14 (29%) were positive only at week 0 and two of the four were on the routine arm (Table 
1). One of these patients (C364) were positive for LCASS, gMasks and CASS and were 
recorded as being non-adherent. The remaining patient was enrolled in the intervention arm 
and was also LCASS-positive at week 8 of treatment in the intervention arm using the MPN 
assay with EPCFE included to promote growth of DCTB (this person was also gMask positive 
at week 8)  
Cough aerosol sampling comparison across methods 
At week 0, of the 10 gMask-positive patients, 2 were also positive for CASS alone – both of 
which were pre-treatment patients not enrolled in the longitudinal drug trial (Table 3). One was 
also positive for LCASS (routine DR-TB treatment arm). Finally, one patient was also positive 
for both CASS and LCASS, and who was recorded as non-adherent. Of the 7 CASS-positives 
at week 0,  two were also positive for gMask and one was also positive for both gMask and 
LCASS as mentioned above (the other three were gMask contaminated, and one was pre-
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treatment for DS-TB). There were no patients that were positive for both CASS and LCASS 
only. Of four LCASS-positives, two were on the routine arm and one on the intervention arm 
(Table 3). The patient that was on the intervention treatment arm that was LCASS-positive, 
was also LCASS-positive at week 8 using the MPN assay which selects for DCTB as 
mentioned above.  At week 1 of treatment there were no patients that were positive for at least 
two of the methods (Figure 4). Patients were more likely to be positive for any method if they 
were on the routine arm (20/28 vs 8/28; p=0.001). Of those who were positive for the 
intervention arm 3/4 (75%) either showed signs of clinical treatment failure late into treatment 
and had their regimens extended or had an unfavourable outcome.  
Sputum culture and smear 
At week 0, 31/45 (69%) of patients were sputum culture-positive and 23/27 (62%) had positive 
smear microscopy results (Table 2). Of the 10 aerosol gMask-positives at week 0, seven (70%) 
were also sputum culture-positive (including 2 CASS-positives, one of which was the patient 
that positive for all 3 methods). Interestingly, the one patient that was gMask -and LCASS-
positive at week 0 was culture negative. All patients CASS-positive at week 0 were also 
positive for both sputum culture and smear. Of the LCASS-positive patients at week 0, 2/4 
(50%) were sputum culture-positive, and only one was smear positive (C364, the patient that 
was positive for all 3 methods). At week 1, 2/4 (50%) of patients that were gMask positive 
were also sputum culture positive and the one positive CASS patient was also culture positive. 
The patient that was positive for both gMask and LCASS EPCFE-positive at week 8 was 




We have shown: 1) the gMasks are a non-invasive, mobile means to act as a potential measure 
of infectiousness and has higher rates of detection than either the CASS or LCASS, 2) 1 hr is 
sufficient for a patient to wear the gMask to detect aerosols and there was minimal additional 
yield from longer sampling durations, 3) gMasks suggests that some patients may remain 
infectious up to 2 months after treatment initiation, 4) that the novel LCASS system designed 
by our lab is comparable to that of the CASS for solid media and 5) using novel means of 
culturing such as adding EPCFE may help detect differentially culturable bacilli in aerosols 
and that a positive sputum culture does not also indicate when a patient may be infectious. 
gMask has advantages in that is it mobile, small and easy to use, and relies on spontaneous 
rather than forced cough. It has also been shown to detect culturable bacilli later into treatment 
than either CASS or LCASS, however, this was a pilot study and more data are needed. The 
improved yield of gMasks. This may be due to the fact that patients are free to cough when 
they need and are not limited to testing in only a 5 min forced cough window. It may also be 
due to the fact that sputum spray is produced and is caught on the filter. However, we did ask 
patients to record when they coughed and encouraged patients to deposit any sputa produced 
into a collection cup after lifting the gMask. It also has the advantage that molecular testing 
(such as polymerase chain reactions to detect the presence of bacteria) can be done on bacteria 
that are actually aerosolized, captured in the filter and subsequently dissolved in media. 
Recently, a study from India also assessed whether RNA could be detected from bioaerosol 
from cellulose acetate masks or normal face masks thereby allowing detection of viable 
aerosols only, which is promising25. 
The LCASS provides an alternative measure of infectiousness to the solid agar method within 
the conventional CASS. This is useful for molecular techniques such as polymerase chain 
reaction (PCR) which could allow faster detection of aerosolised bacilli. As with the CASS, it 
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requires the necessary infrastructure to allow for safe and comfortable sampling. It is important 
to note that the gMask detected some patients as aerosol-positive while culture missed these 
patients. 
The results of the study must be interpreted within its limitations. Firstly, it must be noted that 
the patients with DS-TB were sourced from various other case finding and house-hold contact 
studies and were all treatment naïve whereas those that had DR-TB were all sourced from the 
NExT study and received either the then-standard-of-care MDR-TB treatment or the new 
regimen containing bedaquiline. However, the enrolment criteria for the NExT study was 
altered to allow patients that have been on treatment for up to 4 weeks to enrol. This very likely 
had an effect on the number of patients that were able to produce detectable and culturable 
aerosols and may have biased the results presented here. However, it is still important to note 
that this study proves the promise of both the LCASS and gMasks and shows that they are 
likely at least as useful as the CASS. However, it must be noted that in the validation 
experiments, all patients that were enrolled were controlled for treatment status, and so we were 
confident in those findings. 
In conclusion, it is clear that each approach has its advantages, but it would be useful to 
combine at least two of these for thorough aerosol testing, as each test missed patients that were 
picked up by the others. In the future, it would also be beneficial to test both gMask and LCASS 
using molecular methods in a systematic longitudinal manner starting with pre-treatment 




Figure 1: Flow diagram showing [A] testing of gMasks and liquid cough aerosol sampling 
system (LCASS) against the cough aerosol sampling system (CASS) as a reference standard 
(grey boxes). Patients from ongoing studies that are routinely sampled with CASS were asked 
to also wear gMasks and/or LCASS sampling. Studies included a longitudinal drug trial 
measuring a new bedaquiline containing regimen for MDR-TB against the routine standard of 
care regimen as well as pre-treatment DS-TB patients. [B] Flow diagram showing protocol for 
preliminary feasibility study of gMask design. [C] A study was then designed to determine the 
optimal time for which the gMask can be worn and still give reasonable results. 
Figure 2: [A] The Anderson Cascade Impactor – each stage has different diameter holes to 
allow particles through that lessen with size. Stages 4 onward correspond to particles within 
the respirable range (<5µm) 26. [B] The CASS machine (with outer cover removed) that 
contains the Anderson Cascade Impactor. Patients sit in a negative pressure room and cough 
down a sterile pipe (with a disposable mouth piece which the patient puts their mouth around 
to cough) into the CASS (attached to a pump which draws the air through) for 5 min. [C] The 
set-up of a liquid sampling system which consists of an inlet for the pipe (1) where the patients 
cough (as for CASS) into a canister containing the first 3 stages of the Anderson Cascade 
Impactor (2) to trap the larger particles. The canister is connected to a cabinet containing two 
SKC BioSamplers with phosphate buffer or 7H9 inside to trap smaller aerosols (3) the whole 
system is connected to a pump that draws air through the apparatus (as for the CASS) and 
creates a vortex in the SKC Samplers (4). [D] The inside set up of the LCASS. The two SKC 
samplers are placed in the cabinet and contain liquids as mentioned above. The inlet (that is 
connected to the canister) comes in at the top and air is drawn through the outlet on the side of 
the samplers thus creating a vortex.  
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Figure 3: Example of a gMask. [A] N-95 mask modified to contain aluminium holder 
containing gelatine filter. [B] A gMask that has been worn for 1 hour, the filter (which is now 
clear and jelly-like) is removed with sterile forceps, dissolved and decontaminated with NALC-
NaOH before culture. 
Figure 4: Venn-diagram showing the total number of positive cases for both CASS, LCASS 
and gMasks at week 0 and week 1 after treatment initiation. At week 0, three of the 10 gMasks 
were also positive for CASS, one was also positive for LCASS and one was positive for both 
LCASS and CASS. No CASS and LCASS were both positive while gMask was negative. At 
















Table 1:  Number of positive tests across time points for different aerosol sampling methods. CASS, LCASS and gMask had similar positivity at 
week 0. CASS and LCASS had similar rates of positivity but gMask remained positive through to week 8 of treatment. Data are n/N (%). 
 











































































































0/2 (0)  0/2 (0) 
 At week 0, 2 patients were positive for both gMask and CASS, 1 was positive gMask and LCASS and 1 was positive for all 3 methods. At week 1 none that 
were gMask positive were CASS positive (see Figure 5). At week 8 the patient that was LCASS EPCFE positive was also gMask positive. Given the small 





Table 2: Results of the feasibility study for which growth was seen in 3/10 (30%) of gMasks 
(one contaminated) and the duration study where 4/10 (40%) patients were gMask-positive. 
No significant difference in time to positivity (TTP) was seen with sampling duration. There 
were 2 patients that were gMask negative but CASS positive, indicating that gMask may miss 








PID Time (h) Aerosol culture result (TTP) Culture (TTP) CASS result 
Feasibility study 
M003 12 C (40) N/A N 
M005 8 P (21) N/A N 
M006 10 P(16) N/A P 
Duration study 
M014 
1 P (14) 
P (4) P 3 P (27) 
6 P (18) 
M016 
1 P (22) 
P (5) P 3 P (20) 
6 P (17) 
M017 
1 P (23) 
P (9) N 3 P (3)* 













n=2 CASS P 
n=4 CASS N 
* Culture was contaminated which contributed to faster TTP (however, acid fast bacilli were also 
visible). + Patient was ill and could not produce sputum. † Patient was ill and did not wear mask 
for the full 3 and 6 hours. 
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Table 3: Summary of patients who had at least one positive aerosol result at any time point. DS-TB patients had once-off sampling and those in 
DR-TB had multiple time points for both treatment arms. DR-TB patients were more likely to be positive by any methods if they were enrolled in 
the routine arm (20/28 vs. 8/28; p=0.003). Data are shown as n/N (%) (where N is all patients tested at that time point, not all are shown here). 
 
* These patients showed clinical signs of treatment failure and have their treatment regimens extended beyond 6 months (intervention arm). † This patient passed away at month 
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General conclusions and future work 
We have developed methods to potentially reduce time-to-treatment by providing a way to 
salvage used Xpert and Ultra CE for further second-line drug susceptibility testing. This means 
that a full diagnosis for rifampicin, FQ and SLIDs can be obtained from a single specimen, 
without the need for further DNA extraction, potentially within 24 hrs. This has implications, 
especially in low resource settings where patients often do not return or cannot produce a second 
sputum of sufficient quality for further drug-susceptibility testing. Routine diagnostics 
laboratories can save on time and costs involved with the collection and processing of secondary 
sputa and the additional consequences of a patient remaining infectious and contributing to 
transmission1,2. We have further shown that potential cross-contamination of rpoB amplicons 
that may occur during the extraction process, though possible, is very unlikely, which further 
supports the adoption of this method. However, future 
work includes the development of an ease-of-use 
device that can clip onto the existing cartridge and 
extract the CE into a sealed container (Figure 1), 
thereby reducing the chance of needle-stick injury 
from the manual method and negating the chance of 
amplicon cross-contamination. As GeneXpert caters 
for a large platform of tests (e.g. HIV, gonorrhoea, 
methods, staphylococcus, influenza), this method can also be applied to other Xpert cartridges. 
This work has been funded by the C-THAN consortium. 
We have also shown that CE may be useful for ultra-deep targeted next generation sequencing 
methods such as SMOR, and that this can give a complete antibiogram for the patient from a 
single specimen. However, since Ultra contains not only rpoB amplicons in CE but also multi-
copy IS610 and IS1081 amplicons (amongst others), SMOR appears to yield less actionable 
 
Figure 1: Example of device for 




results on Ultra CE which warrants further optimisation. Through the addition of ThermoStop 
and ThermoGo to improve total reads was not feasible, there are other options to potentially 
reduce or remove the multiple amplicons present. One such option is to do size fractionation or 
separation prior to the PCR amplification step in the SMOR process which may potentially 
remove small interfering amplicons. This has been done previously by Liu et al by using lysine-
functionalized silica particles to separate DNA fragments with varying sizes and may be useful 
for this approach3. The use of ultra-filtration devices, such as the Vivacon from Sartorius may 
also prove useful as they have been used to remove small primer fragments from larger DNA 
fragments (>300 bp). Another option is to use biotinylated primers and use bead pull-down 
methods to enrich other loci (i.e. non-rpoB and IS6110.1081) in CE prior to SMOR 
amplification. 
Further investigation into the clinical relevance of heteroresistance detected by SMOR on CE, 
and missed by conventional DST methods, must also be done to determine if this 
heteroresistance is also present in subsequent specimens in the diagnostic pipeline (e.g. 
sub-culturing steps during DST) and whether it affects the clinical outcome of these patients.  
We also aimed to improve culturablity of DCTB in sputa of patients undergoing MDR-TB 
treatment (routine and intervention arms). This has been shown in patients undergoing DS-TB 
treatment but never in patients undergoing MDR-TB treatment, including the regimen 
containing bedaquiline and linezolid7. While there was no significance difference seen  at 
specific time points, in the total bacilli detected between MPN assays including EPCFE and 
standard 7H9 cultures, there were more total bacilli detected (including DCTB) using EPCFE 
MPN assays over all, thus suggesting that a sub-population of DCTB not detected by 
conventional methods is present throughout treatment. The significance per time point may be 
improved with larger study numbers. Importantly, including EPCFE in the MPN assay 
improved detection of patients with only DCTB present through treatment that would otherwise 
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have been missed by standard methods. However, this did not inform on potential patient 
outcomes. 
Furthermore, Improving Xpert for treatment monitoring by pre-treating sputa with a 
photoactive to reduce signals from non-viable bacteria proved not to be feasible. This is 
possibly due to DNA present from other bacteria and viruses in the microbiota of the sputum 
that sequesters the dye before it can reach the TB bacteria, which are present in smaller 
numbers. Furthermore, the cell wall of TB is known to be much tougher to penetrate and may 
also be a barrier for the dye. Previous studies have looked at the effect of such dyes, such as 
PMA, to quantify viable cells both in vitro and in clinical samples collected from patients 
undergoing DS-TB treatment, and while it did not seem to influence results in presence of most 
drugs, it had effects when INH and EMB was used4. PMA also increased the CT values through 
treatment, however, as in our study, the changes seen were not as large as described previously 
by Miotto et al4,5 though it was significant. Their results may be due to the treatment of the 
sputa with Sputasol which Nikolayevskyy et al have shown inactivates PMA6. This is the reason 
we treated out samples with N-acetyl-cysteine (without NaOH), however, our results still 
indicate that, while there is a change in ΔCTmin, it is not significant and does not improve Xpert 
for treatment monitoring purposes. This may be attributed to the fact that many patients enrolled 
in the study had already undergone 2 weeks of treatment and thus skewed the results.  
Finally we have shown two new methods of aerosol sampling, using the only validated means 
of aerosol sampling in humans to date, the CASS, as reference standard8-10. Previous studies by 
Williams et al looked at using face masks as sampling tools for aerosols and their findings 
support the use of this non-invasive, low cost way of sampling for aerosols produced by patients 
with pulmonary TB. Their studies looked at a smaller sample size and used either Xpert or PCR 
to quantify the aerosols11,12. While that is indeed a much faster method of diagnosis, we opted 
to culture the gelatine masks to determine if culturable bacilli were being produced, as PCR 
methods do not differentiate between DNA from viable and non-viable bacilli. Furthermore, 
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while they sampled mainly drug-susceptible patients, we also wanted to sample patients with 
MDR-TB and sample them longitudinally to determine how treatment may affect aerosol 
production. We likewise found that the gMasks were a viable way of sampling for aerosols and 
that indeed, they detected culturable bacteria in aerosol further into treatment than the CASS 
(or LCASS), which relies of 5 min forced coughing. It was also found by Kennedy et al that 
these masks could be used for testing patients with COPD, thus there is utility outside the field 
of tuberculosis research, however the gelatine filter interfered with the detection of 
antimicrobial resistance (AMR) genes13. Further investigations using this mask can include the 
use of cellulose acetate membranes as they have been shown to have better bacterial recovery 
than other filters, and may reduce the interference seen in AMR detection14. Shaikh et al also 
showed the feasibility of RNA isolation from face masks that could be used to quantify viable 
bacilli from aerosols, which is promising14. 
The LCASS, which was by designed by us and based on the modified CASS has, to our 
knowledge, not been described to date. This method has potential to be used with various 
culturing media and methods such as including EPCFE to detect growth of DCTB in aerosol 
and may inform on patient infectiousness through treatment. While CASS and LCASS were 
done on the same patients, they were not done on the same day and so variation in aerosol 
production may occur. Furthermore, many of the aerosol sampling were done on patients 
already on treatment for up to 2 weeks. Therefore, in future studies, these methods should be 
sampled on treatment naïve patients and potentially at the same time to ascertain the true worth 
of these methods. Furthermore, this study only looked at 5 min forced cough. Patterson et al 
have shown that Mtb aerosols are produced even during tidal breathing15, and likewise Williams 
et al detected Mtb in mask samples in hospitalised patients, often thought too sick to produce 
aerosols, when no coughing occurred11. It would therefore be pertinent to test these sampling 
methods on not only forced cough, but also tidal breathing or talking for extended periods. 
140
Stellenbosch University https://scholar.sun.ac.za
In conclusion, this study examines at various ways in which DR-TB transmission can ultimately 
be reduced throughout the care cascade. We have identified ways to reduce the need for a 
second sputum collection and effectively reduce time-to-treatment of patients with DR-TB 
(rifampicin and second-line drug susceptibly testing), amongst other downstream uses. We have 
also shown that DCTB are present throughout treatment and may be missed by conventional 
tests. Finally, we have developed and tested novel methods of sampling aerosols from patients. 
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Xpert MTB/RIF Results in Patients With Previous
Tuberculosis: CanWe Distinguish True From False Positive
Results?
Grant Theron,1,2,a Rouxjeane Venter,2 Greg Calligaro,1 Liezel Smith,1 Jason Limberis,1 Richard Meldau,1 Duncan Chanda,1,3 Aliasgar Esmail,1 Jonny Peter,1
and Keertan Dheda1,4
1Lung Infection and Immunity Unit, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town, and 2DST/NRF of Excellence for Biomedical
Tuberculosis Research, and MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University,
Tygerberg, South Africa; 3Institute for Medical Research and Training, Lusaka, Zambia; and 4Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa
Background. Patients with previous tuberculosis may have residual DNA in sputum that confounds nucleic acid amplification
tests such as Xpert MTB/RIF. Little is known about the frequency of Xpert-positive, culture-negative (“false positive”) results in
retreatment patients, whether these are distinguishable from true positives, and whether Xpert’s automated filter-based wash step
reduces false positivity by removing residual DNA associated with nonintact cells.
Methods. Pretreatment patients (n = 2889) with symptoms of tuberculosis from Cape Town, South Africa, underwent a sputum-
based liquid culture and Xpert. We also compared Xpert results from dilutions of intact or heat-lysed and mechanically lysed bacilli.
Results. Retreatment cases were more likely to be Xpert false-positive (45/321 Xpert-positive retreatment cases were false-
positive) than new cases (40/461) (14% [95% confidence interval {CI}, 10%-18%] vs 8% [95% CI, 6%–12%]; P = .018). Fewer
years since treatment completion (adjusted odds ratio [aOR], 0.85 [95% CI, .73–.99]), less mycobacterial DNA (aOR, 1.14 [95%
CI, 1.03–1.27] per cycle threshold [CT]), and a chest radiograph not suggestive of active tuberculosis (aOR, 0.22 [95% CI,
.06–.82]) were associated with false positivity. CT had suboptimal accuracy for false positivity: 46% of Xpert-positives with CT > 30
would be false positive, although 70% of false positives would be missed. CT’s predictive ability (area under the curve, 0.83 [95% CI,
.76–.90]) was not improved by additional variables. Xpert detected nonviable, nonintact bacilli without a change in CT vs controls.
Conclusions. One in 7 Xpert-positive retreatment patients were culture negative and potentially false positive. False positivity
was associated with recent previous tuberculosis, high CT, and a chest radiograph not suggestive of active tuberculosis. Clinicians may
consider awaiting confirmatory testing in retreatment patients with CT > 30; however, most false positives fall below this cut-point.
Xpert can detect DNA from nonviable, nonintact bacilli.
Keywords. tuberculosis; diagnosis; Xpert; false positivity.
Xpert MTB/RIF (Xpert; Cepheid) is an automated nucleic acid
amplification test (NAAT) for Mycobacterium tuberculosis and
rifampicin resistance [1–3], endorsed by the World Health Or-
ganization and the US Food and Drug Administration [4, 5].
Xpert is increasingly deployed in many countries as the initial
diagnostic test for tuberculosis [6].
Xpert is used routinely in patients who have previously had
tuberculosis [6, 7]. This is despite evidence that approximately
30% of patients who are microbiologically cured after 6 months
of treatment are Xpert positive [8], a proven correlation between
retreatment status and diminished specificity [9–11], and
several case reports detailing false-positive (FP) Xpert results
in retreatment cases [12–14]. Detectable mycobacterial DNA,
which can be extracellular or associated with nonintact cells
(and hence is not culturable), is a possible cause of this false
positivity, which may trigger unwarranted treatment and un-
necessarily expose patients to toxic drugs, delay establishing
the correct underlying diagnosis and its appropriate treatment,
and escalate healthcare costs. Although the manufacturer rec-
ommends that Xpert always be used in conjunction with culture
[15], culture capacity is not mandatory for Xpert’s use in the
field [7] and, even in high-burden countries such as South Af-
rica that do have culture capacity, most Xpert-positive patients
do not receive culture, as per the national algorithm [16].
More than 700 000 patients with a history of tuberculosis
were diagnosed in 2013 [17]; however, there are limited data
about the frequency of Xpert false positivity in retreatment pa-
tients [18] and what factors, if any, may guide clinical practice
[10].We therefore examined the relationship between Xpert re-
sults (including M. tuberculosis complex–specific quantitative
information), routinely collected clinical information, and
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culture results in a large cohort of patients evaluated for tuber-
culosis in the high-burden, high–human immunodeficiency
virus (HIV) setting of Cape Town, South Africa. To interrogate
claims that Xpert does not detect free DNA because of a pream-
plification wash step [19–22], which would potentially reduce
the risk of an FP result in retreatment cases, we performed a lab-
oratory-based substudy to ascertain whether Xpert can detect
DNA from lysed nonviable cells.
METHODS
Patient Recruitment
We analyzed data from 3166 patients who had symptoms sug-
gestive of tuberculosis. Patients were recruited from primary
care clinics or hospitals in Cape Town, South Africa, as part
of studies that evaluated the utility of Xpert. Patients included
in the final analysis were Xpert positive and had cycle threshold
(CT) data, were either culture positive or negative, had a known
previous tuberculosis status, had not been on treatment for >48
hours, and had not taken antituberculosis treatment 60 days
prior to testing. This study was approved by the University of
Cape Town Faculty of Health Sciences Ethics Committee.
Diagnostic Tests
Two paired sputum specimens were collected at recruitment; 1 was
randomly selected for an Xpert test, and the other was used for a
BACTECMGIT 960 liquid culture (Becton, Dickinson, and Co). If
patients were unable to expectorate sputum, sputum induction
with hypertonic saline was performed. Tuberculosis morbidity
score [23] data and chest radiograph (CXR) data were collected
in a subset of patients, as determined by the parent protocol.
Xpert MTB/RIF Cell Lysis Experiment
To assess whether Xpert detected nonviable cells, 1 mL of M.
tuberculosis H37Rv in phosphate-buffered saline and 0.25%
Tween 80 (10 000, 1000, 500, and 0 colony-forming units
[CFU] mL−1) was added to Xpert sample buffer (2:1 ratio)
and, after 15 minutes of incubation with intermittent shaking,
2 mL was added to the Xpert cartridge (direct Xpert). In paral-
lel, a 1.5-mL aliquot of each concentration underwent heat
treatment (80°C, 1 hour), followed by mechanical disruption
using Lysing Matrix B tubes (0.1 mm zirconium beads; MP
Biochemicals) and a Fast Prep-24 machine (MP Biochemicals)
(6.5 meters per second for three 30-second intervals with 1 mi-
nute resting on ice between intervals). After bead-beating, the
lysate was allowed to settle for 2 minutes and 1 mL of superna-
tant was used for Xpert (lysed Xpert). Ten 10-µL aliquots of
each dilution (direct and lysed) were plated on Middlebrook
7H10 agar supplement with oleic acid albumin dextrose
complex and incubated for 6 weeks at 37°C to check for viabil-
ity. This experiment was performed in triplicate.
Statistical Analysis
Xpert-positive, culture-positive patients were defined as true
positive (TP) and Xpert-positive, culture-negative patients
were defined as false positive (FP). The χ2 test was used for com-
parisons between proportions. The Mann–Whitney test was
used to compare differences in nonparametric continuous
data. Multivariable logistic regression was performed to adjust
for potential confounding. A backward elimination strategy
using the likelihood ratio test was used to finalize each model.
Analyses were performed using GraphPad Prism version 6.0
(GraphPad Software) and Stata version 13 (StataCorp) software.
All statistical tests are 2-sided at α = .05.
RESULTS
Of the 3166 patients, we excluded 263 (8%) patients (73 had did
not have a positive- or negative-culture result, 86 were on treat-
ment >48 hours, 104 Xpert-positive patients were missing CT
data, and 14 were missing data on their previous tuberculosis
history). Of the remaining 2889 patients with a known culture
status, 837 (29%) were culture positive and 782 (27%) were
Xpert positive. A total of 1220 (42%) patients were retreatment
cases. A summary of the demographic and clinical characteris-
tics of the cohort is shown according to previous tuberculosis
status in Table 1. Retreatment patients were more likely to be
older and HIV-infected. Differences in Xpert CT and years
since completion of previous antituberculosis treatment in
new and retreatment patients are shown in Figure 1.
Xpert MTB/RIF False Positivity in Patients With Newly Diagnosed
Tuberculosis
Xpert had a sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) of 83% (95% confidence in-
terval [CI], 80%–86%), 97% (95% CI, 95%–98%), 91% (95% CI,
88%–94%), and 93% (95% CI, 91%–94%), respectively, in new pa-
tients. Forty of 461 (9%) Xpert-positive results were FP.
Table 1. Demographic and Clinical Characteristics of Patients Included









Female sex, No. (%) 773/1617 (48) 548/1181 (46) .463
Age, y, median (IQR) 36 (28–46) 39 (32–49) <.001
Clinical characteristics
HIV-infected, No. (%) 695/1617 (42) 623/1198 (53) <.001
TB morbidity score,
median (IQR)




506/1669 (30) 331/1220 (27) .062
Time-to-positivity,
d, median (IQR)
12 (8–17) 13 (8–17) .352
Xpert MTB/RIF-
positive, No. (%)
461/1669 (28) 321/1220 (26) .434
CT, median (IQR) 21.20 (17.92–26.64) 22.00 (17.23–27.06) .309
CXR compatible with
active TB, No. (%)
402/928 (43) 329/708 (46) .204
Abbreviations: CT, cycle threshold; CXR, chest radiograph; HIV, human immunodeficiency
virus; IQR, interquartile range; TB, tuberculosis.
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Correlates of Xpert MTB/RIF False Positivity
New tuberculosis patients with an FP Xpert were, compared
to those who were TP, more likely to have higher median
Xpert CT (28.03 [interquartile range {IQR}, 21.20–32.23] vs
21.50 [IQR, 17.72–26.10]; P < .001) and more likely to be
female (25/40 [63%] of FP cases were women vs 187/414
[45%] of TP cases; odds ratio [OR], 2.02 [95% CI, 1.04–
3.95]). In a multivariate logistic regression analysis (Table 2),
each unit increase in CT was associated with a 14% increase in
the relative risk (adjusted OR [aOR], 1.14 [95% CI, 1.08–
1.21]) of Xpert false positivity, presuming the other variables
held constant. Morbidity in patients with tuberculosis symp-
tom score data (n = 168) was similar in those with an FP or
TP Xpert result (median, 4 [IQR, 2–6] vs 4 [IQR, 4–5];
P = .389).
Where CXR data (n = 193) were available, FP patients were
less likely to have a CXR compatible with active tuberculosis
than TP patients (9/19 [47%] vs 144/174 [83%]; P = .001)
and, when included in a multivariable logistic regression
model with previous tuberculosis and CT, a CXR compatible
with active tuberculosis was associated with a 79% reduction
in the relative odds of Xpert false positivity (aOR, 0.21 [95%
CI, .08–.57]; Supplementary Table 2).
Receiver Operating Characteristic Curve Analyses
The area under the curve (AUC) for CT (0.70 [95% CI, .61–.80])
did not increase when CXR (0.78 [95% CI, .71–.86]) was includ-
ed (Figure 2) (receiver operating characteristic [ROC] curves for
CT only, and not those who also had CXR data, are shown in
Supplementary Figure 1). At a rule-out cut-point (CT > 14.22)
for Xpert false positivity (selected based on 95% sensitivity; ie,
95% of the 40 FP Xperts fell above this cut-point), CT alone had
a specificity, NPV and negative likelihood ratio (LR) of 6%, 93%,
and 0.78, respectively (Table 3). At a rule-in cut-point (selected
based on 95% specificity) of >32.19, CT had a sensitivity, PPV,
and positive LR of 3%, 33%, and 5.5, respectively. At a cut-point
(CT > 27.08) corresponding to Youden index, CT had a sensitiv-
ity, specificity, NPV, PPV, positive LR, and negative LR of 55%,
80%, 21%, 95%, 2.79, and 0.56, respectively.
Xpert MTB/RIF False Positivity in Retreatment Tuberculosis Patients
Xpert had a sensitivity, specificity, PPV, and NPV of 84% (95%
CI, 79%–87%), 94% (95% CI, 93%–96%), 85% (95% CI, 82%–
Figure 1. Box-and-whisker plot comparison of Xpert MTB/RIF quantitative information (cycle threshold [CT] values) in true-positive (Xpert-positive, culture-positive) and false-
positive (Xpert-positive, culture-negative) specimens for new (A) or retreatment (B) patients, and a comparison of the years since the completion of previous tuberculosis (TB)
treatment in Xpert-positive retreatment patients according to culture status (C). Median values with interquartile ranges in parentheses are shown.
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90%), and 94% (95% CI, 92%–95%) in retreatment patients.
Forty-five of 321 (14%) Xpert-positive results were false positive
(P = .018 compared to new cases).
Correlates of Xpert MTB/RIF False Positivity
Although retreatment patients with an FP Xpert were older than
those with a TP Xpert in a univariate analysis (Median [IQR],
41 {21–48} vs 37 {30–45} years; P = .030), after multivariable
adjustments were performed, only CT (aOR, 1.25 [95% CI,
1.15–1.35]; P < .001) and the number of years since stopping
treatment for the previous episode of tuberculosis (aOR, 0.91
[95% CI, .84–.99]; P = .048) were independent predictors of
Xpert FP (Table 2). There was no correlation between CT and
years since stopping treatment for previous tuberculosis
(P = .427; Supplementary Figure 2). When radiographic data
were available, a CXR compatible with active tuberculosis was
also an independent predictor of Xpert false positivity (aOR,
0.22 [95% CI, .06–.82]; Supplementary Table 2).
Receiver Operating Characteristic Curve Analyses
ROC curve AUCs of 0.83 (95% CI, .76–.90), 0.83 (95% CI,
.75–.91), 0.78 (95% CI, .79–.86), and 0.84 (95% CI, .72–.95)
were obtained for CT alone, a model incorporating CT
and the number of years since stopping treatment, a model
incorporating CT and CXR, and a model incorporating all 3 var-
iables, respectively (Figure 2). CT had, at a cut-point for ruling
out Xpert false positivity (selected based on 95% sensitivity; ie,
95% of the 45 FP Xperts in retreatment patients fell above this
cut-point), a specificity, NPV, and negative LR of 36%, 98%, and
0.12, respectively (cut-point >18.28), whereas at a rule-in cut-
point (selected based on 95% specificity), it had a sensitivity,
PPV, and positive LR of 27%, 46%, and 5.26, respectively
(cut-point >30.56) (Table 3). At a cut-point (>28.36) corre-
sponding to Youden index, CT had a sensitivity, specificity,
NPV, PPV, positive LR, and negative LR of 64%, 90%, 52%,
94%, 6.59, and 0.39, respectively.
Detection of DNA From Nonviable Bacilli
Each dilution of bacilli (10 000, 1000, and 500 CFU mL−1) was
detected as positive when Xpert was done directly or on lysate.
Similar CTs (SEM) were obtained (direct vs lysed): 16.58 (0.70)
vs 16.98 (0.98; P = .826), 19.03 (0.53) vs 21.04 (0.88; P = .266),
and 21.15 (0.37) vs 21.62 (0.86; P = .730) for the 10 000, 1000,
and 500 CFU mL−1 dilutions, respectively (Figure 3). The 0
CFU mL−1 dilutions were undetected. After 6 weeks of incuba-
tion, each aliquot used for direct Xpert grew the expected num-
ber of CFUs, whereas no growth was observed from the aliquots
of heat inactivated, bead-beaten bacilli.
Table 2. Factors Associated With Xpert False Positivity in New and Retreatment Cases







(n = 40) OR (95% CI) P Value
Adjusted OR
(95% CI) P Value
Demographic variables
Age, y, median (IQR) 33 (27–43) 32 (25–44) 1.00 (.97–1.02) .780 . . . . . .
Female, No. (%) 187/414 (45) 25/40 (63) 2.02 (1.04–3.95) .039 . . . . . .
Smoker, No. (%) 125/347 (36) 13/30 (43) 1.36 (.64–2.89) .427 . . . . . .
Clinical variables
HIV-infected, No. (%) 162/404 (58) 21/39 (50) 1.74 (.90–3.37) .099 . . . . . .
Xpert information
TB-specific CT values, median (IQR) 21.50 (17.72–26.10) 28.03 (21.20–32.23) 1.14 (1.07–1.21) <.001 1.14 (1.08–1.21) <.001




(n = 45) OR (95% CI) P Value
Adjusted OR
(95% CI) P Value
Demographic variables
Age, y, median (IQR) 37 (30–45) 41 (21–48) 1.03 (1–1.07) .030 . . . . . .
Female, No. (%) 108/274 (39) 15/42 (36) 1.17 (.60–2.30) .647 . . . . . .
Smoker, No. (%) 100/229 (44) 18/32 (56) 1.66 (.79–3.50) .184 . . . . . .
Clinical variables
HIV-infected, No. (%) 122/273 (45) 20/43 (47) 1.08 (.57–2.05) .823 . . . . . .
Previous TB treatment not completed, No.
(%)
55/239 (23) 26/39 (26) 1.15 (.53–2.51) .719 . . . . . .
Years since previous TB treatment
stopped or completed, median (IQR)
2 (0–5) 1 (0–1) 0.92 (.85–.99) .033 0.91 (.84–.99) .048
Xpert information
TB-specific CT values, median (IQR) 20.30 (16.71–25.05) 29.28 (26.18–30.60) 1.27 (1.18–1.37) <.001 1.25 (1.15–1.35) <.001
Versions of this table for all patients (Supplementary Table 1) or restricted to the subset of patients with chest radiographic data (Supplementary Table 2) are provided in the Supplementary Data.
Abbreviations: CI, confidence interval; CT, cycle threshold; HIV, human immunodeficiency virus; IQR, interquartile range; OR, odds ratio; TB, tuberculosis.
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Our key findings are as follows: (1) patients with an FP Xpert
are more likely to have previous tuberculosis (and to have had
this more recently), low mycobacterial DNA load (measured by
CT), and a CXR not compatible with active tuberculosis; (2)
about 1 in 7 Xpert-positive results in retreatment patients will
be FP; (3) CT predicts false positivity, but has suboptimal dis-
criminatory power (a specificity of 10% at a rule-out cut-
point [95% sensitivity], and a sensitivity of 20% at a rule-in
cut-point [95% specificity]) that is not enhanced by the incor-
poration of additional variables; (4) using a cut-point of CT > 30
in retreatment patients, 7 of 10 FP cases will be missed; however,
about half of the patients falling above this cut-point will be FP;
and (5) Xpert detects DNA from nonviable cells that are not in-
tact, thereby suggesting that free DNA—and not just DNA from
intact cells—is detected by Xpert.
Early evaluations of Xpert [25] contributed the majority of
data to meta-analyses of test accuracy [26, 27]; however these
studies excluded patients who were culture-negative and treated
based on symptoms (including many Xpert-positive patients),
despite the known poor specificity of empirical treatment [28,
29]. This led to calls that Xpert’s specificity might be overesti-
mated, especially in retreatment cases [12, 17]. A reanalysis of
the pooled data found that, when these early evaluations were
excluded, no significant change in specificity occurred; however,
Figure 2. Receiver operating characteristic curves of Xpert MTB/RIF cycle thresh-
old values and clinical information for the prediction of Xpert MTB/RIF false posi-
tivity in new (A) or retreatment (B and C) patients. Abbreviations: AUC, area under
the curve; CI, confidence interval; CT, cycle threshold; CXR, chest radiograph; TB,
tuberculosis.
















New patients (n = 461)
Rule-in >32.19 3 (2–4) 95 (92–97) 34 (19–.54) 93 (90–95) 5.51 (2.87–10.60) 0.76 (.63–.92)
Rule-out >14.22 95 (82–99) 6 (4–9) 9 (6–12) 93 (76–99) 1.02 (.94–1.09) 0.78 (.19–3.22)
Youden indexa >27.08 55 (39–70) 80 (76–84) 21 (14–30) 95 (92–97) 2.79 (1.99–3.92) 0.56 (.40–.79)
Retreatment patients (n = 321)
Rule-in >30.56 27 (15–42) 95 (91–97) 46 (27–66) 89 (85–92) 5.26 (2.60–10.63) 0.77 (.65–.92)
Rule-out >26.80 95 (84–99) 36 (30–42) 20 (15–26) 98 (92–100) 1.39 (1.33–1.66) 0.12 (.03–.49)
Youden indexa >28.36 64 (49–78) 90 (86–93) 52 (38–65) 94 (90–96) 6.59 (4.33–10.01) 0.39 (.27–.58)
Abbreviations: CI, confidence interval; CT, cycle threshold; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
a Defined as the best compromise between sensitivity and specificity assuming equal weighting [24].
Figure 3. Comparison of Xpert MTB/RIF cycle threshold values (mean ± SEM)
from a dilution series of bacilli, showing similar CT when Xpert MTB/RIF was per-
formed on intact bacilli or nonviable, heat- and mechanically-lysed bacilli. Three ex-
perimental replicates were performed. Abbreviations: ANOVA, analysis of variance;
CFU, colony-forming units; CT, cycle threshold; SEM, standard error of the mean.
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when patients’ history of previous tuberculosis was included as a
covariate, a trend between an increased prevalence of retreat-
ment cases and diminished specificity existed [9].
The specificity of Xpert in retreatment cases in our study was
95% (95% CI, 93%–96%), indicating that 1 in 20 culture-nega-
tive patients will be FP by Xpert. This is less than the specificity
reported in meta-analyses that included (99% [95% CI, 98%–
99%]) [9] or excluded (98% [95% CI, 97%–99%]) data from
the initial Xpert validation studies [25]. Our specificity is also
less than that reported previously in retreatment cases in
South Africa (99% [95% CI, 98%–100%]) [11], but higher
than that seen among retreatment cases in Harare (87% [95%
CI, 75%–94%]) [10]. As suggested by others [10, 11], our
study indicates that about 1 in 7 Xpert-positive retreatment pa-
tients will be FP. In settings such as Cape Town, South Africa,
where approximately 1 in 4 tuberculosis notifications are re-
treatment cases (approximately 7500 per annum) [30], this rep-
resents a potentially large public health problem.
We found CT to differentiate poorly between TP or FP Xpert
results. For example, at an optimized rule-out cut-point (CT-
> 26.80; 95% sensitivity) in retreatment patients, only a third of
true-positive patients would be correctly classified, and only 1 in 5
FP Xpert results would be correctly classified. Conversely, 70% of
FP cases would bemissed at an optimized rule-out cut-point (CT-
> 30.56; 95% specificity), and less than half of the Xpert-positive
results with CT above this cut-point would be correctly classified
as FP. Although suboptimal for use in routine clinical practice,
this result suggests that clinicians should be cautious in interpret-
ing Xpert-positive results in retreatment patients with CT > 30,
and that they may wish to await the results of confirmatory cul-
ture-based testing before starting treatment. This study, as well as
others that have demonstrated CT to be a useful proxy of bacterial
load [31–33] and infectiousness [34–36], suggests that laborato-
ries should consider routinely reporting these values.
Our study is the first to describe an inverse association be-
tween Xpert FP results and the time since previous treatment
was stopped, and the utility of CXR in discriminating Xpert
TP from FP patients. Although these tools reduced the odds
of an FP result, they did not, unfortunately, improve upon the
relatively poor discriminatory ability of CT alone. This is be-
cause several TP patients had recently been treated for active tu-
berculosis (which is reflective of our high transmission setting),
or had a CXR not suggestive of active tuberculosis.
As Xpert does not detect DNA from nontuberculous myco-
bacteria [37], almost all positive results likely reflect the true de-
tection of M. tuberculosis complex DNA [32]; however, this
does not always correspond to the presence of active disease
caused by viable, intact bacilli. Our research shows that the
on-board sample processing system of Xpert is unable to re-
move genomic DNA from nonintact, nonviable cells, which
may be present in retreatment cases. This is likely the mecha-
nism by which Xpert FP occurs, and suggests that Xpert’s
automated mechanism to isolate intact bacilli prior to DNA ex-
traction requires optimization if false positivity due to the detec-
tion of extracellular DNA or DNA in nonintact, nonviable cells
is to be minimized. Notably, a study observed Xpert to effective-
ly remove large numbers of amplicons in spiked sputum, pre-
venting detection [37]; however, unlike our study, this earlier
work used free DNA of low molecular weight.
Our study has limitations. Other causes of Xpert false posi-
tivity include variations in specimen quality and bacterial load
in the different samples used for Xpert and culture, and the
overlapping stochastic limits of detection of these 2 tests,
which can cause false-negative reference standard results (and
hence false-positive Xpert results, which may be minimized
by repeated cultures). Culture itself is an imperfect reference
standard with incomplete sensitivity, although it is used widely
in both clinical practice and research. Several factors may un-
derpin this incomplete sensitivity including sampling error, dif-
ferential immune reactivity in retreatment cases, and technical
reasons, among others. Furthermore, we lacked long-term sys-
tematic clinical outcome data to incorporate into a reference
standard; however, this lacks specificity as empiric overtreat-
ment is frequent in high-burden settings [28, 38, 39], patients
without tuberculosis can still improve when on antituberculosis
treatment, and patients with tuberculosis and a concomitant in-
fection (eg, Pneumocystis) can still fail to improve. Laboratory
error and sample cross-contamination are, as always, potential
sources of error; however, Xpert is a closed system that generates
few aerosols [40], and we performed Xpert in a quality-assured
laboratory separate to that used for culture. Finally, it should
also be noted that these findings, which are from a high-burden
setting with a high intensity of transmission and where retreat-
ment tuberculosis is relatively common, should undergo further
validation, especially in different settings.
In summary, patients with a history of tuberculosis, more re-
cent previous tuberculosis, and a CXR incompatible with active
tuberculosis are at a higher risk of Xpert false positivity; howev-
er, these do not add discriminatory power over and above CT
alone. Although most FP cases would be missed, clinicians
should treat CT > 30 in retreatment cases with caution. Further
investigation is needed to discriminate NAAT FP patients from
TP patients, including research into technologies that exclude
DNA from nonintact cells (such as propidium monoazide or
ethidium monoazide staining [41, 42]) or detect messenger
RNA in live bacilli [43]. This is important as next-generation
NAATs, such as Xpert Ultra, will purportedly have a sensitivity
approaching that of culture [44], and hence be more likely to de-
tect low quantities of residual tuberculosis DNA and have poor
specificity in patients who have previously had tuberculosis.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
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materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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ABSTRACT Globally, Xpert MTB/RIF (Xpert) is the most widely used PCR test for the
diagnosis of tuberculosis (TB). Positive results in previously treated patients, which
are due to old DNA or active disease, are a diagnostic dilemma. We prospectively re-
tested sputum from 238 patients, irrespective of current symptoms, who were previ-
ously diagnosed to be Xpert positive and treated successfully. Patients who retested
as Xpert positive and culture negative were exhaustively investigated (repeat cul-
ture, chest radiography, bronchoscopy with bronchoalveolar lavage, long-term clini-
cal follow-up). We evaluated whether the duration since previous treatment comple-
tion, mycobacterial burden (the Xpert cycle threshold [CT] value), and reclassification
of Xpert-positive results with a very low semiquantitation level to Xpert-negative re-
sults reduced the rate of false positivity. A total of 229/238 (96%) of patients were
culture negative. Sixteen of 229 (7%) were Xpert positive a median of 11 months (in-
terquartile range, 5 to 19 months) after treatment completion. The specificity was
93% (95% confidence interval [CI], 89 to 96%). Nine of 15 (40%) Xpert-positive,
culture-negative patients reverted to Xpert negative after 2 to 3 months (1 patient
declined further participation). Patients with false-positive Xpert results had a lower
mycobacterial burden than patients with true-positive Xpert results (CT, 28.7 [95% CI,
27.2 to 30.4] versus 17.6 [95% CI, 16.9 to 18.2]; P  0.001), an increased likelihood of
a chest radiograph not compatible with active TB (5/15 patients versus 0/5 patients;
P  0.026), and less-viscous sputum (15/16 patients versus 2/5 patients whose spu-
tum was graded as mucoid or less; P  0.038). All patients who initially retested as
Xpert positive and culture negative (“Xpert false positive”) were clinically well with-
out treatment after follow-up. The duration since the previous treatment poorly pre-
dicted false-positive results (a duration of 2 years identified only 66% of patients
with false-positive results). Reclassifying Xpert-positive results with a very low semi-
quantitation level to Xpert negative improved the specificity (3% [95% CI, 2 to
5%]) but reduced the sensitivity (10% [95% CI, 4 to 15%]). Patients with pre-
vious TB retested with Xpert can have false-positive results and thus not require
treatment. These data inform clinical practice by highlighting the challenges in inter-
preting Xpert-positive results, underscore the need for culture, and have implications
for next-generation ultrasensitive tests.
KEYWORD Mycobacterium tuberculosis
Xpert MTB/RIF (Xpert) is a widely used DNA-based PCR test for the diagnosis ofactive tuberculosis (TB) (1). Mycobacterial DNA and Xpert positivity can persist in
the absence of culturable bacilli for years after treatment (2–4). However, the signifi-
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cance of Xpert-positive, culture-negative results (Xpert false-positive results) remains
uncertain because culture is an imperfect “gold standard” susceptible to sampling error
and technical variation (5, 6). Understanding these Xpert false-positive results is critical
given the large global burden of symptomatic patients who present for investigation
for active TB but have previously been treated for active TB (15% of the 10 million
cases in 2015) (7, 8), Xpert’s routine use as a frontline test in those with previous TB (20
to 30% of presumptive TB patients in South Africa) (9), and Xpert-based active case
finding in people with previous TB (10).
This issue is compounded by the imminent introduction of a new, highly sensitive
version of Xpert called the Xpert MTB/RIF Ultra test (Ultra) that, by virtue of its superior
limit of detection (11), is likely confounded by residual mycobacterial DNA to a greater
extent than the current-generation Xpert cartridge. For example, as described in a
recent World Health Organization policy document, Ultra’s preliminary specificity (rel-
ative to the results of culture) was lower in patients with a history of TB than in those
with no history of TB, and this specificity reduction was greater than that seen with
Xpert (5.4% [95% confidence interval {CI}], 9.1 to 3.1%) versus 2.4% [95% CI,
4.0 to 1.3%] (12). The significance, however, of supposedly false-positive results is
not well understood. Furthermore, the persistence of PCR positivity in the absence of
culturable bacilli may predict relapse or subclinical disease (13, 14); however, few
studies have monitored Xpert-positive patients after treatment completion.
Previously, in a retrospective evaluation using biobanked sputa from patients with
presumptive TB, we described the frequency and predictors of Xpert false positivity in
previously treated patients (2). We also showed that Xpert detects DNA from nonintact
cells, suggesting that dead bacilli contribute to the false positivity. However, as culture
is a suboptimal reference standard (15) and adjunct diagnostic tools like chest radiog-
raphy have poor specificity, especially in high-risk populations infected with HIV (16,
17), we could not discriminate whether Xpert-positive, culture-negative patients were
true Xpert false positives in the absence of prospective follow-up and further investi-
gations. In the current study, we performed repeat microbiological testing, bronchos-
copy, and prospective clinical follow-up in a new cohort of patients with previous TB to
discern the characteristics, profiles, and frequencies of patients with Xpert-positive,
culture-negative results. We also present the results of new analyses performed using
pooled data from both our new cohort and a previous study (2).
MATERIALS AND METHODS
Participant recruitment. We consecutively recruited adults (age, 18 years) from April 2015 to June
2016, irrespective of whether they were symptomatic, from Cape Town, South Africa, who were
previously diagnosed to be sputum Xpert positive in diagnostic research studies at the University of Cape
Town (18, 19). Patients had been successfully treated for TB in the program. Through the details provided
previously, patients were contacted and asked to return for enrollment in this study. Thus, all enrolled
patients had been previously treated for proven TB and were recontacted for opportunistic sampling. We
excluded patients currently on treatment. This study was approved by the University of Cape Town
Faculty of Health Sciences Ethics Committee (approval 698/2014).
Diagnostic tests, procedures, and clinical follow-up. At recruitment, patients gave two induced
sputum specimens (20) and received a previously validated morbidity score, administered by a research
nurse (21). One sputum specimen was randomly selected for testing with Xpert, and the other was used
for both Ziehl-Neelsen smear microscopy and liquid culture with the MGIT 960 system. Prior to the
addition of the Xpert sample reagent, the viscosity of the Xpert sputum was subjectively graded (as
mucopurulent, purulent, mucosalivary, or salivary) as previously described (22). At the first visit, patients
who tested Xpert positive and culture negative were referred for a clinical examination prior to
bronchoscopy. We recorded the semiquantitative level of Xpert-positive results, which are automatically
reported by the GeneXpert software on the basis of predefined cycle threshold (CT) values (CT values are
inversely proportional to the concentration of mycobacterial DNA in a specimen) (23, 24). At examination,
patients underwent another round of sputum-based testing with Xpert and culture, as well as chest
radiography. Irrespective of the test results from this prebronchoscopy visit, all Xpert-positive, culture-
negative patients from enrollment were asked to undergo bronchoscopy with bronchoalveolar lavage as
previously described (25). Testing by Xpert and culture was done on the bronchoalveolar lavage fluid
(BALF). Patients who were culture positive from any specimen were referred to the program for
treatment and exited the study. Patients who initially retested Xpert false positive were visited at home
or contacted telephonically in December 2016 to ascertain their health status.
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Statistical analyses. We defined patients who were Xpert positive, culture negative using sputa from
their first visit as false positive. The 2 and Mann-Whitney tests were used to compare the proportions
and differences in nonparametric continuous data, respectively. McNemar’s test was used to calculate the
changes in sensitivity and specificity after reclassification of Xpert-positive results on the basis of their
semiquantitative levels. All specificity calculations were done using the paired Xpert and culture result
from the first visit (culture served as a reference standard). To analyze how Xpert specificity changed over
time since previous treatment completion, we constructed fractional polynomial prediction plots locally
weighted to the number of Xpert-negative, culture-negative (true-negative) patients at each time point.
Exact binomial 95% confidence intervals were calculated. We used a sliding time window (e.g., at 2
months, only patients for whom 2 months or longer had passed since the completion of treatment for
their previous case of TB were included in the specificity calculation). To achieve greater statistical power
for analyses involving years, we combined our data with those from a previously described cohort of
patients with a history of TB who were symptomatic and underwent Xpert testing (2). We used GraphPad
Prism (version 6.0; GraphPad Software) and Stata (version 14; StataCorp) software. All statistical tests were
two-sided at an  level of 0.05.
RESULTS
Xpert-positive results in previously treated TB patients. Of the 262 patients
recruited, 24 were excluded (Fig. 1). A median of 11 months (interquartile range [IQR],
5 to 19 months) passed between the completion of treatment for the previous episode
and recruitment. As determined using sputa collected at recruitment, 9 of the 238 (4%)
included patients were culture positive and 5/9 (55%) were Xpert positive. Sixteen of
229 (7%) culture-negative patients were Xpert positive (specificity, 93%; 213/229 [95%
CI, 89 to 96%]). False-positive patients had a lower bacillary burden (mycobacterial
DNA) than true-positive patients (median Xpert CT, 28.66 [IQR, 27.21 to 30.4] versus
17.64 [16.86 to 18.20]; P  0.001), an increased likelihood of a chest radiograph not
compatible with active TB (5/15 patients versus 0/5 patients; P  0.026), sputum that
was less viscous (15/16 patients versus 2/5 patients had a grade of mucoid or less; P 
0.038), and trends toward more recent previous TB (5 months [IQR, 5 to 6 months]
versus 11 months [IQR, 4 to 16 months] since treatment completion; P  0.112) and a
lower morbidity score (0 [IQR, 0 to 1] versus 3 [IQR, 3 to 4]; P  0.067). Internal positive
control CT values, used to detect possible PCR inhibition (26), did not differ between
FIG 1 Study flow diagram and test results.
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false- and true-positive patients (24.8 [IQR, 22.4 to 26.1] versus 25.4 [IQR, 24.5 to 26.2];
P  0.561). Six of the 16 Xpert-positive, culture-negative patients (38%) met WHO
symptom criteria for TB testing (Table 1) (10).
Repeat Xpert and culture results in false-positive patients with a history of TB.
Fifteen false-positive patients were successfully referred for clinical examination (me-
dian time since recruitment, 2 months [IQR 2 to 3 months]) prior to bronchoscopy.
Xpert and culture were repeated with sputum, and the number of Xpert-positive
patients decreased to six (nine were now Xpert negative). We detected no significant
differences, including the time between repeat testing (2 months [IQR, 2 to 2 months]
versus 2 months [IQR, 1 to 2.25 months]; P  0.723), between patients whose Xpert
result remained positive and those whose Xpert result changed to negative. All 15
patients were still sputum culture negative. Of the 12 patients who underwent bron-
choscopy (Fig. 1; three patients declined bronchoscopy), 6 patients were BALF Xpert
positive and 6 were BALF Xpert negative (all 12 were BALF culture negative). The results
of Xpert with BALF had a poor concordance with the results of Xpert with sputum
collected at the prebronchoscopy clinical examination visit: half of sputum Xpert-
positive patients were BALF Xpert negative (3/6), and half of BALF Xpert-positive
patients were sputum Xpert negative (3/6). An overview of each false-positive patient,
their clinical characteristics, and their results are provided in Table 1.
Clinical follow-up. Of the 16 Xpert false-positive patients, 15 were successfully
followed up after a median time of 17 months (IQR, 16 to 18 months) (patient RX102
relocated). Fourteen patients were reported to be healthy and asymptomatic, including
the 3 (patients RX59, RX122, and RX146) who opted out of bronchoscopy. One patient
(patient RX124; a heavy smoker) reported a persistent cough but had recently been
screened for TB at the local clinic and was Xpert and culture negative.
Period since previous TB and Xpert false positivity. Of the 229 culture-negative
patients, 214 (94%) had data on the number of months that had passed since their
previous TB treatment. A total of 172/214 (80%) had treatment within 24 months,
including 15 false-positive patients (1 false-positive patient was missing this informa-
tion). Hence, when the data for culture-negative patients who had received treatment
within the last 2 years were excluded (Fig. 2A), the specificity rose from 93% (95% CI,
89 to 96%; 213/229) to 100% (95% CI, 92 to 100%; 42/42).
As our cohort of retested patients included those with relatively recent TB, to
explore the impact of time since previous treatment on a larger scale (years), we did
new analyses with data pooled with data from another cohort of patients with a history
of TB (2). Using these pooled data, the overall specificity in patients with previous TB
was 94% (95% CI, 93 to 95%; 951/1,011), and the specificity increased to 95% (95% CI,
94 to 96%; 974/920) and 97% (95% CI, 95 to 98%; 689/713) when the data for patients
who had completed treatment within 1 and 2 years, respectively, were excluded from
calculations (Fig. 2B). The specificity plateaued thereafter.
We next evaluated whether the time (in years) since previous treatment completion
could accurately classify false-positive patients in our pooled data (Fig. 3). This could be
useful to channel patients into different diagnostic algorithms for those with a recent
history of TB that account for Xpert’s compromised specificity. If a same-year cutoff
point were used, 30% (95% CI, 24 to 35%; 52/203) of Xpert false-positive patients would
be correctly classified, increasing to 52% (95% CI, 46 to 58%; 106/203) and 64% (95%
CI, 58 to 70%; 130/203) when cutoff points of 2 and 3 years, respectively, were used.
However, high proportions of patients with active TB who would be correctly detected
by Xpert would be erroneously excluded as likely false positive (83% [95% CI, 82 to 85%;
1,315/1,582], 67% [95% CI, 65 to 69%; 1,062/1,582], and 54% [95% CI, 52 to 56%;
854/1,582] for each of the three cutoff points, respectively). The amount of time since
the previous treatment alone is, hence, unsuitable for accurately discriminating be-
tween patients that are likely to be Xpert false or true positive.
Reclassification of Xpert MTB/RIF-positive patients with a semiquantitative
level of very low as Xpert negative. Using pooled data, Xpert’s sensitivity and
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specificity in previously treated patients were 84% (95% CI, 80 to 88%; 326/388) and
93% (95% CI, 88 to 96%; 984/1,049), respectively, whereas after reclassification they
were 75% (95% CI, 70 to 79%; 289/388; P  0.001) and 97% (95% CI, 96 to 98%;
1,020/1,049; P  0.001), respectively. The specificity hence improved (3% [95% CI, 2
to 5%]), but sensitivity was reduced (10% [95% CI, 4 to 15%]).
DISCUSSION
This study is the first to undertake a prospective follow-up and an exhaustive
investigation to correctly classify Xpert-positive, culture-negative results in patients
with previous TB. The key findings are as follows: (i) false-positive Xpert results occur in
a significant minority of patients with previous TB, (ii) Xpert-positive, culture-negative
patients remained healthy (or had minimal symptoms) and were consistently culture
negative without treatment, suggesting that they do not have active disease, (iii)
although the characteristics of false-positive patients differ significantly from those of
true-positive patients, these characteristics (most importantly, the time since previous
TB) have a poor predictive capability for identifying patients likely to be false positive,
and (iv) Xpert-positive results in previously treated patients were transient, and about
half transitioned to Xpert-negative results after later retesting.
We have previously described the increased likelihood of Xpert false-positive results
in symptomatic patients with previous TB; however, here we show for the first time that
this can occur in patients who are healthy or have minimal symptoms. In a routine
FIG 2 Specificity of Xpert MTB/RIF at different time points, in months (A) and years (B), after the
completion of treatment for the previous episode of TB. Sliding windows including patients at each time
point or thereafter were used to calculate specificity. When the analyses were restricted to patients
without recent previous TB, the specificity improved.
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context, such individuals may be tested with highly sensitive nucleic acid amplification
tests as contacts of index cases or as part of targeted active case finding in special
populations. Xpert has been reported to have a high specificity in the community-
based screening of healthy individuals; however, this was in a setting with a very low
prevalence of previous TB (27). This requires confirmation in settings with a high
burden of patients with previous TB.
Importantly, we found that the amount of time since previous treatment was likely
not useful to programs or clinicians looking to accurately discriminate between patients
with a history of TB who are likely to be Xpert false positive and those who are true
positive. Although the decreasing likelihood of Xpert false positivity since the time
since previous treatment has been described before (2, 3), here we describe this
phenomenon for the first time on a fine scale (i.e., months), which is important, as most
recurrences occur within 1 to 2 years of treatment completion and the use of this more
granular time scale may be more sensitive than the use of a blunter years-based
approach (28, 29). This finding regarding time is similar to our previous findings
regarding the mycobacterial load (CT value), where, although patients with false-
positive results had significantly fewer bacilli in their sputum than patients with
true-positive results, this did not translate into clinically useful predictive values (2).
Interestingly, we also found patients with false-positive results to have less-viscous
sputum. This is congruent with our findings regarding CT values, as more salivary
sputum has previously been shown to be associated with a lower bacillary load (30).
Importantly, Xpert false positivity was transient. After an average of 2 months
between recruitment and repeat sputum testing (prior to bronchoscopy), over half of
Xpert false-positive patients were Xpert negative. Thus, detection of DNA from a
previous TB episode can be stochastic (this may be due to sampling error or the gradual
elimination of pathogen DNA by the host). HIV-positive patients, even those on
antiretroviral therapy, have compromised pulmonary immune clearance (31) and may
thus be more susceptible to sustained false positivity.
After long-term follow-up, false-positive patients remained culture negative and
asymptomatic without treatment, indicating that they were highly unlikely to go on to
develop active TB. This is despite the fact that most false-positive patients, including
those with HIV infection, had a chest radiograph compatible with active TB. This
complicates the management of Xpert-positive patients with prior TB. Thus, in our
cohort of retested patients with a history of previous TB and minimal symptoms, all
Xpert-positive, culture-negative patients overall had little evidence of active TB after an
intensive workup.
We found that reclassifying Xpert false-positive patients with the lowest semiquan-
FIG 3 Suboptimal sensitivity (squares, dashed line) and specificity (circles, solid line) of different cutoff
points (years) for classifying patients with previous TB as likely to be false or true positive with Xpert.
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titative level as negative increased the specificity. However, the resultant reduction in
sensitivity was more than 2-fold the specificity gained. This may limit the attractiveness
of this approach, which has been mooted for the new Ultra’s trace level. Such a
reclassification in Ultra may result in changes in sensitivity different from those in Xpert
(12); however, the payoffs should be modeled in different patients and settings.
In terms of limitations, first, at the time of our study, Ultra was not available, and its
specificity requires investigation in patients with previous TB. Our findings also require
validation in different populations, settings, and studies containing larger sample sizes.
Second, we targeted known previous TB cases irrespective of their symptoms. Although
many had symptoms upon retesting, they are a population distinct from self-presenting
patients with prior TB. It is also possible that patients who are Xpert positive after
treatment completion might still benefit from treatment, despite being culture nega-
tive (e.g., to reduce relapse); however, this requires prospective investigation.
In conclusion, these findings have implications for the interpretation of Xpert-
positive results in patients with previous TB and provide evidence of Xpert’s suboptimal
specificity. It also informs how clinicians should manage false-positive patients. Impor-
tantly, given that clinical and test characteristics (including the CT values) and the time
since previous treatment cannot accurately classify which patients will likely have a
false-positive Xpert result, careful clinical assessment and additional tools (e.g., culture,
clinical follow-up) remain essential for the management of Xpert-positive patients with
previous TB.
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A burgeoning epidemic of drug-resistant tuberculosis now threatens to derail global 27 
tuberculosis control efforts. Although the mechanisms remain poorly clarified, drug-resistant 28 
strains are widely believed to be less efficient at airborne transmission and hence less infectious 29 
than drug-susceptible strains. We hypothesised that multiple factors, including mycobacterial 30 
genomic variation, would be associated with infectiousness. We quantified infectiousness 31 
using a cough aerosol sampling system that enumerated Mycobacterium tuberculosis colony 32 
forming units in respirable (≤10µm) cough-generated aerosols from 500 tuberculosis patients 33 
(227 with drug-resistance), performed mycobacterial whole genome sequencing, dormancy 34 
phenotyping, and drug susceptibility analyses, and compared clinical characteristics. Even after 35 
taking into account treatment duration, we found that almost half of drug-resistant tuberculosis 36 
patients were highly infectious, challenging current beliefs. Surprisingly, neither mycobacterial 37 
genomic variants, lineage, nor dormancy status predicted high infectiousness. Several 38 
mycobacterial and clinical characteristics, including minimal symptoms and stronger cough, 39 
were associated with infectiousness, supporting a change in public health strategy to one of 40 
active rather than passive case finding. Effective treatment largely abrogated infectiousness but 41 
some patients remained infectious despite effective treatment. These data question current 42 
paradigms, inform public health strategies to reduce tuberculosis transmission, and suggest the 43 
need to redirect tuberculosis transmission-associated research efforts towards host-pathogen 44 
interactions.  45 
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Drug-resistant tuberculosis (TB), an underdiagnosed disease characterised by high mortality, 47 
unsustainable costs, limited effective drugs, and severe treatment-related adverse events, is 48 
predominantly caused by airborne transmission rather than reactivation or acquired drug 49 
resistance.1-5 Animal6-9, epidemiological10-18, and modelling studies19,20 all indicate that an 50 
infectious minority of patients drive TB epidemics. Understanding and identifying these 51 
sentinels of transmission – sometimes termed “super-spreaders” – and rendering them non-52 
infectious is critical for epidemic control.19,21 There are, however, few data about the 53 
infectiousness of patients with drug-resistant TB, which might be associated with the 54 
differential fitness and transmission potential of strains23,24. We defined infectiousness as the 55 
combined ability of the index case and pathogen to generate infectious quanta measured using 56 
Mycobacterium tuberculosis colony forming units from inhalable cough aerosol22. We 57 
hypothesised that drug-resistant and drug-susceptible patients would exhibit large variation in 58 
infectiousness. We reasoned this would be explained by host and mycobacterial factors, 59 
including those known fitness-encoding mutations25, given that these genomic variations 60 
would likely underpin the ability of more infectious strains to better withstand the 61 
environmental stress of aerosolisation, dehydration, and airborne travel compared to less 62 
infectious ones. We also evaluated the effect of treatment on infectiousness, which has 63 
implications for transmission interruption interventions.   64 
We therefore undertook the largest study to date of inhalable cough aerosols (Supplementary 65 
Figure 1) from adult drug-susceptible and drug-resistant pulmonary TB patients (n=500 total). 66 
This approach used a cough aerosol sampling system (CASS) (Figure 1A) that enumerates and 67 
size-classifies aerosol particles with culturable Mycobacterium tuberculosis.22,26,27 We 68 
collected comprehensive clinical data that included symptom score, HIV status, lung function, 69 
radiographic disease severity28, and treatment history. Microbiological information included 70 
sputum Xpert MTB/RIF, Nile-Red staining of dormancy-associated intracellular fatty acids29, 71 
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smear microscopy, MGIT960 culture, sequencing and phenotypic drug susceptibility testing30 72 
(Online Methods). We categorised patients into Groups 1 (non-rifampicin resistant; n=227), 73 
2 (rifampicin-resistant but not to fluroquinolones and aminoglycosides; n=162), or 3 74 
(extensively drug-resistant; resistance to rifampicin, fluroquinolones and aminoglycosides; 75 
n=109). We defined “CASS-positives” as patients with any M. tuberculosis aerosol colony 76 
forming units (CFUs) and a drug as “likely effective” if in vitro resistance was undetected. We 77 
re-sampled CASS-positive patients and separately assessed reproducibility.  78 
Compared to Groups 1 and 2, Group 3 patients had more disease on chest radiography, more 79 
previous TB episodes (including more previous drug-resistance episodes), worse lung function 80 
[peak expiratory flow (PEF), forced expiratory volume (FEV1)] and, despite more TB drugs, 81 
received fewer likely effective drugs and were on treatment longer before CASS 82 
(Supplementary Tables 1-2). Of 452 patients with reliable (non-contaminated) CASS results, 83 
142 (31%) were CASS-positive (Figure 1B). 42/142 (30%) of CASS-positives had ≥10 CFU 84 
in aerosol (reflecting high infectiousness) and 60% of patients’ CFU was in particles ≤4.7 µm 85 
likely to be deposited in the smallest airways31 (Figure 1C). 24/34 (70%) of Group 2 and 9/23 86 
(40%) of Group 3 CASS-positives were outpatients, reflecting risk of community-based 87 
transmission. Although a small number of smear-negatives were CASS-positive [9/137 (7%)], 88 
aerosol CFU positively correlated with sputum bacillary load (Figures 1D-E). We then 89 
calculated the diagnostic accuracy of different biomarkers for infectiousness using CASS as a 90 
reference standard (Supplementary Table 3). Receiver operator characteristic areas under the 91 
curves (smear grade, CTmin; Figure 1F) were similar and, at rule-out thresholds (≥95% 92 
sensitivity), specificities were suboptimal (42% for smear, 33% for Xpert). At rule-in 93 
thresholds (≥95% specificity), sensitivities were poor (14%, 15%).  94 
A greater proportion of Group 1 patients were CASS-positive than in Groups 2 and 3 combined 95 
[82/201 (41%) vs. 60/249 (24%); p<0.001] (Figure 1G). After stratification by treatment 96 
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duration, similar proportions of patients on treatment ≤48h were CASS-positive in Group 1 vs. 97 
Groups 2 and 3 combined [38/73 (52%) vs. 18/48 (48%); p=0.116] and the median (IQR) 98 
aerosol CFU from CASS-positives did not differ [4 (2-16) vs. 2 (1-20); p=0.757]. CASS-99 
positivity was more frequent in patients on treatment for shorter durations [e.g., Group 1: 28/73 100 
(53%) ≤48h vs. 86/329 (26%) >48h, p<0.001; Supplementary Table 4] and aerosol CFU 101 
exhibited a similar pattern (Supplementary Figure 3). However, some patients posed an 102 
infectious risk despite likely effective treatment for several days and adherence per records 103 
(Supplementary Tables 5 and 6). For example, 7/27 (26%) of Group 1 patients treated for 104 
eight days were CASS-positive.  105 
Surprisingly, neither lineage spoligotype nor M. tuberculosis genomic variants (SNPs, indels) 106 
were associated with CASS-positivity (Figure 2A; Supplementary Results).  107 
Nonsynonymous rpoB and pks1 variants trended towards an association but did not reach 108 
significance. Similarly, genomic analyses for sputum culture time-to-positivity (itself a 109 
predictor of CASS-positivity26 and transmission32) did not detect associations (Supplementary 110 
Figure 4). Furthermore, clusters comprised of ≥1 CASS-positive isolate(s) had similar inter-111 
isolate single nucleotide polymorphism distances and number of linkages to other isolates 112 
compared to clusters comprised exclusively of CASS-negatives (Supplementary Table 7). 113 
Nile-Red straining did not detect an association with CASS-positivity (Figure 2B). 114 
In unadjusted univariate analyses (Table 1), CASS-positivity was associated with younger age, 115 
male sex, smoking, being community-based, fewer symptoms, no HIV infection, not receiving 116 
TB treatment, better lung function (PEF, FEV1), higher peak cough flow (PCF), mucopurulent 117 
sputum, sputum bacillary load, and drug-susceptibility (patient group). However, in 118 
multivariate analyses that considered treatment duration but not individual drugs (Table 1), 119 
fewer symptoms, stronger PCF and increased sputum bacillary load independently-predicted 120 
CASS-positivity. Patients with HIV or in Group 2 were less likely to be CASS-positive. 121 
167
Stellenbosch University https://scholar.sun.ac.za
Similarly, in a clinically-orientated model including data only available from rapid tools, Xpert 122 
CTmin and treatment ≤48h independently-predicted CASS-positivity. When these variables were 123 
incorporated into a clinical prediction rule, the rule had higher AUC than CTmin alone; correctly 124 
classifying approximately double the proportion of CASS-positives [32% vs. 15%, p<0.001)] 125 
(Figure 2F, Supplementary Table 2). Although pulmonary cavitation was weakly associated 126 
with sputum bacillary load and CASS-positivity (Supplementary Figure 4), the latter 127 
relationship was absent in multivariate analyses.   128 
We examined the association of drug regimen with CASS-positivity. In univariate analyses, 129 
CASS-positivity was inversely associated with each additional drug in the regimen [OR (95% 130 
CI) 0.75 (0.65, 0.87) per drug; p<0.001] and a fluoroquinolone (FQ)-based regimen [0.32 (0.19, 131 
0.53); p<0.001]. The latter was the only drug-related variable significant in a multivariate 132 
model [0.34 (0.17, 0.65); p=0.001] (Supplementary Tables 8-9).  133 
66/80 (83%), 29/34 (85%), and 18/23 (78%) baseline CASS-positive patients in Groups 1, 2, 134 
and 3, respectively were re-sampled at least once (Figure 3). 3/66 (5%) in Group 1 were repeat 135 
CASS-positive despite likely effective treatment and adherence (one Group 2 repeat positive 136 
non-adherent). Group 3 patients displayed prolonged infectiousness with 7/18 (40%) repeat 137 
CASS-positive. In a separate cohort of pre-treatment TB patients(n=29; Supplementary 138 
Tables 10-11), CASS was most reproducible across morning samplings ( “fair”33 CASS-139 
positivity kappa, “substantial”34 aerosol CFU intraclass correlation coefficient).  140 
Our two main findings are that almost half the patients with drug-resistant TB (including 141 
community-discharged therapeutically destitute patients) are highly infectious within the first 142 
48h of treatment, and there is a lack of association between infectiousness and mycobacterial 143 
genomic variants. Other key findings were that 1) mycobacterial physiological state was similar 144 
in CASS-positives versus negatives, 2) specific host factors (fewer symptoms, stronger cough, 145 
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no HIV, treatment ≤48h) and mycobacterial factors (higher sputum bacillary load) 146 
independently predict infectiousness, 3) a subset of patients had elevated infectiousness during 147 
likely effective treatment (although more pronounced for drug-resistant TB, this was also 148 
observed for drug-susceptible TB), and 4) fluoroquinolones were associated with reduced 149 
infectiousness. 150 
The transmissibility of differentially drug resistant strains is controversial23,35. We have now 151 
shown that drug-resistant patients are highly infectious based on culturable aerosol production. 152 
We hypothesised that lineage and genomic variants influence infectiousness; however, we 153 
found no such linkages. This suggests that there are alternative post-aerosolisation mediators 154 
of strain success, including host genetic background, strain epigenetics, inhalational burden 155 
reaching alveoli, and repetitive infection events. Sputum with high Nile-Red positivity is 156 
associated with reduced culturability39,40 but we did not detect associations with CASS-157 
positivity. Alternative methods of measuring dormancy, like those that use resuscitation-158 
promoting factors36, might be more sensitive. 159 
We identified new host factors that overwhelmingly drove infectiousness, in addition to those 160 
described earlier.27,37 Our finding that healthier patients are more infectious support rollout of 161 
community-based active case finding as a public health strategy that targets cases with minimal 162 
symptoms. The advent of portable molecular diagnostics makes this approach feasible38.  163 
Patients with drug-sensitive TB are often considered non-infectious approximately two weeks 164 
after effective treatment initiation39-41 and animal models suggest that, even within 48h, drug-165 
resistant cases may be non-infectious42. By contrast, we found culturable aerosol in 34% of 166 
drug-susceptible cases on likely effective treatment >48h. Although we did not recruit drug-167 
susceptible cases on treatment beyond two weeks, a low proportion of drug-susceptible CASS-168 
positives (4%) were still detected a month after re-sampling, suggesting that a persistently 169 
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infectious drug-susceptible subset exists. This may be because of suboptimal 170 
pharmacokinetics, including due to poor cavitary penetration43, heteroresistance, or 171 
undocumented treatment non-compliance. These data support cautious approaches to decide 172 
when TB patients are non-infectious.41,44,45 Indicative of few treatment options available at the 173 
time, when baseline Group 3 CASS-positives were re-sampled, 40% remained CASS-positive 174 
– including some over a year since treatment initiation. This underscores the need for scale-up 175 
of new drugs, and provision of community-based palliative and long stay facilities46,47. Our 176 
inability to establish an accurate clinical prediction rule suggests the need for a user-friendly 177 
test for infectiousness. 178 
A strength and limitation of our approach is that we measured infectiousness (transmission 179 
potential) rather than transmission itself, which is a complex multifactorial process48. Indeed, 180 
we could not measure the effects of inhalation, alveolar germination, and host immunity all of 181 
which animal models can do9,42,49-55. However, CASS-measured cough aerosol culturability is 182 
the biomarker most highly associated with transmission-related outcomes (e.g. skin test 183 
conversion and active TB) in humans.27,56,57 Low infectiousness (CASS-negativity) may still 184 
result in transmission if exposure is prolonged, repetitive, or occurs in poorly ventilated areas. 185 
Characterising M. tuberculosis in aerosol, especially in its de novo physiological state, is 186 
challenging and we hence interrogated Nile Red status, however, this measures only one 187 
dimension of dormancy.  188 
In conclusion, drug-resistant TB is highly infectious. Mycobacterial genomic variation and 189 
physiological state were not associated with infectiousness. Increased infectiousness among 190 
patients with minimal symptoms supports the urgent need for community-based active case 191 
finding approaches, and new infection control strategies as patients can remain infectious 192 
despite prolonged effective treatment.   193 
170
Stellenbosch University https://scholar.sun.ac.za
Data availability statement 194 
The datasets generated during and/or analysed during the current study are available from the 195 
corresponding author on reasonable request. 196 
Acknowledgements 197 
The authors are indebted to the patients who participated. The study would not have been 198 
possible without the remarkable efforts of Sr Ruth Wilson and Mr Gerrit Pretorius. We also 199 
thank Srs Maria Pienaar and Marietjie Pretorius, Drs Paul Spiller, Marinus Barnard, and John 200 
Simpson, Tania Dolby, Ruzayda van Aarde, Charlene Clarke, and Brigitta Derrendinger for 201 
their invaluable assistance. WGS computations were done using facilities provided by the 202 
University of Cape Town’s ICTS High Performance Computing team. 203 
Funding statement 204 
The project was funded by the NIH (1R01AI104817-01), Wellcome Trust (099854/Z/12/Z), 205 
and the South African Medical Research Council (SA-MRC; Career Development Award, 206 
Self-initiated Research Award). The content is solely the responsibility of the authors and does 207 
not necessarily represent the official views of the South African Medical Research Council. 208 
GT acknowledges funding from SA-MRC (RFA-IFSP-01-2013), the EDCTP2 programme 209 
supported by the European Union (SF1401, OPTIMAL DIAGNOSIS), and the Faculty of 210 
Medicine and Health Sciences, Stellenbosch University. KD and this work were supported by 211 
the SAMRC (RFA-EMU-02-2017) and the EDCTP2 programme (TMA-2015SF-1043, TMA-212 
1051-TESA). KF was supported by the Intramural Research Program of the NIH, National 213 
Heart, Lung, and Blood Institute. The financial assistance of the National Research Foundation 214 
(NRF) towards this research is acknowledged. Opinions expresses and conclusions arrived at, 215 




1 Pooran, A., Pieterson, E., Davids, M., Theron, G. & Dheda, K. What is the Cost of Diagnosis 218 
and Management of Drug Resistant Tuberculosis in South Africa? PloS one 8, e54587 (2013). 219 
2 Dheda, K. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management 220 
of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The lancet 221 
Respiratory medicine 5, 291-360 (2017). 222 
3 Dheda, K. et al. Global control of tuberculosis: from extensively drug-resistant to untreatable 223 
tuberculosis. The Lancet Respiratory Medicine 2, 321-338 (2014). 224 
4 Shean, K. et al. Drug-Associated Adverse Events and Their Relationship with Outcomes in 225 
Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. 226 
PloS one 8, e63057 (2013). 227 
5 Kendall, E. A., Fofana, M. O. & Dowdy, D. W. Burden of transmitted multidrug resistance in 228 
epidemics of tuberculosis: a transmission modelling analysis. The Lancet Respiratory 229 
Medicine 3, 963-972 (2015). 230 
6 Riley, R. et al. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of 231 
infected air: comparative infectiousness of different patients. The American review of 232 
respiratory disease 85, 511 (1962). 233 
7 Nardell, E. A. Environmental control of tuberculosis. The Medical clinics of North America 77, 234 
1315 (1993). 235 
8 Sultan, L. et al. Tuberculosis disseminators. A study of the variability of aerial infectivity of 236 
tuberculous patients. American Review of Respiratory Disease 82, 358-369 (1960). 237 
9 Escombe, A. R. et al. The infectiousness of tuberculosis patients coinfected with HIV. PLoS 238 
medicine 5, e188 (2008). 239 
10 Tostmann, A. et al. Tuberculosis transmission by patients with smear-negative pulmonary 240 
tuberculosis in a large cohort in the Netherlands. Clinical infectious diseases : an official 241 
publication of the Infectious Diseases Society of America 47, 1135-1142, doi:10.1086/591974 242 
(2008). 243 
11 Walker, T. M. et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis 244 
outbreaks: a retrospective observational study. The Lancet. Infectious diseases 13, 245 
doi:10.1016/s1473-3099(12)70277-3 (2013). 246 
12 Behr, M. et al. Transmission of Mycobacterium tuberculosis from patients smear-negative 247 
for acid-fast bacilli. The Lancet 353, 444-449 (1999). 248 
13 Van Geuns, H., Meijer, J. & Styblo, K. Results of contact examination in Rotterdam, 1967-249 
1969. Bulletin of the International Union against Tuberculosis 50, 107 (1975). 250 
14 Alland, D. et al. Transmission of tuberculosis in New York City--an analysis by DNA 251 
fingerprinting and conventional epidemiologic methods. New England Journal of Medicine 252 
330, 1710-1716 (1994). 253 
15 Hamburg, M. A. & Frieden, T. R. Tuberculosis transmission in the 1990s. New England 254 
Journal of Medicine 330, 1750-1751 (1994). 255 
16 Small, P. M. et al. The epidemiology of tuberculosis in San Francisco--a population-based 256 
study using conventional and molecular methods. New England Journal of Medicine 330, 257 
1703-1709 (1994). 258 
17 Melsew, Y. A. et al. The role of super-spreading events in Mycobacterium tuberculosis 259 
transmission: evidence from contact tracing.  19, 244, doi:10.1186/s12879-019-3870-1 260 
(2019). 261 
18 Ypma, R. J., Altes, H. K., van Soolingen, D., Wallinga, J. & van Ballegooijen, W. M. A sign of 262 
superspreading in tuberculosis: highly skewed distribution of genotypic cluster sizes. 263 
Epidemiology 24, 395-400 (2013). 264 
19 Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. Superspreading and the effect of 265 
individual variation on disease emergence. Nature 438, 355-359 (2005). 266 
172
Stellenbosch University https://scholar.sun.ac.za
20 McCreesh, N. & White, R. G. J. S. r. An explanation for the low proportion of tuberculosis 267 
that results from transmission between household and known social contacts.  8, 5382 268 
(2018). 269 
21 Woolhouse, M. E. J. et al. Heterogeneities in the transmission of infectious agents: 270 
implications for the design of control programs. Proceedings of the National Academy of 271 
Sciences 94, 338 (1997). 272 
22 Fennelly, K. P. et al. Cough-generated aerosols of Mycobacterium tuberculosis: a new 273 
method to study infectiousness. American journal of respiratory and critical care medicine 274 
169, 604 (2004). 275 
23 Kodama, C. et al. <em>Mycobacterium tuberculosis</em> transmission from patients with 276 
drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis.  50, 277 
1701044, doi:10.1183/13993003.01044-2017 %J European Respiratory Journal (2017). 278 
24 Gagneux, S. Ecology and evolution of Mycobacterium tuberculosis. Nature Reviews 279 
Microbiology (2018). 280 
25 Gagneux, S. et al. Impact of Bacterial Genetics on the Transmission of Isoniazid-Resistant 281 
Mycobacterium tuberculosis. PLoS Pathogens 2, e61, doi:10.1371/journal.ppat.0020061 282 
(2006). 283 
26 Fennelly, K. P. et al. Variability of Infectious Aerosols Produced During Coughing by Patients 284 
with Pulmonary Tuberculosis. American journal of respiratory and critical care medicine 285 
(2012). 286 
27 Jones-López, E. C. et al. Cough Aerosols of Mycobacterium tuberculosis Predict New 287 
Infection: A Household Contact Study. American journal of respiratory and critical care 288 
medicine (2013). 289 
28 Wejse, C. et al. TBscore: Signs and symptoms from tuberculosis patients in a low-resource 290 
setting have predictive value and may be used to assess clinical course. Scandinavian Journal 291 
of Infectious Diseases 40, 111-120 (2008). 292 
29 Garton, N. J., Christensen, H., Minnikin, D. E., Adegbola, R. A. & Barer, M. R. Intracellular 293 
lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 148, 2951-2958 294 
(2002). 295 
30 Lee, J. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis 296 
susceptibility to first-and second-line drugs. Antimicrobial agents and chemotherapy 58, 11-297 
18 (2014). 298 
31 Six and Two Stage Viable Samplers Instruction Manual. ThermoFisher Scientific, O. 299 
32 O'Shea, M. K. et al. Time-to-Detection in Culture Predicts Risk of Mycobacterium 300 
tuberculosis Transmission: A Cohort Study. Clinical Infectious Diseases, ciu244 (2014). 301 
33 Landis, J. R. & Koch, G. G. The measurement of observer agreement for categorical data. 302 
biometrics, 159-174 (1977). 303 
34 Koo, T. K. & Li, M. Y. A guideline of selecting and reporting intraclass correlation coefficients 304 
for reliability research. Journal of chiropractic medicine 15, 155-163 (2016). 305 
35 Khan, P. Y. et al. Transmission of drug-resistant tuberculosis in HIV-endemic settings.  (2018). 306 
36 Chengalroyen, M. D. et al. Detection and quantification of differentially culturable tubercle 307 
bacteria in sputum from patients with tuberculosis. American journal of respiratory and 308 
critical care medicine 194, 1532-1540 (2016). 309 
37 Acuña-Villaorduña, C. et al. in Open forum infectious diseases.  ofz184 (Oxford University 310 
Press US). 311 
38 Calligaro, G. L. et al. Effect of new tuberculosis diagnostic technologies on community-based 312 
intensified case finding: a multicentre randomised controlled trial. The Lancet Infectious 313 
Diseases 17, 441-450 (2017). 314 
39 Rouillon, A., Perdrizet, S. & Parrot, R. Transmission of tubercle bacilli: The effects of 315 




40 Conditions, N. C. C. f. C.    (Royal College of Physicians). 318 
41 Noble, R. C. Infectiousness of pulmonary tuberculosis after starting chemotherapy: review of 319 
the available data on an unresolved question. American Journal of Infection Control 9, 6-10 320 
(1981). 321 
42 Dharmadhikari, A. S. et al. Rapid impact of effective treatment on transmission of multidrug-322 
resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease 18, 1019-323 
1025 (2014). 324 
43 Dheda, K. et al. Drug-penetration gradients associated with acquired drug resistance in 325 
patients with tuberculosis.  198, 1208-1219 (2018). 326 
44 Fitzwater, S. P. et al. Prolonged infectiousness of tuberculosis patients in a directly observed 327 
therapy short-course program with standardized therapy. Clinical infectious diseases 51, 328 
371-378 (2010). 329 
45 Menzies, D. Effect of treatment on contagiousness of patients with active pulmonary 330 
tuberculosis. Infection control and hospital epidemiology: the official journal of the Society of 331 
Hospital Epidemiologists of America 18, 582-586 (1997). 332 
46 Dheda, K. & Migliori, G. B. The global rise of extensively drug-resistant tuberculosis: is the 333 
time to bring back sanatoria now overdue? The Lancet 379, 773-775 (2012). 334 
47 Pietersen, E. et al. Long-term outcomes of patients with extensively drug-resistant 335 
tuberculosis in South Africa: a cohort study. The Lancet (2014). 336 
48 Yates, T. A. et al. The transmission of Mycobacterium tuberculosis in high burden settings. 337 
The Lancet Infectious Diseases 16, 227-238, doi:http://dx.doi.org/10.1016/S1473-338 
3099(15)00499-5 (2016). 339 
49 Escombe, A. R. et al. Tuberculosis transmission risk and infection control in a hospital 340 
emergency department in Lima, Peru. The international journal of tuberculosis and lung 341 
disease : the official journal of the International Union against Tuberculosis and Lung Disease 342 
14, 1120-1126 (2010). 343 
50 Escombe, A. R. et al. The detection of airborne transmission of tuberculosis from HIV-344 
infected patients, using an in vivo air sampling model. Clinical Infectious Diseases 44, 1349-345 
1357 (2007). 346 
51 Dharmadhikari, A. S. et al. Natural infection of guinea pigs exposed to patients with highly 347 
drug-resistant tuberculosis. Tuberculosis 91, 329-338 (2011). 348 
52 Dharmadhikari, A. S., Nardell, E. A. J. A. j. o. r. c. & biology, m. What animal models teach 349 
humans about tuberculosis.  39, 503-508 (2008). 350 
53 Nardell, E. A.     (American Thoracic Society, 2004). 351 
54 Cadena, A. M., Flynn, J. L. & Fortune, S. M. J. M. The importance of first impressions: early 352 
events in Mycobacterium tuberculosis infection influence outcome.  7, e00342-00316 353 
(2016). 354 
55 Lin, P. L. et al. Early events in Mycobacterium tuberculosis infection in cynomolgus 355 
macaques.  74, 3790-3803 (2006). 356 
56 Jones-Lopez, E. C. et al. Cough Aerosols of Mycobacterium tuberculosis Predict Incident 357 
Tuberculosis Disease in Household Contacts. Clinical infectious diseases : an official 358 
publication of the Infectious Diseases Society of America, doi:10.1093/cid/ciw199 (2016). 359 
57 Acuña-Villaorduña, C., White, L. F., Fennelly, K. P. & Jones-López, E. C. Tuberculosis 360 
transmission: sputum vs aerosols. The Lancet Infectious Diseases 16, 770-771 (2016). 361 
58 Centre for Disease Control and Prevention. NIOSH Manual of Analytical Methods (NMAM), 362 
5th Edition.  (2017). 363 
  364 
174
Stellenbosch University https://scholar.sun.ac.za
Figure legends 365 
Figure 1. A cough aerosol sampling system (CASS) was used to measure infectiousness (A) 366 
consisting of (i) a six-stage Anderson Cascade Impactor [median expected droplet diameter 367 
(µm) for each stage is shown]  that (ii) lies horizontally in a 10 l autoclavable chamber that (iii) 368 
patients cough into (iv) permitting CFU from individual aerosol droplets to be isolated in a 369 
size-dependent manner. (B) Most patients (n=310) were CASS-negative and a minority of 370 
CASS-positives with varied infectiousness (1-310 CFU) were identified. (C) CFU counts were 371 
highest in the 2.1-4.7 µm particle size range (stages 3-4) (circles, left y-axis), and, on average, 372 
most patients’ total CFU came from particles 2.1-3.3 µm in diameter (stage 4) [bars (standard 373 
deviation, right y-axis]. CFU in aerosol correlated with (D) sputum smear microscopy grade 374 
and (E) Xpert MTB/RIF semi-quantitation grade [both D and E have the proportion of CASS-375 
positive patients and median (IQR) aerosol CFU in CASS-positives indicated], and (F) these 376 
translated into moderate-to-high receiver operator characteristic curve areas under the curves 377 
(AUCs) in analyses for CASS-positivity (shown for sputum Xpert MTB/RIF-positive patients) 378 
that were improved by a clinical prediction rule. (G) CASS-positivity is shown by patient group 379 
and treatment status (all patients, treatment ≤48 h, treatment >48h). Black, grey, and white 380 
indicate the proportions of patients with >10, 1-9, or 0 aerosol CFU. P-values are for 381 
comparisons of Group 1 vs. Groups 2 and 3 within patients of the same treatment status. After 382 
adjustment for treatment status, no differences in infectiousness by drug susceptibility were 383 
detected (Table S5 provides additional data). B, D-E: black indicates no treatment or on 384 
treatment ≤48 h, grey indicates treatment >48 h. C and D have logarithmic axes and one was 385 
added. A is adapted from 58. Abbreviations: AUC, area under the curve; CASS, cough aerosol 386 
sampling system; CFU, colony forming units; CI, confidence interval; IQR, interquartile range; 387 
RifR, rifampicin resistant. 388 
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Figure 2. Comparison of mycobacterial factors in CASS-positive and negative patients. (A) 389 
Manhattan plot showing that whole genome sequencing of sputum culture isolates identified 390 
no variants associated with CASS-status that met significance thresholds (n=115 CASS-391 
positives, n=203 CASS-negatives). The top variant was in rpoB (a S531L mutation known to 392 
cause rifampicin resistance). The dashed lines above panel represent the p-value threshold for 393 
significant associations. Analyses sub-stratified by treatment status, HIV status, and different 394 
CASS CFU cut-points reached similar conclusions. (B) A representative image of Auramine 395 
and Nile-Red strained sputum showing a mixture of Auramine-positive bacilli (green) with or 396 
without Nile-Red co-localisation (red; left panel) and a dot plot (mean, standard deviation) of 397 
the proportion of Auramine-positive bacilli also Nile-Red positive. Additional analyses by 398 
CASS status after sub-stratification by patient group (i.e., drug susceptibility) and/or treatment 399 
status revealed no differences. 400 
Figure 3. Repeat cough aerosol sampling results in patients initially CASS-positive who were 401 
re-sampled until CASS-negative. Most Group 1 (A) or Group 2 (B) patients were CASS-402 
negative at repeat sampling after treatment (the only Group 2 patient with persistent CASS-403 
positivity was non-adherent) but many Group 3 patients were repeatedly CASS-positive (C). 404 
Each line represents a patient and each symbol a sampling. Microbiology results (microscopy, 405 
Xpert MTB/RIF, culture) from paired sputa are below the panels and continued to have poor 406 
diagnostic accuracy for CASS-positivity. Patients CASS-positive more than once are thick 407 
black lines. Patients not on treatment are dashed lines. Triangles in (C) indicate patients 408 
discharged with programmatically uncured drug-resistant TB (three baseline CASS-positives 409 
of this type and not on treatment were CASS-negative at re-testing). Vertical dashed lines 410 
indicate the median days to the second and third CASS. Y-axes are logarithmic and one was 411 
added to CFU counts. Abbreviations: ACI, Andersen Cascade Impactor; CASS, cough aerosol 412 
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sampling system; CFU, colony forming units; MDR, multidrug resistant; IQR, interquartile 413 
range; Xpert, Xpert MTB/RIF; XDR, extensively drug-resistant.  414 
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Figure 1. 415 
 
Missing data: Smear microscopy grade (n=2); Xpert MTB/RIF grade (n=46). 
B: 16 of the 142 (11%) CASS-positives had CFU exclusively in particles corresponding to ≥4.7 µm, 
however, 10/16 (63%) had at least three plates discarded due to the contamination. 
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Figure 2.  416 
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100%)




1. Smear-positive (1/3, 33%)
2. Xpert-positive (2/3, 66%)
3. Culture-positive (1/2, 50%)
CASS-negative (n=63)
1. Smear-positive (30/62, 48%)
2. Xpert-positive (51/60, 85%)
3. Culture-positive (41/62, 66%)
Baseline
CASS-positive (n=29) 
1. Smear-positive (27/29, 
93%)
2. Xpert-positive (27/27, 
100%)




1. Smear-positive (1/1, 100%)
2. Xpert-positive (1/1, 100%) 
3. Culture-positive (1/1, 100%)
CASS-negative (n=28)
1. Smear-positive (12/28, 43%)
2. Xpert-positive (22/26, 85%)















1. Smear-positive (17/18, 94%)
2. Xpert-positive (17/17, 100%)
3. Culture-positive (18/18, 100%)
Second sampling
CASS-positive (n=7)
1. Smear-positive (6/7, 86%)
2. Xpert-positive (7/7, 100%)
3. Culture-positive (7/7, 100%)
CASS-negative (n=11)
1. Smear-positive (9/11, 82%)
2. Xpert-positive (9/11, 82%)

























Table 1. Univariate and multivariate logistic regression analyses of predictors of cough aerosol culture-positivity. When analyses were repeated for only 419 
patients on treatment >48h (Supplementary Tables 7-8), the same predictors remained significant. Data are median (IQR) or n/N (%) unless otherwise stated. 420 
 
Univariate analyses (n=452) 
Multivariate analyses† 
Sputum culture-positive  
n=254 













ratio (95% CI) 
P-
value 
Adjusted odds ratio 
(95% CI) P-value 
Demographic characteristics 
Age, years 35 (28-45) 33 (27-43) 9.83 (9.65, 10.00) 
(per 10 years) 
0.061 - -   
Female sex 137/308 (45) 43/142 (30) 0.54 (0.36, 0.83) 0.004 - -   
Smoker (current or previous) 184/308 (60) 100/142 (70) 1.59 (1.03, 2.43) 0.034 - -   
Based in community 195/308 (63) 117/142 (83) 2.69 (1.65, 4.38) <0.001 - -   
Clinical characteristics 
TB symptom score 4 (2-5) 3 (2-5) 0.91 (0.63, 1.00) 
(per unit) 
0.054 0.78 (0.68, 0.90) 
(per unit) 
0.001 0.79 (0.69, 0.91) (per unit) 0.001 
HIV-positive 142/307 (46) 41/141 (29) 0.48 (0.31, 0.74) 0.001 0.41 (0.23, 0.75) 0.003 0.55 (0.32, 0.96) 0.034 
On TB treatment >48 h§ 241/308 (78) 77/142 (54) 0.33 (0.21, 0.50) <0.001 - - 0.54 (0.31, 0.94) 0.030 
Prior TB  167/308 (54) 67/142 (47) 0.75 (0.51,1.12) 0.165 -  - - - 
CXR disease extent         
Bilateral*  208/276 (75) 100/130 (77) 1.09 (0.67, 1.78) 0.732 -  - - - 
Disease score 7 (4-10) 7 (5-9.25) 1.02 (0.96, 1.09) 
(per unit) 
0.448 -  - - - 
Any cavitation 99/276 (36) 66/130 (51) 1.84 (1.21, 2.81) 0.004     
Cavitation score 0 (0-1) 0.25 (0-1) 1.17 (0.93, 1.48) 
(per unit) 
0.174 -  - - - 
Lung function         
PEF (l/min) 165 (58-252) 223 (43-280) 1.22 (1.04, 1.40) 
(per 100 units) 
0.014 -  - - - 
PCF (l/min) 300 (240-363) 330 (280-
397) 
10.05 (10.02, 
10.07) (per 10 
units) 
<0.001 10.08 (10.04, 
10.11) (per 10 
units)  
<0.001 10.07 (10.03, 10.10) (per 
10 units)  
<0.001 




1.42 (1.06, 1.91) 
(per unit) 
0.018 -  - - - 
Aerosol sampling 
Cough count 83 (62.5-107) 85.5 (66-110) 1.03 (0.99, 1.11) 
(per 10 units) 
0.259 -  - - - 
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Ambient conditions         
Room temperature (°C) 19.3 (17.8-
22.1) 
20 (18-22.3) 1.04 (0.97, 1.11) 0.260 -  - - - 
Humidity 61 (56-69) 62.5 (55-72) 1.01 (0.99, 1.03) 0.335 -  - - - 
Sputum microbiology 
Nile-Red positive bacilli (in patients with a 
sputum smear grade ≥2+), mean proportion (SD) 
0.76 (0.30) 0.80 (0.59) 1.24 (0.41, 3.81) 0.701     
Sputum viscosity          
Salivary/mucosalivary 188/259 (73) 73/124 (59) Reference N/A -  - - - 
Purulent/mucopurulent 71/259 (27) 51/124 (41) 1.86 (1.19, 2.91) 0.007 -  - - - 
Smear grade     Omitted in favour of time-
to-positivity Omitted in favour of CTmin 
Negative 127/306 (42) 91/142 (6) Reference N/A -  -  
Positive 179/306 (58) 133/142 (94) 10.49 (5.14, 21.38) <0.001 -  -  
SC 43/306 (14) 10/142 (7) 3.28 (1.25, 8.61) 0.016 -  -  
P+ 54/306 (18) 28/142 (20) 7.31 (3.24, 16.54) <0.001 -  -  
P++ 42/306 (14) 35/142 (25) 11.76 (5.22, 26.47) <0.001 -  -  
P+++ 29/306 (10) 40/142 (28) 19.46 (8.50, 44.55) <0.001 -  -  
P++++ 11/306 (4) 20/142 (14) 25.65 (9.45, 69.69) <0.001 -  -  
Xpert-positive  252/287 (87) 136/136 
(100) 







0.84 (0.80, 0.88) 
(per unit) 
<0.001 - 0.80 (0.76, 0.86)  <0.001 
Culture-positive 253/297 (85) 141/142 (99) 24.58 (3.35, 180.38) 0.002 N/A N/A Omitted in favour of CTmin. Culture 
unavailable for rapid decision making 
TTP (days) 12 (8-16) 8 (5-10) 0.80 (0.76, 0.86) <0.001 0.78 (0.72, 0.84) <0.001 - - 
Strain family (spoligotype)         
Bejing 159/245 (65) 86/138 (62) Reference N/A -  - - - 
LAM 30/245 (12) 18/138 (13) 1.06 (0.55, 2.03) 0.821 -  - - - 
T 35/245 (14) 18/138 (13) 1.54 (0.50, 4.74) 0.368 -  - - - 
X 4/245 (2) 2/138 (1) 0.52 (0.51, 1.79) 0.890 -  - - - 
Other 7/245 (3) 7/138 (5) 1.40 (0.50, 5.01) 0.267 -  - - - 
Unknown 10/245 (4) 7/138 (5) 0.90 (0.16, 5.02) 0.651 -  - - - 
Drug-resistance category         
Group 1 119/308 (39) 82/142 (58) Reference N/A Reference N/A Reference N/A 
Group 2 112/308 (36) 36/142 (25) 0.47 (0.29, 0.75) 0.001 0.48 (0.26, 0.90)  0.023 0.45 (0.25, 0.82) 0.010 
Group 3 77/308 (25) 24/142 (17) 0.45 (0.26, 0.77) 0.004 0.57 (0.27, 1.21) 0.144 0.51 (0.25, 1.01) 0.053 
Group 2 and 3 combined 119/308 (37) 60/142  (42) 0.46 (0.31, 0.69) <0.001 Omitted in favour of individual groups (1, 2, or 3). 
*Patients with a normal CXR were pooled with those with unilateral disease for the comparison with patients with bilaterial disease. 421 
†Values as in the final models. 422 
§Due to the small number of patients not on any treatment whatsoever, a treatment duration cut-point of 48h used. 423 
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Abbreviations: CASS, cough aerosol sampling system; CXR, chest radiography; IQR, interquartile range; PEF, peak expiratory flow; FEV, forced expiratory volume; SC, scanty; SD, standard 424 
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Participant recruitment 26 
We identified adult outpatients (≥18 years) through a programmatically-generated list of Xpert 27 
MTB/RIF- (Xpert)- or smear-positive patients at clinics in Cape Town received regularly from 28 
the National Health and Laboratory Service in Cape Town, South Africa from February 2013 29 
to July 2017. We prioritised recruitment of rifampicin-resistant patients. We had no restrictions 30 
based on TB history or HIV status but excluded patients with haemoptysis or unable to 31 
expectorate two sputa. Patients were typically newly-diagnosed and not on treatment or had 32 
recently started treatment (regimens were determined programmatically). If a newly-diagnosed 33 
patient in the community was unavailable, we recruited inpatients with second-line drug-34 
resistance at Brooklyn Chest Hospital (BCH), a specialised provincial drug-resistant TB 35 
hospital, where the CASS facility was installed or, using a prospective registry1, 36 
programmatically home-discharged patients with uncured drug-resistant TB. At BCH, we 37 
favoured the recruitment of inpatients who were recently admitted or had a recent positive 38 
culture-result. Overall, we aimed to recruit at least 100 patients per patient group (defined by 39 
drug-resistance profile), expecting 20-30% in each group to be CASS-positive.  40 
Study profile 41 
Consenting patients underwent a nurse-administered clinical examination, including symptom 42 
severity (TBscore)2, HIV-testing, and chest radiography (radiographs were read in a blinded 43 
standardised manner by a trained reader3; Tables 1-2). Peak expiratory flow (PEF), forced 44 
expiratory volume (FEV1) and peak cough flow (PCF) were measured using an Asma-1 45 
Electronic Respiratory Monitor (Vitalograph, United Kingdom) and a Respi-Aide Peak Flow 46 
Meter (GaleMed, China). The average of three consecutive blows were used. All procedures 47 
were done at one visit in the same order. 48 
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Sputum microbiology 49 
Patients expectorated two sputa, one of which was arbitrarily selected for Xpert (Cepheid) and 50 
the other NALC-NaOH decontaminated before double Ziehl-Neelsen concentrated smear 51 
microscopy4 and one MGIT 960 liquid culture (BD, United States). Patients needed at ≥1 52 
positive smear (including scanty) to be classified as smear-positive. When gradings were 53 
discrepant, the highest was used. The viscosity of the sputum used for Xpert was graded by 54 
appearance5 and an aliquot used for Auramine O-Nile Red staining to detect dormancy-55 
associated intracellular lipid bodies.6 Culture isolates were confirmed as positive for acid-fast 56 
bacilli (AFB) and M. tuberculosis complex (MTBDRplus, Hain Lifesciences) and used for 57 
minimum inhibitory concentration determination using Sensititre MYCOTB plates 58 
(Thermofisher, United States; Table 3).7  59 
Sputum Auramine-Nile Red staining  60 
We used a modified version of previously-described protocols.6,8 Briefly, a NALC-NaOH 61 
decontaminated sputum was centrifuged and resuspended in 125 µl phosphate buffer. 30 µl of 62 
the resuspension was mixed with 10 µl fixative (National Health Laboratory Service) and the 63 
mixture smeared on a slide before fixation using a heating block at 80 °C for 2 h. In parallel, 64 
an additional 125 µl phosphate buffer was added to the resuspended decontaminated sputum 65 
(in order to minimise background fluorescence seen in some specimens) and the same 66 
procedure followed using both undiluted and diluted slides. Once heat fixed, the slide was 67 
sprayed with Mercofix (Merck, United States). Prior to visualization, the slide was flooded 68 
with Auramine O (National Health Laboratory Service, South Africa) for 15 min, rinsed with 69 
water, decolourised with 0.5% (v/v) acid alcohol, rinsed again, flooded with Nile Red solution 70 
(Sigma-Aldrich, South Africa; 10 µg/ml in phosphate buffered saline), rinsed again, flooded 71 
with 0.1% (w/v) potassium permanganate for 1 min, rinsed a final time and dried. Three drops 72 
of Mowiol mounting agent with DABCO (Merck, United states) were added and slides 73 
186
Stellenbosch University https://scholar.sun.ac.za
visualised within 24 h using an 880 LSM confocal microscope (Carl Zeiss, Germany) and Zen 74 
2011 software (Carl Zeiss, Germany). Stained slides were stored in the dark at 4 °C before 75 
visualisation. We counted bacilli with intact Auramine O-positive cell walls as positive for M. 76 
tuberculosis up to a maximum of 100 per slide. After Auramine O-positive bacilli were 77 
identified, we switched to the red-light channel and counted the proportion with Nile Red-78 
positive co-localisation. We encountered significant levels of Nile Red-positive background 79 
that made it difficult to consistently distinguish individual cells. After consultation with an 80 
imaging specialist, we only counted Auramine O-positive bacilli as Nile Red-positive if the 81 
intensity of the red light at that location was at least 50% higher than the background red. Each 82 
slide was independently counted by at least two trained readers and the average proportion 83 
reported. If readers’ counts differed by ≥20%, a third reader was used and the average of the 84 
two closest counts reported. We only did Nile Red staining on sputum due to concentrations of 85 
bacilli in aerosol below the limit of detection. 86 
Cough aerosol sampling 87 
Procedure  88 
The CASS9 consists of a six-stage Andersen Cascade Impactor (ACI; Thermofisher, United 89 
States) within a 10 l chamber (the maximum autoclavable size in our laboratory). CASS 90 
collects aerosol in a particle size-dependent manner. Each ACI stage holds 7H11 solid agar 91 
plates (Middlebrook, United States) supplemented with OADC (Middlebrook) and Selectatab 92 
(Kircher, United States). CASS was done before sputum expectoration, typically by late 93 
morning, using a modified version of a previously-described procedure.9 Briefly, patients 94 
coughed as forcefully and as frequently as possible into the CASS for 5 min via a 1 m silicone 95 
pipe that ran from the patient in a sputum induction booth into the 10 l chamber. Ambient 96 
temperature and humidity and the number of coughs were recorded. If patients were CASS-97 
positive, they underwent repeat CASS and sputum sampling until CASS-negative. For all 98 
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CASS samplings (as with all other clinical and microbiological methods except smear 99 
microscopy), measurements were done in a discrete fashion and the same patients or samples 100 
were not measured repeatedly. 101 
Biosafety 102 
The apparatus was autoclaved after each use and the plates loaded in a class-2 biosafety cabinet. 103 
chamber. The 1 m pipe patients coughed into which was chemically-disinfected and autoclaved 104 
after each use. A disposable mouthpiece was used. After passing through the ACI, air was 105 
drawn through high efficiency HEPA filters (Whatman, United States) by a pump (Thermo 106 
Fischer, United States) at 28 l/min. Flow rate was monitored using a flow meter (Dri Cal, 107 
United States). After completion, CASS parts were double-bagged, transported to the 108 
Stellenbosch University Biosafety Level-3 facility, dissembled and autoclaved. If patients had 109 
to expectorate sputum during CASS, they first turned away from the sampling pipe. 110 
Microbiology  111 
Plates from the ACI were incubated for 10 weeks at 37 °C and checked weekly for growth from 112 
week four and AFB-positive CFU counted. Plates overgrown with non-acid fast contaminants 113 
were discarded. Patients with contaminated aerosol had unknown CASS status (method of 114 
designation as contaminated below).  115 
Classification of agar plates as contaminated 116 
Agar plates from the ACI were checked for M. tuberculosis CFU (off-white, grey, crinkled and 117 
Ziehl-Neelsen acid fast bacilli positive) for eight weeks. The presence and morphology of any 118 
other growth were recorded. Plates with non-M. tuberculosis growth, which most frequently 119 
appeared fungal, were transferred to a separate container. These plates were subsequently 120 
checked for M. tuberculosis CFU weekly until a lawn of overgrowth was seen. Plates were 121 
discarded prior to eight weeks if overgrown. The median (IQR) time until M. tuberculosis CFU 122 
detection was 28 (25-39) days. We classified patients as having contaminated aerosol if 1) no 123 
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M. tuberculosis CFU were observed and 2) at least three (half of their total plates) were 124 
discarded prior to the median time to M. tuberculosis CFU detection (28 days). Such patients 125 
could not be confidently classified as CASS-positive or –negative.  126 
Reproducibility sub-study 127 
We used a modified version of a previously-described protocol.9 We did two CASS samplings 128 
per day (at least 4 h apart) on two consecutive days and counted the number of CFU from the 129 
ACI from each sampling. We recruited patients (n=29) independent of the parent study. 130 
Patients typically expectorated sputum during the CASS, however, if they did not, they were 131 
asked to expectorate sputum after CASS. Sputa underwent smear microscopy and culture or 132 
Xpert (if only one sputum was available, it was used for smear and culture). To improve 133 
chances of CASS-positivity, we recruited patients with high sputum bacillary load (at least 134 
smear-grade 2+ positive or Xpert semi-quantitation level “medium”), and had been on 135 
treatment less than 48 h. Fleiss kappa values were used to compare dichotomous test results 136 
and intraclass correlation coefficients were assessed for continuous data. 137 
DNA extractions, genotyping, and whole genome sequencing 138 
DNA for spoligotyping and whole genome sequencing (WGS) was extracted from sputum 139 
culture isolates.10  140 
Sequence analysis  141 
Processing, alignment and single nucleotide variant calling 142 
Whole-genome sequencing was done using Illumina HiSeq2500. Library preparation was done 143 
using the Illumina Genomic DNA Sample Preparation Kit to achieve paired-end sequencing 144 
(2×101 bp) with an average insert size of 500 bp. The data processing pipeline used has been 145 
described previously1. Briefly, we mapped raw sequence data uniquely to the corrected H37Rv 146 
reference genome (Genbank accession AL123456.3) using bwa-mem (v0.7) software. We used 147 
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SAMtools (v1.3) and GATK (v3.3-0) to call single nucleotide polymorphisms (SNPs) and 148 
indels. We selected the intersection of variants with quality scores of Q30 or higher, equating 149 
to one error per 1000 base positions for further analysis. Genotypes were called in positions of 150 
ten-fold coverage; otherwise positions were classified as missing. Highly repetitive and 151 
variable regions were removed by calculating mappability values along the reference genome 152 
using a k-mer length of 50 base pairs and 0.04% of allowed substitutions while mapping. 364 153 
of the 394 (93%) culture-positive isolates from patients with a valid CASS status had DNA 154 
was extracted and sequencing was attempted.  155 
Genome-wide association studies 156 
Genome wide associations (GWAS) were computed using R11 (v 3.3.0). After excluding 157 
isolated with a high proportion of missing SNP or less than ten-depth coverage, 318/364 (87%) 158 
isolates were included in further analyses, including 115 (36%) from CASS-positives. 159 
Univariate analysis with binomial phenotypes (response variables) were computed using a 160 
Fisher’s Exact test. For multivariate analysis of binomial phenotypes, GWAS was done with 161 
nsSNPs on a gene level using an efficient mixed model approach with a kinship matrix to adjust 162 
for population structure or using a logistic regression with correction for population structure 163 
using principal components. We also performed GWAS by investigating phylogenetic 164 
convergence: RaxML was used to construct a best scoring maximum likelihood tree and 165 
association analysis was done using the R package treeWAS. Similar methods were applied to 166 
the presence of indels on a gene level (i.e., if an indel overlapped a gene region, then it was 167 
marked as a mutation in a matrix of all genes by all isolates). Only variants where the minor 168 
allele frequency was at least 0.1 were investigated. SNP interactions were investigated using 169 
the logitFS R-package. Benjamini-Hochberg multiple test correction was applied.  170 
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Inter-isolate SNP comparisons  171 
These were done using all SNPs. 326/364 (90%) of isolates were included in these analyses 172 
after filtering those with >10% of the genome having less than ten-depth coverage and 173 
presumed mixed-infections. An inter-isolate SNP threshold of 5 (0 to 10 in sub-analyses) was 174 
used to link similar strains. Low coverage positions were excluded on a per pair basis. Graphs 175 
were constructed in R using igraph (v1.2.4.1). Fisher’s exact test was used to test the 176 
differences between the number of linked isolates by the dependent variable and the number of 177 
connections to and from isolates. 178 
Drug susceptibility categorisation 179 
We used a “rule-in” strategy, where if Sensititre MYCOTB plates indicated phenotypic 180 
resistance (isoniazid, rifampicin, ethambutol, ethionamide, kanamycin, ofloxacin, p-181 
aminosalicylic acid, rifabutin, streptomycin, cycloserine, amikacin, and moxifloxacin; critical 182 
concentrations in Table 3), WGS (using a previously-described panel12 for all drugs expect 183 
pyrazinamide and rifabutin, for which different panels were used13-15) indicated genotypic 184 
resistance or, for rifampicin, Xpert indicated resistance, patients were classified as resistant to 185 
that drug. If patients were missing drug susceptibility test (DST) information from the time of 186 
recruitment (e.g., culture-negative or -contaminated), we used DST data available from 187 
programmatic records generated from a specimen collected within six months of recruitment 188 
(Xpert, MTBDRplus, MTBDRsl, phenotypic MGIT960 DST). If no DST data were still 189 
available, we used diagnoses from medical records (listed as DS-, MDR-, pre-XDR-, or XDR-190 
TB).  191 
We first classified patients according to standard definitions as drug-susceptible (susceptible 192 
to rifampicin and isoniazid), rifampicin or isoniazid mono-resistant (resistance to one of these 193 
drugs), MDR- (resistant to both rifampicin and isoniazid and susceptible to the second line 194 
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drugs), pre-XDR (MDR and resistance to fluoroquinolones or the second line injectable 195 
agents), and XDR (MDR and resistance to fluoroquinolones and second line injectable 196 
agents).16 To improve sample size and reduce data over-stratification (which compromises 197 
precision)17, we further categorised patients in a manner congruent with World Health 198 
Organization-treatment guidelines at the time of the study.18 Patients with isoniazid mono-199 
resistance were included with drug-susceptible patients (Group 1), those with rifampicin mono-200 
resistance or pre-XDR were included with MDR patients (Group 2), and XDR- patients were 201 
allocated to a separate category (Group 3).  202 
Spoligotyping  203 
Decontaminated sputum specimens or MGIT culture aliquots were heated at 100oC for ≥1 h. 204 
Two microliters of lysate was used for spoligotyping PCR (Kamerbeek method19). Briefly, 205 
PCR was done to selectively amplified the left and central direct repeat target with the 206 
internationally standardized PCR protocol in combination with primers DRa 207 
(GGTTTTGGGTCTGACGAC, 5′ biotinylated) and DRb (CCGAGAGGGGACGGAAAC).19 208 
Products were then hybridized to a membrane containing bound oligonucleotides and detected 209 
via chemiluminescene on X-ray film. Isolates were assigned a genotype family as described by 210 
SITVIT.20 In silico spoligotypes were predicted using SpolPred on sputum culture isolate 211 
WGS.21 212 
Definitions 213 
“CASS-positive”, patients with any M. tuberculosis CFU from cough aerosol. A drug was 214 
considered “likely effective” if there was documented susceptibility and no evidence of 215 
resistance (phenotypic or genotypic). Patients were classified based on antibiograms or clinical 216 
records into Group 1 (non-rifampicin resistant), Group 2 (rifampicin resistant and pre-XDRs), 217 
and Group 3 (XDRs).22,23  If a susceptible or resistant phenotypic result was not available 218 
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(culture-negative, culture-contaminated, or indeterminate) as well as no WGS (and, for 219 
rifampicin, a positive Xpert result), the drug was classified as being of unknown effectiveness.  220 
Statistical analyses 221 
The chi-squared test was used for comparisons between proportions. We used Fisher’s exact 222 
test with mid-p correction for comparisons between proportions and the Mann-Whitney test 223 
was used to compare differences in non-parametric continuous data. Multivariable logistic 224 
regression was done to adjust for potential confounding (parameters p≤0.100 included in 225 
models). A backward elimination strategy using the log likelihood ratio test was used to finalise 226 
models. Analyses were done using Graphpad Prism (version 6.0; GraphPad Software, United 227 
States) and Stata (version 14; StataCorp, United States). All statistical tests were two-sided at 228 
α=0.05. Continuous data were tested for normality using the D'Agostino-Pearson omnibus test. 229 
Adjustments for multiple comparisons were not done. 230 
Ethics 231 
Research ethics committees at the University of Cape Town (038/2008) and Stellenbosch 232 
University (N13/01/001) approved the study.  233 
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Table 1. Variables used to calculate TB symptom score.2 234 





Chest pain 1 
Night sweats 1 
Clinically examined 
Anaemic conjunctivae 1 
Tachycardia 1 
Positive finding at lung auscultation 1 
Axillary temperature > 37.0 °C 1 
BMI < 18.0 1 
BMI < 16.0 1 
MUAC < 220 mm 1 
MUAC < 200 mm 1 
Abbreviations: BMI, body mass index; MUAC, middle upper arm circumference.  235 
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Table 2. Chest radiography scoring system.3 236 
 237 
  238 
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Table 3. Drug range concentrations and the critical concentrations used to define phenotypic 239 
resistance with Sensititre MYCOTB plates.7 240 
Drug Sensititre range (µg/ml) Critical concertation (µg/ml) 
Isoniazid 0.03-4 1 
Rifampicin 0.12-16 1 
Ethambutol 0.5-32 10 
Ethionamide 0.3-40 5 
Kanamycin 0.6-40 5 
Ofloxacin 0.25-32 2 
P-aminosalicylic acid 0.5-64 2 
Rifabutin 0.12-16 0.5 
Streptomycin 0.25-32 10 
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Amikacin 0.12-16 5 
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*Done using Sensititre MYCOTB plates for isoniazid, rifampicin, ethambutol, ethionamide, kanamycin, ofloxacin, p-
aminosalicylic acid, rifabutin, streptomycin, cycloserine, amikacin, and moxifloxacin 
Figure 1. Study profile and participant overview. Abbreviations: CASS, cough aerosol sampling 
system; DS, drug-susceptible; INH, isoniazid; MDR, multidrug-resistant; MGIT, mycobacterial 
growth indicator tube; RIF, rifampicin; TB, tuberculosis; XDR, extensively drug-resistant; VL, viral 
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Figure 2. M. tuberculosis CFU from cough aerosol particles at recruitment as a function of days on 
treatment before CASS stratified by regimen type. Beyond eight days, no patients receiving the first-
line regimen were CASS-positive, whereas patients receiving second-line regimens had CFU in their 
aerosol for months. The y-axis is logarithmic and one was added. Abbreviations: ACI, Andersen 
Cascade Impactor; CLF, clofazimine; FQ, fluoroquinolone; IQR, interquartile range; SLID, second-

















1 2 7 14 28 180 500 1500





  46 
 
Figure 3. Genome wide association study (GWAS) Manhattan plot of sputum culture time-to-positivity 
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Figure 4. Relationships between sputum bacillary load (liquid culture time to positivity) and disease 
extent (A and B) and cavitation score (C), and between CASS-status and cavitation score (D) assessed 



























































































































Supplementary Tables 49 
Table 1. Patient characteristics by drug susceptibility. Data are median (IQR) or n/N (%) 50 
unless otherwise stated. 51 
 Group 1 




or Pre-XDR XDR 
Demographic characteristics 
Age (years) 35.4 (27.5-45.8) 32.8 (26.8-42.2) 34.3 (28.7-43.5) 
(p=0.748) 
Female gender  85/227 (38) 70/162 (43) 46/109 (42) 
(p=0.472) 
Smoker (current or previous)  143/227 (63) 93/162 (57) 75/109 (69) 
(p=0.160) 
Location     
In community  227/227 (100) 96/162 (60) 27/109 (25) 
(p<0.001) 
In hospital  0 66/162 (40) 82 /109 (75) 
Clinical characteristics 
HIV    
Negative  141/226 (63) 88/162 (54) 65/108 (60) 
(p=0.274) 
Positive 85/226 (38) 74/162 (46) 43/108 (40)  
ARVs 21/85 (25) 43/74 (61) 35/43 (81) 
(p<0.001) 
Viral load 91126 (3982-
260000) 
3420 (47-130000) 43 (40-34432) 
(p<0.001) 
CD4 (cells/µl) 198 (129-347) 217 (84-362) 181 (112-383) 
(p=0.927) 
TB symptom score 3 (2-5) 3 (2-5) 3 (1-5) 
(p=0.369) 
CXR disease extent    
Normal 6/202 (3) 4/147 (3) 1/102 (1) 
(p=0.772) 
Unilateral 46/202 (23) 29/147 (20) 24/102 (24) 
Bilateral 150/202 (74) 114/147 (78) 77/102 (76) 
Disease score 6.5 (4-9) 7 (5-10) 7 (4-10) 
(p=0.026) 
Any cavitation 85/202 (42) 60/147 (41) 41/102 (40) 
(p=0.944) 
Cavitation score 0 (0-1) 0 (0-1) 0 (0-1) (p=0.963) 
Previous TB 84/227 (37) 102/162 (63) 66/109 (61) 
(p<0.001) 
Prior drug-resistant TB 1/81 (1) 37/100 (37) 18/65 (28) 
(p<0.001) 
Lung function    
PEF (l/min) 218 (58-289) 188 (58-248) 164 (114-248) 
(p=0.001) 
    
FEV1 (l) 1.4 (0.5-1.9) 1.3 (0.5-1.7) 1.2 (0.5-1.67) 
(p=0.003) 
Cough strength    
PCF (l/min) 317 (253-373) 307 (250-280) 303 (233-370) 
(p=0.507) 
Sputum microbiology 
Viscosity    




Mucosalivary 68/193 (35) 64/142 (45) 46/93 (50) 
Purulent 30/193 (15) 27/142 (19) 14/93 (15) 
Mucopurulent 31/193 (16) 20/142 (14) 13/93 (14) 
Smear microscopy    
Negative 64/225 (28) 51/162 (32) 39/109 (36) 
(p=0.393) 
Positive 161/225 (72) 111/162 (68) 70/109 (64) 
Proportion Nile Red positive, mean (SD)* 0.80 (0.59) 0.74 (0.30) 0.77 (0.25) 
(p=0.959) 
Culture    
Negative 20/221 (9) 19/158 (12) 11/106 (10) 
(p=0.592) 
Positive 201/221 (91) 139/158 (88) 95/106 (90) 
Strain family (spoligotype)   p<0.001 
Bejing 92/197 (47) 94/136 (69) 79/91 (87)  
LAM 46/197 (23) 10/136 (8) 1/91 (1) 
T 28/197 (14) 26/136 (20) 8/91 (9) 
X 5/197 (3) 1/136 (1) 1/91 (1) 
Other 13/197 (7) 1/136 (1) 1/91 (1) 
Unknown 13/197 (7) 4/136 (3) 1/91 (1) 
Xpert MTB/RIF    
Negative 17/207 (8) 14/157 (9) 9/105 (9) 
(p=0.455) 
Positive 190/207 (92) 143/157 (91) 96/105 (91) 
TB treatment 
On any treatment 201/227 (89) 136/162 (84) 93/109 (89) 
(p=0.332) 
Days treatment for current episode prior 
to cough aerosol sampling 
4 (2-5) 9 (5-96) 72 (35-148) 
(p<0.001) 
Regimen   p<0.001 
First-line 196/198 (99) 4/128 (3) 5/86 (6) 
FQ-based  2/198 (1) 115/128 (90) 76/86 (88) 
SLID- or CLZ-based (no FQ) 0/198 (0) 9/128 (7) 5/86 (6) 
Number drugs received† 4 (4-4) 6 (5-7) 7 (5.5-8) 
(p<0.001) 
Likely effective (susceptible) 4 (3-4) 2 (1-3) 2 (1-2) (p<0.001) 
Likely ineffective (resistant) 0 (0-0) 2 (1-3) 4 (2-5) 
Effectiveness unknown§ 0 (0-1) 1 (1-3) 1 (1-2) 
On treatment >48 h 21/227 (9) 62/162 (38) 30/109 (28) 
(p<0.001) 
Missing data or error or contamination: HIV (n=2), TB symptom score (n=16), chest radiograph (n=47), type of 52 
previous TB (n=6), smear microscopy (n=9), PEF and FEV1 (n=27), PCF (n=32), culture (n=13), spoligotype 53 
(n=74), Xpert (n=25), sputum viscosity (n=71); regimen (n=18). 54 
*Nile-Red staining not possible in all patients (see supplement). 55 
†The regimens in each patient group are in Table S4. 56 
§For DST, we were unable to determine likely effectiveness for the following drugs: RIF, n=16; INH, n=39; PZA, 57 
n=120; EMB, n=62; MOX, n=33; OFL, n=1; KAN, n=15; CAP, n=29; ETH, n=12; PAS, n=33; LNZ, n=3. This 58 
was due to isolates that did not regrow, were contaminated, gave indeterminate DST results, or WGS was of 59 
insufficient quality to allow accurate SNP calling.  60 
Abbreviations: DST, drug-susceptibility testing; IQR, interquartile range; MDR-, multidrug-resistant; PEF, peak 61 
expiratory flow; FEV, forced expiratory volume; INH, isoniazid; RIF, rifampicin; SD, standard deviation; SNP, 62 




Table 2. Individual drugs by patients and likely drug effectiveness, according to drug susceptibility profile 65 
(patient group). 66 
 Group 1 (n=201) Group 2 (n=136) Group 3 (n=97) 
RIF 199/201 (99) 4/136 (3) 5/97 (5) (p<0.001) 
Likely effective 183/183 (100) 0/4 (0) 0/5 (0) (p<0.001) 
INH 199/201 (99) 100/136 (74) 62/97 (64) (p<0.001) 
Likely effective 158/170 (93) 14/93 (15) 1/69 (1) 
PZA 200/201 (100) 123/136 (90) 91/97 (94) (p<0.001) 
Likely effective 141/145 (97) 24/81 (29) 28/68 (41) (p<0.001) 
EMB 200/201 (100) 102/136 (75) 76/97 (87) (p<0.001) 
Likely effective 170/170 (100) 39/80 (49) 10/66 (15) (p<0.001) 
MOX 1/201 (1) 111/136 (82) 75/97 (77) (p<0.001) 
Likely effective 1/1 (100) 58/89 (65) 3/64 (100) (p<0.001) 
OFL 1/201 (1) 10/136 (7) 3/97 (3) (p=0.002) 
Likely effective 1/1 (100) 6/9 (67) 0/3 (0) (p=0.084) 
AMI 0/201 (0) 2/136 (2) 0/97 (0) (p=0.111) 
Likely effective - 2/2 (100) - 
KAN 2/201 (1) 65/136 (48) 12/97 (12) (p<0.001) 
Likely effective 2/2 (100) 47/50 (94) 1/12 (8) (p<0.001) 
CAP 0/201 (0) 49/136 (36) 62/97 (64) (p<0.001) 
Likely effective - 25/33 (76) 8/49 (16) (p<0.001) 
ETH 3/201 (2) 100/136 (74) 60/97 (62) (p<0.001) 
Likely effective 3/3 (100) 23/92 (25) 8/56 (14) (p=0.002) 
PAS 1/201 (1) 56/136 (41) 74/97 (76) (p<0.001) 
Likely effective 1/1 (100) 39/42 (93) 48/55 (87) (p=0.630) 
CLOF 0/201 (0) 55/136 (40) 71/97 (73) (p<0.001) 
Likely effective - 32/32 (100) 54/54 (100)  
LNZ  0/201 (0) 1/136 (1) 5/97 (5) (p=0.001) 
Likely effective - 1/1 (100) 2/5 (40) (p=0.273) 
TERI 2/201 (1) 120/136 (88) 88/97 (91) (p=0.001) 
CLA 0/201 (0) 3/136 (2) 2/97 (2) (p=0.111) 
Abbreviations: RIF, rifampicin; INH, isoniazid; PZA, pyrazinamide; EMB, ethambutol; MOX, moxifloxacin; OFL, ofloxacin; 67 
AMI, amikacin; KAN, kanamycin; CAP, capreomycin; ETH, ethionamide; PAS, p-aminosalicylic acid; CLOF, clofazimine; LNZ, 68 
linezolid; TERI, terizidone; CLA, clarithromycin 69 
  70 
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Table 3. Diagnostic accuracy of smear microscopy grade, Xpert MTB/RIF quantitative information (CTmin), 71 
and a clinical prediction rule for culture-positive cough aerosol in different clinical scenarios (rule-out, rule-72 
in, Youden). Data are % (95% confidence interval). 73 
 74 





point* Sensitivity Specificity PPV NPV 
Positive LR Negative LR 
































 Xpert MTB/RIF  
CTmin  










0 (0, 0.28) 














0.9 (0.8, 1) 








 Clinical prediction score 
-0.2 × CTmin – 0.2 × TBscore – 1 × HIV – 1 × TB treatment (>48 h) + 1 × (0 if Group 0, -1 if Groups 2 or 3) + 
0.005 × PCF (l/min) + 3 




1.39 (1.6, 1.6) 0.17 (0.44, 
0.06) 
















*≥95% sensitivity, ≥95% specificity, and the maximum sum of sensivity and specificity (assuming equal weighting) were used to 75 
select cut-points for the rule-out, rule-in, and Youden scenarios2, respectively. 76 
Abbreviations: CTmin, minimum cycle threshold value; LR, likelihood ratio; PCF, peak cough flow; PPV, positive predictive value; 77 
NPV, negative predictive value.78 
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Table 4. Cough aerosol microbiology results by patient group, treatment status and treatment duration. Data are n/N (%) or median (IQR).  79 
























48/500 (10) 26/227 (11) 22/271 (8) 
(p=0.209)* 
9/132 (7)  
 
4/77 (5)  
 







17/218 (8)  
(p=0.035)* 
(p<0.001)†  
CASS-negative 310/452 (69) 119/201 (59) 189/249 (76) 67/123 (55) 35/73 (48) 30/48 (63) 241/329 (73) 83/128 (65) 91/201 (45) 
Days 
treatment 
6 (4-72) 4 (3-5) 12 (5-116) 
(p=0.001)* 




5 (4-5.5)  26 (6-164) 
(p=0.001)* 



















CFU 4 (1-11) 3.5 (1-10) 3 (1-9) 
(p=0.429)* 






3 (1-5)  
(p=0.523)* 
(p=0.525)† 
1-9 CFU 100/142 (70) 60/82 (73) 40/60 (67) 34/56 (61) 24/38 (63) 10/18 (55) 66/86 (77)  36/44 (82)  30/42 (71)  





















































*P-values for comparisons between Groups 2 and 3 vs. Group 1 within patients of the same treatment status (i..e, within the all, no treatment or treatment ≤48 h, or treatment 80 
48 h categories)  81 
†P-values for comparions between patients of the same group (Overall, Groups 2 and 3, or Group 1) of different treatment status (no treatment or treatment ≤48 h vs. 82 
treatment 48 h)  83 
‡P-values for comparisons within columns for CASS-positives vs. –negatives. 84 
Abbreviations: CASS, cough aerosol sampling system; CFU, colony-forming units; IQR, interquartile range.85 
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Table 5. Time-specific proportion of patients CASS-positive by the number of days on TB 86 
treatment prior to the first CASS, stratified by drug susceptibility. Despite being on likely 87 
effective treatment for seven days, almost 1/5 (20%) Group 1 patients were CASS-positive at 88 
recruitment. Patients who first received treatment on the same day as their baseline CASS were 89 
included in the day one row.  Data are % (n/N). 90 
Treatment duration (days) All  Group 1  Groups 2 and 3 
1 60 (25/42) 63 (17/27) 53 (8/15) (p=0.542) 
2 46 (13/28) 55 (12/22) 17 (1/6) (p=0.099) 
3 28 (9/32) 35 (9/26) 0 (0/6) (p=0.089) 
4 36 (13/36) 35 (11/31) 40 (2/5) (p=0.845) 
5 33 (16/49) 32 (12/37) 33 (4/12) (p=0.954) 
6 28 (13/46) 27 (7/26) 30 (6/20) (p=0.818) 
7 0 (0/4) - (0/0) 0 (0/4)  
8 43 (3/7) 63 (17/27) 25 (1/4) (p=0.151)  
≥14 16 (21/132) 0 (0/1) 16 (21/131) 
  91 
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Table 6. Individual patient regimens according to drug susceptibility profile (patient group). 92 






First-line*  195 4 5 
RIF/INH/PZA/EMB 195 4 5 
FQ-based plus AMI or KAN  2 58 11 
INH/MOX/KAN/PZA/EMB/ETH/TERI 0 17 3 
MOX/KAN/PZA/ETH/TERI 0 7 0 
INH/MOX/KAN/PZA/EMB/TERI 0 6 0 
MOX/KAN/PZA/EMB/ETH/TERI 1 2 1 
INH/MOX/KAN/PZA/ETH/TERI 0 4 0 
INH/OFL/KAN/PZA/ETH/TERI 1 1 1 
INH/MOX/KAN/PZA/EMB/ETH/TERI/PAS 0 1 1 
INH/MOX/KAN/PZA/EMB/ETH/TERI/PAS/CLF 0 1 1 
OFL/KAN/PZA/ETH/TERI 0 2 0 
INH/MOX/KAN/EMB/ETH/TERI 0 2 0 
INH/OFL/KAN/PZA/EMB/ETH/TERI 0 2 0 
INH/MOX/KAN/PZA/EMB/ETH 0 2 0 
MOX/AMI/PZA/EMB/TERI/PAS/CLF/CAP 0 1 0 
MOX/KAN/PZA/EMB/ETH/TERI/PAS 0 1 0 
INH/MOX/KAN/PZA/EMB/ETH/TERI/PAS/CLF/CAP 0 0 1 
INH/MOX/KAN/PZA/EMB/ETH/CLF 0 1 0 
INH/MOX/KAN/PZA/EMB/ETH/TERI/CLF 0 0 1 
MOX/KAN/PZA/EMB/ETH/TERI/PAS/CLF 0 1 0 
INH/MOX/KAN/ETH/PAS 0 1 0 
INH/MOX/KAN/PZA/ETH/TERI/PAS/CLF 0 0 1 
MOX/OFL/KAN/PZA/EMB/ETH/TERI/PAS/CLF 0 1 0 
MOX/KAN/PZA/EMB/ETH/TERI/CAP 0 1 0 
OFL/KAN/PZA/EMB/ETH/TERI 0 1 0 
INH/OFL/KAN/PZA/TERI 0 1 0 
INH/MOX/KAN/PZA/TERI/CLF 0 0 1 
INH/MOX/KAN/TERI 0 1 0 
MOX/KAN/PZA/TERI 0 1 0 
FQ-based plus CAP 0 43 56 
INH/MOX/PZA/EMB/ETH/TERI/PAS/CLF/CAP 0 16 19 
INH/MOX/PZA/EMB/TERI/PAS/CLF/CAP 0 6 3 
MOX/PZA/EMB/ETH/TERI/PAS/CLF/CAP 0 2 6 
MOX/PZA/EMB/TERI/PAS/CLF/CAP 0 0 6 
INH/MOX/EMB/TERI/PAS/CLF/CAP 0 3 1 
INH/MOX/PZA/EMB/ETH/TERI/PAS/CAP 0 2 2 
INH/MOX/PZA/ETH/TERI/PAS/CLF/CAP 0 1 3 
INH/MOX/EMB/ETH/TERI/PAS/CLF/CAP 0 2 1 
MOX/PZA/ETH/TERI/PAS/CLF/CAP 0 2 1 
MOX/EMB/TERI/PAS/CLF/CAP 0 1 2 
INH/MOX/PZA/EMB/ETH/TERI/CLF/CAP 0 0 2 
MOX/PZA/EMB/ETH/TERI/PAS/CAP 0 1 1 
MOX/PZA/EMB/PAS/CLF/CAP 0 0 2 
MOX/PZA/EMB/ETH/TERI/CLF/CAP 0 0 2 
INH/MOX/PZA/EMB/ETH/TERI/PAS/CAP 0 1 0 
INH/MOX/PZA/EMB/ETH/TERI/PAS/CLF/CAP 0 1 0 
INH/MOX/ETH/TERI/PAS/CLF/CAP 0 0 1 
INH/MOX/PZA/EMB/PAS/CLF/CAP 0 1 0 
INH/MOX/PZA/EMB/TERI/CLF/CAP 0 0 1 
INH/MOX/PZA/ETH/TERI/CLF/CAP 0 1 0 
INH/MOX/PZA/EMB/ETH/CLF/CAP 0 1 0 
INH/MOX/PZA/EMB/ETH/PAS/CAP 0 0 1 
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MOX/PZA/ETH/TERI/CAP 0 0 1 
MOX/PZA/EMB/TERI/CLF/CAP 0 1 0 
INH/MOX/OFL/PZA/EMB/ETH/TERI/PAS/CAP 0 0 1 
MOX/TERI/PAS/CLF/CAP 0 1 0 
SLID-based (no FQ) 0 9 5 
KAN-based  0 5 0 
INH/KAN/PZA/ETH/TERI/PAS 0 1 0 
INH/KAN/PZA/ETH/TERI 0 1 0 
KAN/PZA/EMB/ETH 0 1 0 
INH/KAN/PZA/EMB/ETH/TERI 0 1 0 
INH/KAN/PZA/TERI/CLF 0 1 0 
CAP-based  0 4 5 
INH/PZA/EMB/ETH/TERI/PAS/CLF/CAP 0 2 1 
PZA/EMB/TERI/PAS/CLF/CAP 0 1 1 
INH/PZA/EMB/ETH/PAS/CLF/CAP 0 1 0 
PZA/TERI/PAS/CLF/CAP 0 0 1 
INH/PZA/EMB/ETH/TERI/PAS/CAP 0 0 1 
PZA/EMB/TERI/PAS/CAP 0 0 1 
CLF-based (no FQ, no SLID)    
PZA/TERI/PAS/CLF 0 0 3 
PZA/TERI/PAS/CLF 0 0 2 
INH/PZA/EMB/ETH/TERI/PAS/CLF 0 0 1 
INH/PZA/TERI/PAS/CLF 0 1 0 
PZA/EMB/TERI/PAS/CLF 0 0 1 
INH/PZA/TERI/CLF 0 0 1 
INH/PZA/TERI/PAS/CLF 0 0 1 
PZA/TERI/PAS/CLF 0 0 3 
*Includes one Group 1 patient with ETH substituted for INH 93 
Abbreviations: RIF, rifampicin; INH, isoniazid; PZA, pyrazinamide; EMB, ethambutol; MOX, moxifloxacin; 94 
OFL, ofloxacin; AMI, amikacin; KAN, kanamycin; CAP, capreomycin; ETH, ethionamide; PAS, p-95 




Table 7. Inter-isolate single nucleotide polymorphism (SNP) comparisons of 326 isolates by cough aerosol sampling (CASS) status. All SNPs 98 
identified were used, and low coverage positions (<10x depth) were excluded on a per pair basis. Edge directionality was determined using patients’ 99 
date of diagnosis. Differences between the number of linked isolates by CASS status and the number of connections to and from isolates were 100 
tested using Fisher’s Exact test. The table below summarises the results with varying SNP distances between CASS-positive and CASS-negative 101 





Connections (edges) between 
isolates (degree) 
Connections (edges) between 






Odds Ratio  
(95% CI) 
p 
value   




Odds Ratio  











10 1.06 (0.65, 1.74) 0.905 0.73 (0.44, 1.21) 0.230 0.81 (0.40, 80) 0.618 80 1.5 (1, 2) 37 1.5 (1, 2) 
9 1.07 (0.61, 1.89) 0.893 0.67 (0.40, 1.13) 0.140 0.71 (0.32, 74) 0.458 74 1.5 (1, 2) 32 1.5 (1, 2) 
8 0.82 (0.42, 1.59) 0.638 0.80 (0.46, 1.37) 0.443 0.71 (0.27, 62) 0.505 62 1.5 (1, 2) 30 1.5 (1, 2) 
7 0.77 (0.36, 1.66) 0.588 0.83 (0.46, 1.47) 0.586 0.66 (0.21, 51) 0.446 51 1.5 (1, 2) 25 1.5 (1, 2) 
6 0.63 (0.26, 1.46) 0.322 0.91 (0.48, 1.69) 0.883 0.69 (0.19, 40) 0.566 40 1.5 (1, 2) 21 1.4 (1, 2) 
5 0.61 (0.23, 1.60) 0.375 0.99 (0.50, 1.93) 1 0.84 (0.19, 32) 1 32 1.6 (1, 2) 18 1.4 (1, 2) 
4 0.42 (0.10, 1.57) 0.241 0.79 (0.33, 1.75) 0.582 0.82 (0.13, 24) 1 24 1.6 (1, 2) 11 1.4 (1, 2) 
3 0.32 (0.04, 1.83) 0.259 1.04 (0.41, 2.51) 1 0.47 (0.02, 17) 0.584 17 1.6 (1, 2) 10 1.3 (1, 2) 
2 0.21 (0.02, 1.72) 0.193 1.19 (0.41, 3.27) 0.811 0.60 (0.02, 12) 1 12 1.6 (1, 2) 8 1.3 (1, 1) 
1 0 (0.00, 5.05) 0.429 0.58 (0.06, 3.32) 0.716 0 (0.00, 6) 1 6 1.7 (1, 2) 2 1.0 (1, 1) 




Table 8. Univariate and multivariate logistic regression analyses of drug-related predictors of 104 
CASS-positivity in sputum culture-positive patients on different treatment regimens. Each 105 
model (all patients, first-line regimen, FQ-regimen) was individually adjusted using the non-106 
drug predictors of cough aerosol culture-positivity in sputum culture-positive patients shown 107 
in Supplementary Table 8. Data are median (IQR) or n/N (%) unless otherwise stated. 108 
 
Univariate analyses Multivariate analyses† 










Adjusted odds ratio 




treatment 6 (4-56) 4 (2-6) 
0.99 (0.99, 
1.00) 0.065 - - 
No. drugs 6 (4-7) 4 (4-6) 0.75 (0.65, 0.87) <0.001 - - 
Regimen 
First-line 91/163 (56) 
72/163 
(44) Reference - Reference - 




















Adjusted odds ratio 
(95% CI) (n=145) P-value 
Days 
treatment 4 (2-5) 3 (1-5) 
0.88 (0.74, 
1.04) 0.132 
No drug-related variables significant 
in univariate analyses. None included 




4 (3.5-4) 4 (3-4) 0.96 (0.61, 1.52) 0.868 
Drug likely effective 
RIF  77/83 (93) 64/67 (95) 
0.84 (0.47, 
1.51) 0.570 
INH  75/92 (91) 57/67 (85) 
0.53 (0.20, 
1.41) 0.203 
PZA  70/72 (97) 54/57 (95) 
1.00 (0.90, 
1.12) 0.948 














Adjusted odds ratio 
(95% CI) (n=141) P-value 
Days 








3 (2-4) 3 (2-4) 0.78 (0.58, 1.04) 0.088 0.68 (0.41, 1.14) 0.151 
Drug likely effective 
FQ  44/111 (40) 5/27 (19) 
0.38 (0.15, 
1.02) 0.057 0.99 (0.25, 3.84) 0.992 
SLID  50/98 (51) 12/24 (50) 
0.96 (0.38, 
2.42) 0.931 - - 
PZA  29/104 (36) 7/23 (30) 
0.87 (0.73, 
1.04) 0.129 - - 
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EMB  29/86 (34) 7/23 (30) 0.75 (0.39, 1.46) 0.407 - - 
ETH  23/90 (26) 1/23 (4) 0.13 (0.20, 1.04) 0.054 0.16 (0.02, 1.41) 0.099 
PAS  57/63 (91) 14/17 (82) 
0.49 (0.11, 
2.21) 0.354 - - 





Not included as no 
resistance observed - 
†Values as in the final model. 109 
For second-line regimens not comprised of a FQ, analyses were not done due to the small number of CASS-110 
negative (n=9) and CASS-positive (n=5) patients. 111 
Abbreviations: CASS, cough aerosol sampling system; CI, confidence interval; IQR, interquartile range.   112 
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Table 9. Non-drug predictors of cough aerosol culture-positivity in sputum culture-positive 113 
patients on treatment used to adjust models in Supplementary Table 7.  Data are median (IQR) 114 
or n/N (%) unless otherwise stated. 115 
 
Univariate analyses Multivariate analysis† 






ratio (95% CI) 
P-
value 
Adjusted odds ratio 






4 (2-5) 3 (2-4) 0.88 (0.78, 0.98) 
(per unit) 
0.017 0.80 (0.68, 0.94) (per 
unit) 
0.007 
HIV-positive 87/210 (41) 30/106 
(28) 
0.47 (0.29, 0.78) 0.003 0.44 (0.22, 0.86) 0.017 





(per 10 units) 
<0.001 10.08 (10.04, 10.13) 





12 (8-16) 8 (6-10) 0.80 (0.75-0.86) <0.001 0.75 (0.68, 0.83) (per 
unit) 
<0.001 






ratio (95% CI) 
P-
value 
Adjusted odds ratio 






4 (3-5) 3 (2-4) 0.74 (0.61, 0.90) 
(per unit) 





42/83 (51) 21/69 (30) 0.43 (0.22, 0.83) 0.013 0.30 (0.13, 0.70) 0.005 





(per 10 units) 
<0.001 10.11 (10.04, 10.16) 





11.5 (8-15) 9 (7-10) 0.86 (0.79-0.93) <0.001 0.80 (0.71, 0.90) (per 
unit) 
<0.001 






ratio (95% CI) 
P-
value 
Adjusted odds ratio 






4 (2-5) 3 (1-4) 0.92 (0.78, 1.09) 
(per unit) 
0.357 - - 
HIV-
positive  
41/114 (36) 7/29 (24) 0.57 (0.22, 1.44) 0.232 - - 





(per 10 units) 




13 (9-17) 7 (5-8) 0.71 (0.61-0.83) <0.001 0.75 (0.62, 0.87) (per 
unit) 
<0.001 
†Values as in the final model. 116 
Abbreviations: CASS, cough aerosol sampling system; CI, confidence interval; IQR, interquartile range; TTP, 117 
time-to-positivity; MDR-, multidrug-resistant; PCF, peak cough flow.  118 
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Table 10. List of cough aerosol sampling system (CASS), sputum smear microscopy, sputum Xpert MTB/RIF, and sputum MGIT960 liquid 119 
culture reproducibility results in pre-treatment patients newly programmatically diagnosed as Xpert MTB/RIF-positive. 120 
 Day 1 Day 2 





































R1 0 N P (M, 20.3) P (13) 0 P+ P (M, 21.1) N 0 P (SC) P (M, 21.6) N 0 N P (L, 22.3) N (0) 
R2 15 P+++ P (H, 11.4) P (4) 7 P+++ P (H, 13.2) P (4) 27 P+++ P (M, 19.7) P (5) 0 P+++ P (M, 17.2) P (4) 
R3 1 N P (H, 15.6) P (7) 2 P+ P (H, 16.3) P (8) 0 P+++ P (M, 20.1) P (6) 0 P+ P (M, 18.7) P (6) 
R4 51 P+++ P (H, 14.5) P (4) 48 P+++ P (H, 14.4) P (3) 20 P+++ P (H, 14.2) P (5) 33 P++++ P (H, 15.4) P (3) 
R5 0 P+++ P (L, 24.3) P (6) 0 P+ P (M, 18.3) P+C† 0 P+++ P (H, 16.1) P (6) 0 P+++ P (M, 21.5) P (7) 
R6 184 P++ P (M, 18.2) P (4) 4 P+ P (H, 15.7) P (5) 124 P+ E (0) P (5) 26 P+++ P (M, 16.5) P (5) 
R7 9 P+++ P (M, 17.9) P+C† 0 P+++ P (M, 19.4) P (6) 4 P+++ P (H, 15.5) P (6) 4 P++ P (H, 15.4) P (6) 
R8 1 N P (M, 21.7) P (11) 1 N P (L, 22.4) P (10) 0 P (SC) P (L, 22.7) P (13) 0 P (SC) P (L, 22.3) P (11) 
R9 2 P+++ P (H, 16.3) P (4) 2 P+++ P (H, 14.6) P (4) 2 P+++ P (H, 14.9) P (5) 3 P+++ P (H, 15.2) P (4) 
R10 0 N N N 0 N N C† 0 N N C† 0 N N N 
R11 1 P+ P (M, 19.3) P (9) 9 P++ P (M, 17.2) P (8) 5 P++ P (M, 18.6) P (8) 1 P (SC) P (M, 17.1) P (10) 
R12 C P+++ P (H, 11.3) P (3) 191 P+++ P (H, 15.8) P (3) 21 P++ P (H, 15.4) P (5) 20 P++ P (H, 11.6) P+C†  
R13 C N P (M, 18.8) N 4 P+++ P (H, 15.5) P (6) 3 P++ P (M, 19.4) P (9) 8 P++ P (M, 17.8) P (6) 
R14 11 P+ P (H, 15) P (6) 12 P+ P (M, 16.5) P (4) 0 P+++ P (H, 13.5) P (6) 4 P+++ P (H, 13.4) P (3) 
R15 3 P+++ P (H, 15.4) P (6) 13 P+++ Not done* P (5) 14 P++ P (H, 15.1) P (6) 6 P+++ P (H, 14.6) P (7) 
R16 16 P++ P (M, 18.4) P (4) 0 P+++ P (H, 16.1) P (3) 21 P+++ P (M, 16.5) P (6) 45 P+++ P (H, 16.1) P (6) 
R17 9 P++ P (H, 16) P (4) 7 P++ P (M, 17.3) P (3) 0 P+++ P (H, 13.4) P (3) 9 P+++ P (H, 14.4) P (3) 
R18 13 P++ P (H, 12.9) P (8) 12 P++ P (M, 17.1) P (9) 4 P++ P (H, 14.6) P (9) 0 N/A P (M, 17) P (18) 
R19 25 N P (M, 21.2) P (10) 3 N P (M, 20.4) P (9) 17 P+ P (M, 21.5) P (10) 0 N P (L, 22.8) P (10) 
R20 0 P++ P (M, 17.6) P (7) 20 P+++ P (M, 17.4) P (5) 0 P (SC) P (H, 15.1) P (8) 12 P++ P (H, 14.6) P (6) 
R21 34 P+ P (M, 16.5) P (8) 43 P+++ P (H, 16.2) P (9) 18 P++ P (M, 17.8) P (5) 28 P+++ P (M, 19.6) P (5) 
R22 0 P++ P (M, 17.2) P (9) 5 P++ P (M, 16.7) P (7) 0 P+++ P (H, 15.4) P (9) 2 P++ P (M, 22.1) P (8) 
R23 2 P++ P (M, 19.3) P (11) 2 P++ P (M, 19.3) P (11) 0 P++ P (L, 23.7) P (9) 1 P++ P (M, 19.8) P (8) 
R24 284 P++++ Not done* P (8) 9 P+++ P (M, 17.5) P (6) 86 P+++ P (M, 17.1) P (9) 6 P+++ P (H, 15.5) P (7) 
R25 
0 P+++ P (M, 17) P+C† 0 P+++ P (M, 19.9) P (5) 0 P+++ Not done* P (5) C 
Not 
done* Not done* 
Not 
done* 
R26 4 P++ P (M, 17.4) N 1 P+ P (M, 16.5) P (5) 0 P+++ P (H, 15.2) P (6) 0 P+ P (M, 17.6) P (8) 
R27 0 P++++ P (H, 11.4) P (2) 52 P+++ P (H, 12.4) P (3) 0 P++++ P (H, 10.5) P (3) 0 P+++ Not done* P (3) 
R28 41 P+++ P (H, 12.3) P (3) 0 P++ P (H, 14.8) P (5) 0 P++ P (H, 12.7) P (3) 0 P+ P (H, 13.2) P (5) 


























26/27 (96) 26/28 
(93) 
*Missing data: Xpert (n=3), if patients could produce one sputum it was used for microscopy and culture; CASS (n=1), patient unwell and CASS not done; smear microscopy 121 
and culture (n=1), patient unable to produce sputum. †TTP not given if contamination was observed. Abbreviations: P, positive; N, negative; C, contamination; CFU, colony 122 
forming units; CTmin, minimum cycle threshold value; E, error; H, high; M, medium; L, low; VL, very low; SC, scanty; TTP, time-to-positivity. 123 
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Table 11. Cough aerosol sampling and sputum microbiology reproducibility. CASS grade was classified based on the number of CFU in aerosol 124 
(no growth = 0, 1-9 CFU = 1, ≥10 CFU = 2). Data are shown with 95% CI. 125 
 Overall Day 1 Morning vs. Day 1 
Afternoon 
Day 2 Morning vs. Day 2 
Afternoon 
Day 1 Morning vs. Day 2 
Morning 
Day 1 Afternoon vs. Day 2 
Afternoon 
Smear status, kappa 0.46 (0.13, 0.84) 0.61 (0.23, 1.00) 0.36 (-0.16, 0.89) 0.24 (-0.15, 0.64) 0.51 (0.03, 0.99) 
Smear grade, kappa 0.23 (0.14, 0.30) 0.34 (0.26, 0.47) 0.27 (0.24, 0.27) 0.12 (-0.02, 0.23) 0.26 (0.14, 0.28) 
Culture status, kappa 0.54 (0.37, 1.00) -0.05 (-0.15, 0.05) 1.00 (1.00, 1.00) -0.05 (-0.15, 0.05) 1.00 (1.00, 1.00) 
TTP, average ICC 0.91 (0.83, 0.96) 0.93 (0.82, 0.97) 0.80 (0.55, 0.91) 0.91 (0.79, 0.96) 0.80 (0.53-0.91) 
Xpert status, kappa 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 
Xpert grade, kappa 0.33 (0.15, 0.47) 0.41 (0.20, 0.51) 0.43 (0.29, 0.48) 0.41 (0.27, 0.64) 0.24 (0.16, 0.56) 
CTmin, average ICC 0.86 (0.74, 0.94) 0.82 (0.58, 0.92) 0.82 (0.59, 0.92) 0.72 (0.37, 0.88) 0.73 (0.389, 0.88) 
CASS status, kappa 0.37 (0.29, 0.56) 0.47 (0.10, 0.83) 0.43 (0.10, 0.76) 0.50 (0.23, 0.78) 0.31 (-0.03, 0.65) 
CASS grade, kappa 0.38 (0.22, 0.56) 0.39 (0.09, 0.43) 0.45 (0.29, 0.66) 0.51 (0.40, 0.62) 0.36 (0.26, 0.56) 
CASS CFU, average 
ICC 
0.59 (0.25, 0.80) 0.04 (-1.10, 0.56) 0.46 (-1.68, 0.75) 0.80 (0.56, 0.91) 0.32 (-0.47, 0.69) 
Kappa interpretation: 0.01-0.20 slight; 0.21-0.40 fair; 0.41-0.60 moderate; 0.61-0.80 substantial; 0.81-1.00 almost perfect.3 126 
ICC reliability interpretation: <0.5 poor, 0.5-0.75 moderate, 0.75-0.90 good, >0.90 almost perfect.4 127 
Abbreviations: CASS, cough aerosol sampling system; CI, confidence interval; CFU, colony forming units; CTmin, minimum cycle threshold value; ICC, intraclass correlation; 128 
TTP, time-to-positivity; Xpert, Xpert MTB/RIF. 129 
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Supplementary Results 130 
Sputum Auramine-Nile Red staining  131 
Initially, Auramine-Nile Red straining was done on all Ziehl-Neelson smear-positive patients; 132 
however, due to low numbers of bacilli observed after Auramine-Nile Red straining - even 133 
after extensive optimisation and troubleshooting - we changed our protocol to visualise slides 134 
only from patients who had a Ziehl-Neelson sputum smear-grade of two or higher.  135 
Of the 194 sputum smear grade 2+ or greater patients, 66 (34%) had at least one Auramine-136 
positive bacilli after Auramine-Nile Red straining and all but 3/66 (5%) had Nile-Red co-137 
localization. Overall, the mean (standard deviation) proportion of Auramine-positives bacilli 138 
co-localization was 0.76 (0.47). In CASS-negative vs. positive-patients, no differences were 139 
detected [0.75 (0.30) vs. 0.74 (0.30); p=0.644].  140 
Genome wide association studies 141 
We investigated if nonsynonymous SNPs on a gene level in M. tuberculosis from sputum 142 
culture isolates were associated with CASS-positivity. This analysis included 318 isolates with 143 
115 (36%) from CASS-positive individuals and 857 genes. We detected no associations with 144 
CASS-status in univariate, logic regression (interaction analysis), phylogenetic convergence, 145 
or efficient mix-models analyses (Figure 3). We also did not detect associations using a 146 
multivariate logistic model that included two principal components, patient age, TB symptom 147 
score, HIV-status, duration of treatment less than 48h, PCF, culture time to positivity, and drug-148 
resistance category. An efficient mixed model analysis using 274 isolates (101 from CASS-149 
positive) for sputum culture time to positivity did not detect significant associations (Figure 150 
S3). We further investigated the associations of structural variants with CASS-positivity using 151 
318 isolates with 115 (36%) from CASS-positive individuals and 73 indels. We detected no 152 
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indels associated with CASS-status in logic regression, phylogenetic convergence, or efficient 153 
mix-models analyses. 154 
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A B S T R A C T
Genotyping of Mycobacterium tuberculosis (MTB) isolates has markedly improved our knowledge of its trans-
mission dynamics. MIRU-VNTR is considered the reference molecular tool for MTB fingerprinting. However, the
dependence of this technique on cultured isolates means that we lack molecular epidemiology data from many
settings where culture facilities have not been implemented. Efforts have been made to adapt the MIRU-VNTR
procedure to direct analysis of clinical specimens, although implementation of these efforts has not proven
successful. The large-scale roll-out of Xpert MTB/RIF (Xpert) technology, which is now in almost every TB-
endemic country, including many where MTB is not cultured, provides us with a new opportunity to explore
whether MTB genotyping could be performed from the remnants of the Xpert cartridge. We ran a pilot study in
Mozambique in which the remnants of 24 positive Xpert assays for detection of MTB were used as template
material for the 15-locus or the more discriminatory 24-locus MIRU-VNTR technique. MTB fingerprinting was
possible in specimens with a high bacterial burden, according to the Xpert load categories, and within the first
week after Xpert was performed. Given the wide availability, simple processing, and rapid reporting of results
with Xpert, our findings suggest that MIRU-VNTR–based fingerprinting from remnants of Xpert could play a
major role in extending MTB molecular epidemiology studies to settings where information on the transmission
dynamics of this pathogen is lacking.
1. Introduction
Molecular epidemiology studies help us to identify which patients
within a population are in clusters, thus indicating that they belong to
the same transmission chain, useful indicators to evaluate the efficiency
of control programs.
The MIRU-VNTR technique optimized MTB fingerprinting for epi-
demiological purposes. It analyses the number of tandem repeats from
15 loci or, in its most discriminatory format, 24 loci [1]. MIRU-VNTR
still needs to be applied on cultured isolates to ensure complete typing.
Consequently, there are knowledge gaps in the molecular epidemiology
of TB in many low- and middle-income countries, where MTB culture
facilities are not widely available.
Efforts have been made to adapt MIRU-VNTR to enable direct
analysis of the bacilli present in respiratory specimens [2]. This ap-
proach opens the door to new culture-independent genotyping strate-
gies. However, these new developments still require specific laboratory
facilities for basic sample processing, decontamination, and inactiva-
tion of sputa, thus explaining why they have not been extensively ap-
plied.
The new, rapid, automated test Xpert® MTB/RIF (Cepheid,
Sunnyvale, USA) (Xpert) was developed for detection of both MTB and
rifampin resistance, directly from respiratory samples [3]. This assay
needs no laboratory infrastructure, as the sputa can be mixed directly
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with an inactivation and liquefaction reagent before being transferred
into a cartridge. Since the GeneXpert system is distributed worldwide, it
provides us with an excellent opportunity to evaluate if it is possible to
perform culture-independent MTB genotyping directly from the car-
tridge remnants.
Some studies have shown the feasibility of using Xpert remnants, i.e.
leftover diluted samples, or cartridge extracts, to perform genotypic
drug susceptibility testing, spoligotyping [4,5] or Allele-Specific-Oli-
gonucleotide PCR [6]. Additionally, only one single effort of char-
acterization by VNTR analysis has been made on Xpert remnants, from
leftover diluted samples, and just limited to the 4 VNTR loci set re-
commended for Beijing strains genotyping, with non-optimal results
[5]. Here, we present the results of the first pilot study to evaluate the
feasibility of performing standard MIRU-VNTR analysis from the rem-
nants from the sample chamber of the Xpert cartridge.
2. Materials and methods
2.1. Study setting
The study was performed at the Manhiça Health Research Center
(CISM), located in Manhiça, a low-resource, rural area with a high TB
and HIV burden in Southern Mozambique [7]. Mozambique is one of
the 30 World Health Organization's high burden countries [8]. TB has
been epidemic in the country, with high mortality, and a low case de-
tection rate [9].
2.2. Ethics
The CISM Internal Scientific Committee and the Mozambican
National Bioethics Committee approved the research protocol, which
included the present study (Ref 25/CNBS/16). Informed consent was
obtained.
2.3. Clinical specimens
Respiratory samples received for Xpert analysis (March 1st to June
3rd, 2016) were decontaminated [10] and mixed in a 1:2 proportion
with the Xpert Sample Reagent. Two milliliters were used for the test
following the manufacturer's instructions. Once the Xpert run had fin-
ished, the remnant volume from the sample chamber of the cartridge
was transferred to a tube and stored at 4 °C.
2.4. DNA purification
DNA was purified from the Xpert remnant using a column-based
method (QIAamp DNA minikit; Qiagen, Courtaboeuf, France) following
the manufacturer's instructions with only minor modifications. The
supernatant after the initial centrifugation was also passed through the
column to recover any free DNA. The final elution volume in buffer AE
varied (85 or 130 μl) depending on the MIRU-VNTR format (15- or 24-
locus).
2.5. MIRU-VNTR analysis
MIRU-VNTR was performed based on a simplex-PCR format as de-
scribed elsewhere [11].
2.5.1. Non-optimized starting protocol
The starting protocol was as follows: 5 μl of purified DNA was added
to a final reaction volume of 50 μl containing 0.2 μl of DNA Polymerase
(GoTaq® Hot Start Polymerase Kit [Promega]), 10 μl of Colorless
GoTaq® Flexi Buffer (1×), 0.2mM of dNTPs, 1.5 or 3mM of MgCl2
(3 mM for VNTR 580, 802, 960, 2401, 2996, and 3690, and 1.5mM for
the remaining loci) and 0.1 μM of each unlabelled oligonucleotide.
The PCR conditions were 95ᵒC for 15min followed by 40 cycles of
95ᵒC for 1min, 54ᵒC (for loci VNTR 154, 580, 820, 960, 1644, 2059,
2531, 2687, 2996, 3007, 3192, and 4348) or 59ᵒC (for the remaining
loci) for 1min, and 72ᵒC for 1min and 50 s. A final elongation step was
run at 72ᵒC for 10min. PCR products were sized using electrophoresis
with 2% agarose gels (mixing NuSieve® 3:1 Agarose [Lonza] with TAE
1×).
2.5.2. Optimized protocol
For the loci in which proper amplification was obtained when fol-
lowing the starting protocol, it was considered the final optimized
protocol. However, in the case of the VNTR loci 424, 1644, 1955, 2059,
2347, 2531, 2687, 3171, 3192, 4052, 4156, and 4348 the procedure
was adjusted to ensure optimal results. The final optimized procedure
for these loci consisted of applying the PuReTaq Ready-To-Go PCR
beads system (GE Healthcare, Buckinghamshire, United Kingdom). The
PCR mixture contained 2.5 μl of DNA, 0.25 μM of each oligonucleotide,
and 1.5 μl of DMSO in a final volume of 25 μl.
2.6. Evaluation strategy
Our evaluation strategy was based on a gradient running from less
demanding to more demanding circumstances depending on a series of
factors: i) the number of MIRU-VNTR loci to be analysed (15 or 24; the
need to perform 15 or 24 PCRs determines the final elution volume in
the DNA purification procedure and consequently modifies the DNA
concentration to be used as the PCR template, which could eventually
affect the probability of obtaining appropriate amplification). ii) the
bacterial load in the specimens (based on the semiquantitative in-
formation provided by the GeneXpert software that distributes the
specimens in categories -high, medium, low and very low- depending
on the Ct values) and iii) the length of the delay between the Xpert
assay and DNA purification-MIRU-VNTR analysis.
In order to estimate a potential association between bacillary
burden or delay in MIRU-VNTR analysis with the identification of
complete 15 and 24 loci MIRU-VNTR patterns, we compared the
number of samples with complete MIRUtypes per bacillary load cate-
gory and per length of delay (less than 8 vs 8 or more days). We also
estimated the mean individual loci identified per category of interest.
Given the limited sample size, p-values were obtained using Fisher's
exact test.
3. Results and discussion
A total of 27 samples from 26 patients were Xpert-positive, ri-
fampin-susceptible, during the 3-month study period. Only two speci-
mens were monoresistant to INH. The distribution of samples according
to bacterial load, based on the interpretation that the GeneXpert soft-
ware made from the Ct values was: 17, 5 and 5 samples with high,
medium and low bacterial loads, respectively. These three semi-
quantitative categories have been shown to correlate with the bacterial
loads determined from acid-fast smears (≥2+, ≥1 + and ≤1+, re-
spectively) [12].
Our first objective was to obtain 15-locus MIRU-VNTR data from the
Xpert remnants. We analysed 5 samples with a high bacterial load ac-
cording to GeneXpert and with a maximum delay of 7 days between
Xpert and MIRU-VNTR.
We obtained an interpretable result for 10 of 15 loci in the 5 sam-
ples analysed, indicating that further optimization was needed to en-
sure a full 15-locus MIRU-VNTR analysis. Increasing the primer con-
centration to 0.4mM for locus 424 and applying a PCR bead system for
the VNTR loci 1644, 1955, 4156, and 4052 led to complete 15-locus
MIRU-VNTR patterns in all the specimens analysed (Table 1).
15-locus MIRU-VNTR offers sufficient discriminatory power for
epidemiological purposes [1]. However, we also evaluated whether the
highest discriminatory format (i.e., 24 loci) could also be obtained from
the Xpert remnants when our optimized procedure was applied. In the
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second evaluation step, we selected another 4 specimens, again with a
high bacterial load and a short delay between Xpert and VNTR analysis
(range 1–7 days). Complete 24-locus MIRU-VNTR types (Table 2) were
obtained for all the specimens. For 6 of the new 9 loci, the PuReTaq
Ready-To-Go PCR Beads system was required (Table 2). We also needed
to add the VNTR 3192 locus to those in the 15-locus set that took ad-
vantage of the beads system, which thus defined the protocol to be used
in the evaluation from this point onward.
We then introduced the impact of the bacterial burden in the spe-
cimens in our analysis, by including samples with a lower-than-high
load of bacilli, still assuring a maximum delay of 7 days between Xpert
and MIRU-VNTR. 4 samples with a medium bacterial load and 3 with a
low bacterial load were available for study. We obtained a complete 15-
locus MIRU-VNTR pattern in 1 sample with medium bacillary burden
and in none with low (Table 3). Considering the complete 15-locus
MIRU-VNTR pattern that had been obtained previously from all the
high bacterial load specimens, a statistically significant association
between bacillary load and ability to obtain a complete 15-loci MIRU
type was found (Fisher's exact test p-value: 0.01). The average number
of loci with a result per high, medium and low bacillary burden spe-
cimens was 15, 13 and 7 respectively.
It is known that the efficiency of amplification is not equivalent for
all MIRU loci and it could explain the amplification failures for certain
loci when the amount of DNA was expected to be low/very low. In
addition, some of the amplification failures could be due to poor DNA
quality as result of suboptimal storage conditions of the remnants until
analysis: at 4ᵒC, but not frozen, and not neutralizing the pH, a caution
introduced in other studies [5]. Only 1 MIRUtype was complete
(medium load specimen), and this was possible only thanks to the ad-
dition of beads to locus 3690. In the remaining samples, the failed
amplifications could not be resolved even by adding beads.
In molecular epidemiology studies, to rule in properly the involve-
ment of an isolate in a cluster, a complete MIRU pattern (at least for the
15-loci) is required. However, for the disease tracing it is also relevant
to rule out those cases not related to transmission clusters. For this
reason, some of the incomplete patterns obtained from Xpert remnants
could still be valuable, as differences at the amplified loci of greater
magnitude than the single locus variations tolerated within clusters,
would rule out the relationships between the cases.
Newly diagnosed cases will correspond more frequently to cases
with a high bacterial load [13,14], due to the diagnostic delay expected
in most of the countries where our strategy would improve current
procedures. In fact, in our study 63% of the samples recruited corre-
sponded to high bacterial load specimens. This observation would
probably minimize the size of the subsample (with lower burden spe-
cimens) with incomplete results. However, we must admit that our data
indicate that, in absence of culture facilities, a complete fingerprint
cannot be always assured for specimens with low/medium bacterial
load.
The final step in our evaluation was to assess the impact of a delay
in the acquisition of a complete MIRU-VNTR pattern. The rationale
behind this decision was the fact that in certain settings, Xpert remnants
will have to be transported to other reference laboratories to be geno-
typed. Until now, we had observed that a delay of up to 1 week does not
Table 2
Results for 24-locus MIRU-VNTR.
Sample Bacterial Load Days of delay 24-locus MIRU-VNTR
15-locus MIRU-VNTR
6 HIGH 4 3a 4 2 2 4 3a 2 4 2 2 3 3 1 7b 2b 2 2b 4b 2 6 1 3 1 2
7 HIGH 4 4a 4 2 3 3 3a 5 4 4 4 7 5 3 8b 2b 2 2b 4b 2 5 1b 3 3b 2
8 HIGH 7 2a 4 5 3 4 3b 6 7 8 2 2 4 5 7b 1b 2 1b 3b 5 6 2b 3 3b 7b
9 HIGH 1 4a 4 6 5 5 7b 4 4 10 4 4 5b 11 3b 1b 2 1b 3b 4 11b 8b 3 3b 1
The order of MIRU-VNTR loci in the Table is: 424, 577, 580, 802, 960, 1644, 1955, 2163b, 2165, 2401, 2996, 3192, 3690, 4052, 4156, 154, 2059, 2347, 2461, 2531,
2687, 3007, 3171, 4348.
a Application of a final concentration of 0.4 μM for each oligonucleotide.
b Application of the PuReTaq Ready-To-Go PCR Beads system.
Table 3
Results for 15-locus MIRU-VNTR in medium- and low-load samples.
Sample Bacterial Load Days of delay 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 4052 4156
10 MEDIUM 5 4 9 7 3 4a – 6 3 9a 2a 2a 5 2 – 1
11 MEDIUM 6 2 4 2 4 3 2 10 3 3 2 5 3 3a 4 1
12 MEDIUM 5 2a 9 – 3 – – 12 11a 6a 2a 4 5 2 4 1
13 MEDIUM 4 2 4 – 3 4 3 12 11 6 2 5 5 2 4 1
14 LOW 6 2 4 – 1 – – 2 – 3 2 – – 5 – –
15 LOW 5 – – – 5 – 4 5 – 2 8 8 3 6 7 –
16 LOW 5 6 – – 4 – – 2 – – 5 5 1 6 – –
a Application of the PuReTaq Ready-To-Go PCR Beads system.
Table 1
Results for 15-locus MIRU-VNTR.
Sample Bacterial Load Days of delay 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 4052 4156
1 HIGH 0 3a 4 2 4 4 3 3 2 2 1 5 3 2 8b 3b
2 HIGH 7 2a 2 5 3 4 1b 8b 3 9 2 2 5 7 2b 1b
3 HIGH 0 2a 2 5 3 4 3a 11 3 9 2 2 5 7 3b 1b
4 HIGH 2 2a 4 5 2 4 3a 7 10 7 2 2 5 6 6b 1b
5 HIGH 6 2 4 2 1 3 3a 2 5 3 2 5 3 5 4b 2b
a Application of a final concentration of 0.4 μM for each oligonucleotide.
b Application of the PuReTaq Ready-To-Go PCR Beads system.
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hamper acquisition of MIRU-VNTR data. However, longer delays might
make it possible to accumulate cartridges and minimize the number of
deliveries and costs.
We evaluated the impact of longer delays (8–31 days from Xpert
testing) in a subset of 8 specimens with high bacterial load, all of which
were analysed using the 15 and 24-locus MIRU-VNTR format (Table 4).
The 3 remaining specimens, not included in the analysis until now,
were eliminated from the study because they corresponded to low/
medium bacterial loads that proved to be problematic even in the ab-
sence of a delay. First, focusing on the 15-locus MIRU-VNTR format, a
complete MIRU-VNTR pattern was obtained in 4 samples processed
8–31 days after Xpert testing (although in 1 case it required the ap-
plication of the bead adaptation in 4 additional loci to fulfil the MIRU
pattern). Although the number of samples was small, the association
between acquisition of a complete 15 locus MIRUtype and delay in
processing the samples for MIRU-VNTR analysis was statistically sig-
nificant (comparing delays shorter or longer than 8 days, Fisher's exact
test p-value 0.029). This association is more patent with the more de-
manding 24 locus format, where a complete MIRUtype was obtained in
only 3 out of 8 samples (Fisher's test p- value 0.009). These data lead us
to recommend a best processing time shorter than 8 days.
Correlation is expected between the fingerprinting data obtained
directly from Xpert remnants and those obtained from the corre-
sponding cultures. We did not have access to the cultured isolates from
this study in Mozambique. However, we compared the MIRU-VNTR
patterns obtained directly from four Xpert tests in our institution in
Spain with those obtained from their cultured isolates and they were
identical (data not shown).
In the light of these results, we conclude that the final optimized
procedure succeeded in obtaining full 24-locus MIRU-VNTR finger-
prints on high-load specimens within one week since the Xpert test has
been performed. Based on the improvement of performance when
PuReTaq Ready-To-Go PCR beads system were included, we would
recommend its expanded use.
As a collateral observation, 1 of the specimens included in this last
evaluation led to a MIRU-VNTR pattern with double alleles in 13 loci
(Table 4, sample 19), thus expanding the usefulness of our strategy for
identification of mixed infections, which are expected in countries with
a high TB burden. Furthermore, if strains in mixed infections involve
different susceptibility patterns [15], the efficiency of therapy could be
affected.
Our study is limited by its ability to identify transmission events
owing to the small sample size. As expected, all cases were unclustered.
We must accept a suboptimal sampling when Xpert is used as the re-
ference material, as this test is not recommended for all patients in
some high burden countries. The sampling based on the cases with an
Xpert result available can never substitute the proper population-based
sampling required in any epidemiological rigorous study, however, it
can complement traditional culture-based approaches. As we were
aware of the sample size limitations, our objective was not to run an
epidemiology study but only to demonstrate, that MIRU-VNTR data
could be obtained from Xpert remnants, in those settings where other
higher-quality sampling efforts (systematic culture) are not feasible.
Our study highlights the potential usefulness of remnants from
currently available commercial assays for molecular analysis beyond
the applications proposed by the manufacturer. Our findings indicate
that epidemiologically useful MTB fingerprinting patterns can be ac-
quired in settings where culture is not available, as long as Xpert
technology is available. The results from our pilot study paved the
ground to apply this strategy, with wider sampling efforts, to identify
transmission clusters in molecular epidemiology studies of TB. The
broad global distribution of Xpert, which is supported by the WHO
recommendation to incorporate it into the diagnostic algorithms of
national TB control programmes, enables the performance of TB
transmission studies in low-resource settings, many of which experience
the highest burden of the disease.
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Table 4
Results of 24-locus MIRU-VNTR for samples processed with longer delays.
Sample Bacterial Load Days of delay 24-locus MIRU-VNTR
15-locus MIRU-VNTR
17 HIGH 8 1 4 2 1 4 2 3 – 2 1 6 3 2 8 2 2 2 4 2 – 5 2 3 2
18 HIGH 11 2 4 2 1 4 3 2 3 3 4 6 2 2 7 3 2 1 4 3 5 1 3 2 2
19 HIGH 13 2 4 2/5 1/3 3/4 – 12 4 2/9 2 2 3/5 2/6 3 1/2 2 1/2 3/4 1/6 6 1/2 2/3 3 2/3
20 HIGH 13 5a 4a 2 1 3 1 3 12a 2 1a 4 3 2 8 2 2 2 3 2a 6 5 2 1 2
21 HIGH 15 2 2 5 3 4 3 7 3 9 2 2 4 7 5 1 2 1 3 4 6 – 3 3 1
22 HIGH 23 4 4 2 3 3 3 5 4 4 4 7 5 3 8 2 2 2 4 2 5 1 3 3 2
23 HIGH 28 2 4 2 4 – – 4 3a 2 4 5 2 3 – 3 2 2 – 2 5 1 3 1 2
24 HIGH 31 4 4a 2 3 4 – 4 4a 2 2 5 3 1 7a 2 2 2 4 1 6 1 3 1 2
The order of MIRU-VNTR loci in the Table is: 424, 577, 580, 802, 960, 1644, 1955, 2163b, 2165, 2401, 2996, 3192, 3690, 4052, 4156, 154, 2059, 2347, 2461, 2531,
2687, 3007, 3171, 4348.
a Application of the PuReTaq Ready-To-Go PCR Beads system.
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Table 1: Primer details for amplification of fragments of the gyrA and rss regions using 
























Table 2: Results of MTBDRplus and MTBDRsl drug susceptibility testing using cartridge extract on clinical specimens stratified to smear status. 
MTBDRplus had high indeterminate results rifampicin-resistance false-positive rates for both smear positive and smear negative specimens. 
MTBDRsl had low indeterminate rates for both RIF-susceptible and RIF–resistant specimens. Smear negative specimens had higher rates of non-
actionable results for MTBDRsl.  
Xpert positive  rifampicin-susceptible and -resistant cartridges*  
Smear-positive specimens Smear-negative specimens   













Rifampicin (%) Fluoroquinolones (%) Rifampicin (%) Fluoroquinolones (%) 
p=0.01 
Susceptible 0/32 (0) Susceptible 41/42 (98) Susceptible 0/10 (0) Susceptible 17/21 (81) 
Resistant 32/32 (100) Resistant 1/42 (2) Resistant 10/10 (100) Resistant 1/21 (5) 
Indeterminate 0/32 (0) Indeterminate 0/42 (0) Indeterminate 0/10 (0) Indeterminate 3/21 (14) 
Isoniazid (%) Second-line injectables (%) Isoniazid (%) Second-line injectables (%) 
p=0.01 
Susceptible 10/32 (31) Susceptible 39/42 (93) Susceptible 0/10 (0) Susceptible 16/21 (76) 
Resistant 0/37 (0) Resistant 2/42 (5) Resistant 0/10 (0) Resistant 1/21 (5) 
Indeterminate 22/32 (69) Indeterminate .1/42 (2) Indeterminate 10/10 (100) Indeterminate 4/21 (19) 
TUB-band negative TUB band-negative 
p=0.015 
5/37 (14) 1/43 (2) 3/13 (23) 2/23 (9) 
* Table shows results from both Xpert positive RIF-susceptible and RI-resistant specimens. RIF-susceptible samples had MTBDRplus and MTBDRsl 
done. RIF-resistant specimens only had MTBDRsl. 37/56 (66%) RIF-susceptible specimens were smear positive; 13/56 (23%) were smear negative 
and 6/56 (11%) had no smear results.  6/29 (20%) of RIF-resistant specimens were smear positive while 10/29 (35%) were smear negative and 13/29 
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 Figure S1: Quantitative PCR amplification results on cartridge extract (CE) from both 5 
 Xpert and Ultra cartridges done on both DS-TB and XDR-TB on a dilution series (100 – 6 
 104 CFU/ml).  The 16s rRNA gene was amplified in some diamond CEs, C2, and C4 7 
 replicates; however, results were inconsistent…………………………………………3 8 
Figure S2: FluoroType MTBDR DST results on Ultra and Xpert diamond cartridge 9 
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Table S1: V4 region Mtb specific 16S rRNA primers and thermocycling conditions1 17 
 18 
Mtb Forward primer 5’-GTGCCAGCAGCCGCGGTAA-3’  
Mtb Reverse primer 5’-GGACTACCAGGGTATCTAAT-3’ 
Thermocycling conditions 
(Bio-Rad CFX-96 Real-Time PCR machine) 
95°C for 5 minutes  
35 cycles of 95°C for 5 seconds  
60°C for 30 seconds. 
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Figure S1 19 
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Figure S2:  20 
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Ultra and Xpert cartridge structure and design 21 
First, sample reagent is mixed with the specimen and 2 ml pipetted into the cartridge [Chamber 22 
1 (C1); ~500 µl typically remaining after test completion]. The cartridge lid is then closed 23 
before placement in the GeneXpert machine and the test started. A plunger is automatically 24 
inserted into the cartridge centre. This engages a barrel to sequentially draw buffers and 25 
reagents into the chambers2,3. The plunger first draws the sample mixture into the cartridge 26 
base where bacilli (not necessarily alive or intact) are trapped on a filter prior to DNA extraction 27 
(Figure 2A)4. Wash fluid in Chamber 2 (C2, ~3 ml remaining), is then drawn over the filter 28 
and waste is collected in Chamber 3 (C3, ~5 ml remaining). While this wash can mostly (but 29 
not completely) remove small DNA fragments, it does not remove large DNA, especially if 30 
debris-associated4-6. Liquid reagent is then drawn from Chamber 4 (C4, ~500 µl remaining) 31 
and a sonic horn applied to lyse bacteria and release DNA7. DNA is then drawn into Chamber 32 
5 (C5, no volume remaining) and mixed with reaction beads. This mixture is channelled into 33 
the reaction chamber (diamond protrusion at the back of cartridge where dCE is drawn from) 34 
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Figure S1: Example of a positive MPN plate from a study participant. Each positive well is 
confirmed for acid fast growth by plating on Blood agar plates as well as Ziehl-Neelsen acid 






Figure S2: Standard Xpert (right) and vPCR (PEMAX treated) Xpert (left) CTmin values per 
patient for [A] The routine arm and [B] the intervention arm. CTmin values did not differ 




Figure S3:  
Figure S3: Patient Most Probable Number (MPN) assay results across treatment and post 
treatment month 6 (PT M6) and month 12 (PT M12) for patients on the [A] Routine treatment 
arm and the [B] Intervention treatment arm. There were no significant differences between the 






Table 1: Inclusion and exclusion criteria of the Phase III clinical drug trial (NExT) from 
which sputum samples were sourced for this study.  
Inclusion criteria:  
 
 
Subjects are required to meet ALL of the following inclusion criteria to 
participate: 
• Newly diagnosed culture and/or GeneXpert positive pulmonary TB.  
• Rifampicin resistance detected using at least two susceptibility testing 
assays (GeneXpert, HainMTBDRplus or phenotypic) using a sputum 
sample during screening 
• Provide written informed consent prior to all trial-related procedures 
including HIV testing.  
• Male or female aged 18 years and older.  
• Body weight between 40 and 90 kg, inclusive.  
• Women of non-childbearing potential or participants of either sex who 
are using or willing to use effective methods of birth control. 
Exclusion criteria:  
 
Subjects will be excluded from participation if they meet ANY of the following 
criteria:  
• A subject who in the opinion of the investigator is unlikely to cope 
with regular visits to the trial site either because of travel constraints, 
or because of drug or alcohol abuse, or other reason. 
• Known at screening to have XDR-TB or pre-XDR-TB (i.e. 
fluoroquinolone or second-line injectable drug (SLID) resistance i.e. 
to capreomycin, amikacin and kanamycin).  
• Previous history of treatment for MDR-TB or XDR-TB or previous 
treatment with bedaquiline. 
• Currently on MDR-TB treatment for more than 2 weeks. 
• Any subject with a Karnofsky score < 50. 
• Known allergy to any of the trial drugs or related substances. 
• Having participated in other clinical studies within 8 weeks prior to 
trial start where investigational agents were used that may potentially 
impact current trial outcome. 
• Presence (or evidence) of symptomatic neuropathy grade 3 or higher. 
• Epilepsy where drugs prolonging QT interval are used. 
• Participant who is pregnant, breast-feeding (and not willing to stop), 
or planning to conceive a child within 6 months of cessation of 
treatment.  
• Incompatibility between microbiological and clinical/ radiological 
findings (i.e. where the clinical and/or radiological findings are 
discordant with microbiological testing suggesting laboratory 
contamination). 
• Participants with ECG abnormalities, in particular QT prolongation. 
• Any pre-existing laboratory abnormality which in the opinion of the 
investigator will place the participant at risk (see detailed protocol for 




• Specific prior or concurrent medication/treatments (see detailed 
protocol). 
• Rifampicin-monoresistant TB (this criteria was amended during the 
trial and Rifampicin-monoresistant participants were included) 
• Fluoroquinolone and/or SLID resistance. Although in South Africa, 
the standard of care does not single out MDR-TB with 
fluoroquinolone or aminoglycoside resistance at initiation of MDR-TB 
treatment, in this study the Hain MTBDRsl line probe assay (LPA) 
will be used on the sputum sample to exclude any pre-XDR and XDR 
cases from participation in the study (results from the LPA and 
phenotypic DST testing on the isolate will be available 3-6 weeks 
later). 
• All inclusion and no exclusion criteria must be met prior to enrolment 
and randomisation. Whenever the investigator has reason to suspect 
that there might be a health problem (other than TB) participation 
should only be considered after discussing the case with the medical 
monitor. Note: Subjects who are currently on, or have previously been 
on drug-sensitive TB treatment are not excluded from participation.  
 
Post-randomisation exclusion criteria: 
Fluoroquinolone and/or SLID resistance detected on DST using the 
isolate. 
• Note: A woman who falls pregnant during the treatment phase of the 
trial will not be excluded but will be counselled regarding potential 
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Table S1: Results of duration study including negative results. Of 10 patients tested, 4/10 (40%) 
were gMask-positive of which no significant difference in time to positivity (TTP). There were 
2 patients that were gMask negative but CASS positive, indicating that gMask may miss some 
patients CASS detects and vice versa. 
 
PID Time (h) Aerosol culture result (TTP) Culture (TTP) CASS result 
M014 
1 P (14) 
P (4) P 3 P (27) 
6 P (18) 
M016 
1 P (22) 
P (5) P 3 P (20) 
6 P (17) 
M017 
1 P (23) 
P (9) N 3 P (3)* 
6 P (21) 
M019 
1 N 
N/A+ N 3 N 
6 P (24)   p=0.47 
M011 
1 N 




















N N 3 N 
6 N 
+ Patient was ill and could not produce sputum. † Patient was ill and did not wear mask for 
the full 3 and 6 hours. 
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